Generated by All in One SEO Pro v4.9.10, this is an llms.txt file, used by LLMs to index the site.

# Pharma Advancement

Latest Pharmaceutical News

## Sitemaps

- [XML Sitemap](https://www.pharmaadvancement.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Strategic International Partnership Formed to Support Morocco & Africa’s Aviation and Airport Modernisation Plans](https://www.pharmaadvancement.com/press-statements/strategic-international-partnership-formed-to-support-morocco-africas-aviation-and-airport-modernisation-plans/) - MIE Events and Niche Ideas sign an MoU to launch Global Aviation Africa, advancing airport infrastructure, connectivity and modernization across Africa.
- [Modular GMP Facility Scaling Redefining Biopharma Speed](https://www.pharmaadvancement.com/market-moves/modular-gmp-facility-scaling-redefining-biopharma-speed/) - Modular GMP facility scaling is revolutionizing biopharma speed by significantly reducing construction timelines through prefabrication and standardization.
- [Breaking the 14-Day Barrier with Modern CAR-T Manufacturing](https://www.pharmaadvancement.com/market-moves/breaking-the-14-day-barrier-with-modern-car-t-manufacturing/) - CAR-T manufacturing is being revolutionized through innovations such as closed-system automation, reducing vein-to-vein times and improving patient outcomes.
- [Gene Therapies Expanding Viral Vector Manufacturing Demand](https://www.pharmaadvancement.com/market-moves/gene-therapies-expanding-viral-vector-manufacturing-demand/) - The pharma industry is meeting high viral vector manufacturing demand through suspension culture, bioreactor optimization, and industrial-scale bioprocessing.
- [Rise of Advanced Fill-Finish Solutions for Living Drugs](https://www.pharmaadvancement.com/market-moves/rise-of-advanced-fill-finish-solutions-for-living-drugs/) - Advanced fill-finish solutions are becoming very critical for cell and gene therapies, prioritizing aseptic integrity and cellular viability over raw speed.
- [Innovations Driving Real-Time Cell Therapy Manufacturing](https://www.pharmaadvancement.com/market-moves/innovations-driving-real-time-cell-therapy-manufacturing/) - Real-time cell therapy manufacturing is revolutionizing personalized medicine by replacing batch testing with continuous monitoring and automated QC process.
- [FDA Proposes Rule to Ease Drug Manufacturing Registration](https://www.pharmaadvancement.com/manufacturing/fda-proposes-rule-to-ease-drug-manufacturing-registration/) - The FDA has suggested a drug manufacturing registration rule to streamline distributed manufacturing and help make foreign establishment requirements clearer.
- [UK Launches BARBARA Platform to Speed Up Dementia Drug Tests](https://www.pharmaadvancement.com/pharma-news/uk-launches-barbara-platform-to-speed-up-dementia-drug-tests/) - The UK has launched BARBARA, a platform connecting 180 databases to accelerate dementia research and clinical trials, aiming to boost global life sciences.
- [Intelligent Labelling Transforming Pharma Packaging Dynamics](https://www.pharmaadvancement.com/market-moves/intelligent-labelling-transforming-pharma-packaging-dynamics/) - Adopting intelligent labelling is helping pharma manufacturers improve compliance, serialization, supply chain visibility packaging efficiency and security.
- [Patient Centric Packaging Enabling Better Medication Use](https://www.pharmaadvancement.com/market-moves/patient-centric-packaging-enabling-better-medication-use/) - Designing patient centric packaging for better medication use improves health outcomes by simplifying the administration process for chronic care patients.
- [Eco Friendly Materials Advancing Green Pharma Packaging](https://www.pharmaadvancement.com/market-moves/eco-friendly-materials-advancing-green-pharma-packaging/) - Researching eco friendly materials for pharmaceutical containers helps manufacturers align with global sustainability goals without compromising drug stability.
- [Flexible Packaging Systems Ensuring Efficient Drug Safety](https://www.pharmaadvancement.com/market-moves/flexible-packaging-systems-ensuring-efficient-drug-safety/) - Modern flexible packaging systems for efficient drug safety provide versatile solutions for diverse pharmaceutical dosages while maintaining strict compliance.
- [Innovations in Anti Counterfeit Pharma Packaging Designs](https://www.pharmaadvancement.com/market-moves/innovations-in-anti-counterfeit-pharma-packaging-designs/) - Deploying innovative anti counterfeit pharma packaging designs protects patient safety and secures the legitimate global drug supply against illicit trade.
- [Ensuring Primary Packaging Safety Needs for Sensitive Drugs](https://www.pharmaadvancement.com/market-moves/ensuring-primary-packaging-safety-needs-for-sensitive-drugs/) - Prioritizing primary packaging safety requirements for sensitive drugs prevents chemical leaching and maintains the therapeutic potency of advanced medications.
- [Precision Filling Technology Optimizing Aseptic Pharma Lines](https://www.pharmaadvancement.com/market-moves/precision-filling-technology-optimizing-aseptic-pharma-lines/) - Implementing precision filling technology in aseptic pharma lines minimize product loss and maximize throughput in sterile drug manufacturing environments.
- [Artificial Intelligence Driving Pharma Packaging Designs](https://www.pharmaadvancement.com/market-moves/artificial-intelligence-driving-pharma-packaging-designs/) - Artificial intelligence is advancing pharma packaging designs by creating more efficient and user-friendly containers for a variety of complex drug formats.
- [Secondary Packaging Trends Emerging in the Pharma Industry](https://www.pharmaadvancement.com/market-moves/secondary-packaging-trends-emerging-in-the-pharma-industry/) - Secondary packaging trends emerging in the pharma industry are revealing new ways to optimize shipping volumes and enhance brand protection during transport.
- [Digital Labelling Advancing Global Pharmaceutical Industry](https://www.pharmaadvancement.com/market-moves/digital-labelling-advancing-global-pharmaceutical-industry/) - Utilizing digital labelling for pharmaceutical products is streamlining regulatory updates and providing patients with instant access to critical health data.
- [Machine Learning Driving Predictive Toxicology in Drug Tests](https://www.pharmaadvancement.com/market-moves/machine-learning-driving-predictive-toxicology-in-drug-tests/) - Machine learning in predictive toxicology for drug research improves safety forecasts, flags risks early and helps researchers make better decision-making.
- [EMA Speeds Up Review of Metastatic Pancreatic Cancer Drug](https://www.pharmaadvancement.com/pharma-news/ema-speeds-up-review-of-metastatic-pancreatic-cancer-drug/) - EMA starts a phased review of daraxonrasib for metastatic pancreatic cancer to accelerate regulatory assessment while maintaining quality and safety standards.
- [interpack China 2026 Hits 970 Exhibitors, Shaping the Future of Packaging in November](https://www.pharmaadvancement.com/press-statements/interpack-china-2026-hits-970-exhibitors-shaping-the-future-of-packaging-in-november/) - Interpack China 2026 showcases smart and sustainable packaging innovations driving pharmaceutical excellence and manufacturing efficiency across industries.
- [Novartis to Acquire Myricx Bio to Expand Oncology Pipeline](https://www.pharmaadvancement.com/press-statements/novartis-to-acquire-myricx-bio-to-expand-oncology-pipeline/) - Novartis will acquire Myricx Bio to advance cancer treatment using a new NMTi payload platform and antibody-drug conjugates for solid tumor therapy research.
- [Generative AI Advancing Drug Research for Novel Therapeutics](https://www.pharmaadvancement.com/drug-development/research-development/generative-ai-advancing-drug-research-for-novel-therapeutics/) - Generative AI in drug research is accelerating novel therapeutics discovery, improving target identification and cutting costs in current pharma workflows.
- [AI Solutions Cutting Drug Development Costs and Timelines](https://www.pharmaadvancement.com/drug-development/ai-solutions-cutting-drug-development-costs-and-timelines/) - AI has been reducing drug development costs and timelines by improving trial design, candidate selection and R&D efficiency across pharma pipelines globally.
- [AI Drug Target Discovery Unmasks Neurodegenerative Diseases](https://www.pharmaadvancement.com/drug-development/ai-drug-target-discovery-unmasks-neurodegenerative-diseases/) - AI drug target discovery efforts for neurodegenerative diseases reveal pathways, proteins, and biomarkers faster, supporting earlier therapeutic discovery.
- [AI Drug Discovery Fast-tracking Search for Cancer Treatment](https://www.pharmaadvancement.com/drug-development/ai-drug-discovery-fast-tracking-search-for-cancer-treatment/) - AI drug discovery for cancer treatment speeds target identification, biomarker analysis and lead optimization to move clinical candidates forward faster safely.
- [AI Drug Discovery Speeds Up Potential Cure for Rare Diseases](https://www.pharmaadvancement.com/drug-development/research-development/ai-drug-discovery-speeds-up-potential-cure-for-rare-diseases/) - AI drug discovery to cure rare diseases is speeding up new treatments with better target finding, faster screening, and smarter development for orphan drugs.
- [Insilico, Takeda Formalize AI Drug Discovery Partnership](https://www.pharmaadvancement.com/press-statements/insilico-takeda-formalize-ai-drug-discovery-partnership/) - Insilico Medicine and Takeda Pharmaceutical have formalized an AI drug discovery partnership deal, marking a significant milestone in pharmaceutical research.
- [South Korean Drug Exports Top $10 Billion for First Time](https://www.pharmaadvancement.com/pharma-news/south-korean-drug-exports-top-10-billion-for-first-time/) - South Korean drug exports surpassed $10.44 bn in 2025, driven by biopharmaceutical exports and record pharmaceutical production for a record trade surplus.
- [Anthropic Eyes Pharma Sector with Drug Discovery Expansion](https://www.pharmaadvancement.com/press-statements/anthropic-eyes-pharma-sector-with-drug-discovery-expansion/) - Drug discovery efforts expand as Anthropic launches Claude Science, integrating research, analysis and computing workflows for drug researchers and developers.
- [Annex 1 Compliance Reshaping Sterile Facility Design](https://www.pharmaadvancement.com/facilities-operation/annex-1-compliance-reshaping-sterile-facility-design/) - Annex 1 compliance reshaping sterile facility design strengthens contamination control, sterility assurance and GMP readiness across global pharma sectors.
- [Facility Commissioning Excellence Accelerating GMP Readiness](https://www.pharmaadvancement.com/facilities-operation/facility-commissioning-excellence-accelerating-gmp-readiness/) - Facility commissioning excellence accelerating GMP readiness streamlines validation, startup activities and compliance outcomes across global manufacturing.
- [Cybersecurity Strategies Protecting Connected Pharma Plants](https://www.pharmaadvancement.com/market-moves/cybersecurity-strategies-protecting-connected-pharma-plants/) - Cybersecurity strategies protecting connected pharma plants strengthen OT security, safeguard data and reduce operational risks across manufacturing.
- [Modular Biopharma Facilities Accelerating Capacity Growth](https://www.pharmaadvancement.com/market-moves/modular-biopharma-facilities-accelerating-capacity-growth/) - Modular biopharma facilities accelerating capacity growth enable faster deployment, scalable production and operational agility worldwide today at scale in.
- [Integrated Contamination Control Enhancing Sterile Operations](https://www.pharmaadvancement.com/market-moves/integrated-contamination-control-enhancing-sterile-operations/) - Integrated contamination control enhancing sterile operations improves sterility assurance, monitoring and regulatory compliance globally in pharma sectors.
- [Pharma Facility Decarbonization Driving Net Zero Goals](https://www.pharmaadvancement.com/market-moves/pharma-facility-decarbonization-driving-net-zero-goals/) - Pharma facility decarbonization advancing sustainability goals reduces emissions, improves efficiency and supports ESG targets across pharma sites worldwide.
- [Advanced Environmental Monitoring for Sterility Control](https://www.pharmaadvancement.com/market-moves/advanced-environmental-monitoring-for-sterility-control/) - Advanced environmental monitoring reinforcing sterility assurance improves contamination detection and GMP compliance across sterile manufacturing facility.
- [Supply Chain Risk Mapping Strengthening Pharma Operations](https://www.pharmaadvancement.com/market-moves/supply-chain-risk-mapping-strengthening-pharma-operations/) - Supply chain risk mapping strengthening pharma operations improves resilience, continuity planning and operational agility across global supply networks now.
- [Knowledge Management Systems Strengthening GMP Compliance](https://www.pharmaadvancement.com/market-moves/knowledge-management-systems-strengthening-gmp-compliance/) - Knowledge management systems strengthening GMP compliance improve decision making, training effectiveness and inspection readiness across GMP plants.
- [Single Use Facility Design Supporting Biopharma Agility](https://www.pharmaadvancement.com/market-moves/single-use-facility-design-supporting-biopharma-agility/) - Single use facility design supporting biopharma agility enhances flexibility, reduces changeovers and boosts efficiency in modern biomanufacturing at scale.
- [Digital Validation Platforms Streamlining Facility Qualification](https://www.pharmaadvancement.com/market-moves/digital-validation-platforms-streamlining-facility-qualification/) - Digital validation platforms streamlining facility qualification improve compliance documentation accuracy and validation speed in GMP manufacturing operations.
- [Energy Resilient Cleanrooms Reducing Operational Risk](https://www.pharmaadvancement.com/market-moves/energy-resilient-cleanrooms-reducing-operational-risk/) - Energy resilient cleanrooms reducing operational risk improve uptime, energy efficiency and sterile manufacturing reliability in pharma facilities at sites.
- [Pharma Utility Redundancy Improving Business Continuity](https://www.pharmaadvancement.com/market-moves/pharma-utility-redundancy-improving-business-continuity/) - Pharma utility redundancy improving business continuity minimizes disruptions, protects production and strengthens resilience across manufacturing operations.
- [Flexible Manufacturing Facilities Supporting Cell Therapies](https://www.pharmaadvancement.com/market-moves/flexible-manufacturing-facilities-supporting-cell-therapies/) - Flexible manufacturing facilities supporting cell therapies enable adaptable production, scalability and faster commercialization in pharma plants at scale.
- [Utility Digitization Strengthening Pharma Resilience](https://www.pharmaadvancement.com/market-moves/utility-digitization-strengthening-pharma-resilience/) - Utility digitization strengthening pharma resilience improves utility monitoring, uptime, efficiency and business continuity across plants in modern pharma.
- [Advancing Concussion Care Through Intranasal Therapeutics: A New Frontier in CNS Drug Delivery](https://www.pharmaadvancement.com/market-moves/advancing-concussion-care-through-intranasal-therapeutics-a-new-frontier-in-cns-drug-delivery/) - Intranasal drug delivery may transform concussion treatment through rapid CNS access, neuroprotection, earlier intervention and improved patient outcomes.
- [Z-Library and the Reduction of Uninformed Medical Decisions](https://www.pharmaadvancement.com/pharma-news/z-library-and-the-reduction-of-uninformed-medical-decisions/) - Explore how Z-Library enhances health literacy and reduces uninformed medical decisions through accessible research and evidence-based reading habits.
- [Top Picks: GMP Training Companies Elevating North American Pharma Standards](https://www.pharmaadvancement.com/pharma-news/top-picks-gmp-training-companies-elevating-north-american-pharma-standards/) - Discover leading GMP training companies in North America helping pharma teams meet FDA, EMA standards with expert-led, flexible programs.
- [Nanoparticle-Based Techniques Advancing Pharma Formulations](https://www.pharmaadvancement.com/articles/nanoparticle-based-techniques-advancing-pharma-formulations/) - The innovative nanoparticle-based techniques are advancing the pharmaceutical formulations development for a more effective and safer treatment choices.
- [7 Overlooked Generative AI Database Platforms That Top Lab Scientists Rely On](https://www.pharmaadvancement.com/pharma-trends/7-overlooked-generative-ai-database-platforms-that-top-lab-scientists-rely-on/) - Discover 7 overlooked generative AI research databases that top scientists use to speed drug discovery, enhance lab efficiency, and unlock medical breakthroughs
- [How Research Facilities Transform Unused Equipment Into Working Capital](https://www.pharmaadvancement.com/articles/how-research-facilities-transform-unused-equipment-into-working-capital/) - Explore the best ways to sell your used lab freeze dryer—compare auctions, consignment options and trusted dealers offering fair prices and quick transactions.
- [Who Are the Major Players Producing Single-Use Bag Manifolds?](https://www.pharmaadvancement.com/articles/who-are-the-major-players-producing-single-use-bag-manifolds/) - Discover top single-use bag manifold suppliers for sterile fluid transfer in biopharma, with insights on GMP compliance, design flexibility and quality.
- [Why Standardizing Lab Water Quality is Crucial for Global Pharma R&D](https://www.pharmaadvancement.com/articles/why-standardizing-lab-water-quality-is-crucial-for-global-pharma-rd/) - Standardized lab water quality ensures reliable pharmaceutical R&D using purification systems, accurate testing equipment and global compliance standards.
- [Syneos Health Eyes Commercial Precision with AI Partnerships](https://www.pharmaadvancement.com/press-statements/syneos-health-eyes-commercial-precision-with-ai-partnerships/) - AI partnerships drive Syneos Health’s expanded AI ecosystem, enhancing HCP engagement, accelerating commercial precision, and optimizing biopharma performance.
- [FABRX M3DIMAKER Enables Scalable Automated Capsule Filling](https://www.pharmaadvancement.com/press-statements/fabrx-m3dimaker-enables-scalable-automated-capsule-filling/) - FABRX M3DIMAKER demonstrates automated pharmaceutical 3D printing in precision medicine reaching production of over 10,000 personalized capsules in 24 hours.
- [Going in-depth on proprietary analytical tools by nVentic](https://www.pharmaadvancement.com/interviews/going-in-depth-on-proprietary-analytical-tools-by-nventic/) - Interview with Matthew Bardell, MD at nVentic who talks about proprietary analytical tools and how helpful they have been in serving pharma manufacturing.
- [Bluesight, Pharma Logistics Expand Pharmacy Solutions Access](https://www.pharmaadvancement.com/press-statements/bluesight-pharma-logistics-expand-pharmacy-solutions-access/) - Bluesight and Pharma Logistics expand pharmacy solutions access through a financing model partnership using medication return credits for technology purchase.
- [Bluesight Aims Efficiency with Redesigned 340BCheck Platform](https://www.pharmaadvancement.com/press-statements/bluesight-aims-efficiency-with-redesigned-340bcheck-platform/) - Bluesight has unveiled the redesigned 340BCheck platform to support covered entities strengthen compliance, audit readiness, and protect their 340B programs.
- [Mettler-Toledo Showcases Proven Product Inspection Solutions for Pharmaceutical Manufacturing at Interpack](https://www.pharmaadvancement.com/press-statements/mettler-toledo-showcases-proven-product-inspection-solutions-for-pharmaceutical-manufacturing-at-interpack/) - Mettler Toledo showcases AI driven inspection systems for pharma manufacturing with x ray detection, precision weighing and compliance support worldwide.
- [How To Reduce Sample Interference in CLIA Assays Effectively](https://www.pharmaadvancement.com/pharma-news/how-to-reduce-sample-interference-in-clia-assays-effectively/) - Discover practical methods to reduce sample interference in CLIA assays, improving accuracy across hemolyzed, lipemic, and icteric samples.
- [LogiPharma 2026 Delivers Landmark Edition Marked by Engagement, Innovation and Practical Progress](https://www.pharmaadvancement.com/press-statements/logipharma-2026-delivers-landmark-edition-marked-by-engagement-innovation-and-practical-progress/) - Over 2,300 life sciences professionals converged in Vienna for LogiPharma 2026, tackling AI realism, cold chain innovation and supply chain resilience.
- [Injectable Drug Delivery Systems Advancing Therapeutics](https://www.pharmaadvancement.com/market-moves/injectable-drug-delivery-systems-advancing-therapeutics/) - Injectable drug delivery systems advance therapeutics with precision dosing, rapid action and improved efficacy across complex treatment applications.
- [Personalized Drug Delivery Enabling Precision Therapeutics](https://www.pharmaadvancement.com/market-moves/personalized-drug-delivery-enabling-precision-therapeutics/) - Personalized drug delivery enables precision therapeutics with tailored treatments, targeted delivery, and improved patient-specific outcomes across care.
- [Oral Drug Delivery Innovations Enhancing Patient Outcomes](https://www.pharmaadvancement.com/market-moves/oral-drug-delivery-innovations-enhancing-patient-outcomes/) - Oral drug delivery innovations enhance patient outcomes through improved absorption, bioavailability and patient-friendly dosage forms across therapies.
- [Controlled Release Formulations Improving Drug Efficacy](https://www.pharmaadvancement.com/market-moves/controlled-release-formulations-improving-drug-efficacy/) - Analyze controlled release formulations improving drug efficacy with sustained delivery, optimized dosing and enhanced patient compliance in pharma treatments.
- [Biologics Formulation Challenges and Innovative Solutions](https://www.pharmaadvancement.com/market-moves/biologics-formulation-challenges-and-innovative-solutions/) - Address biologics formulation challenges and innovative solutions focusing on stability, delivery systems and scalable manufacturing in global biopharma now.
- [Nanotechnology Drug Delivery Driving Precision Medicine](https://www.pharmaadvancement.com/market-moves/nanotechnology-drug-delivery-driving-precision-medicine/) - Discover nanotechnology drug delivery driving precision medicine with targeted therapies, improved efficacy, and reduced toxicity in advanced pharma systems.
- [Advanced Drug Delivery Systems Transforming Modern Therapies](https://www.pharmaadvancement.com/market-moves/advanced-drug-delivery-systems-transforming-modern-therapies/) - Explore advanced drug delivery systems transforming modern therapies through targeted delivery, controlled release and bioavailability in pharma development.
- [Novel Formulation Strategies Enhancing Drug Stability](https://www.pharmaadvancement.com/market-moves/novel-formulation-strategies-enhancing-drug-stability/) - Review novel formulation strategies enhancing drug stability via excipient innovation, improved shelf life and optimized performance in pharma products today.
- [Andelyn-ENCell Partner On Global Delivery of Gene Therapies](https://www.pharmaadvancement.com/press-statements/andelyn-encell-partner-on-global-delivery-of-gene-therapies/) - Andelyn Biosciences from US, ENCell from South Korea have partnered on manufacturing corridor between US-APAC regions for global delivery of gene therapies.
- [NLRC5 ELISA Kit Advances Quantification Of Immune Biomarkers](https://www.pharmaadvancement.com/pharma-news/nlrc5-elisa-kit-advances-quantification-of-immune-biomarkers/) - Struggling with NLRC5 ELISA results? Discover common issues, practical fixes, and how to improve consistency and accuracy in your assay.
- [Syntegon Showcases Factory of Future at Interpack 2026](https://www.pharmaadvancement.com/press-statements/syntegon-showcases-factory-of-future-at-interpack-2026/) - Syntegon unveils AI-driven Factory of the Future solutions at Interpack 2026, featuring neXt, SVX and SynTiso for global pharma, biotech and food sectors.
- [How Water Quality Controls Strengthen Pharma Outcomes](https://www.pharmaadvancement.com/drug-development/how-water-quality-controls-strengthen-pharma-outcomes/) - Water quality controls strengthen pharma outcomes by ensuring consistency, minimizing risks, and supporting compliance in drug development and lab testing.
- [Consistent Lab Water Systems Strengthen Pharma Operations](https://www.pharmaadvancement.com/facilities-operation/consistent-lab-water-systems-strengthen-pharma-operations/) - Ensuring consistency in pharma lab water systems enhances testing accuracy, supports compliance, and strengthens global research outcomes in drug development.
- [Water Quality Shapes the Future of Global Drug Development](https://www.pharmaadvancement.com/drug-development/water-quality-shapes-the-future-of-global-drug-development/) - Water quality impacts global drug development by influencing data integrity, reproducibility, and compliance across pharma R&D, manufacturing, and QC labs.
- [Standardized Lab Water Drives Reliable Pharma Research](https://www.pharmaadvancement.com/drug-development/standardized-lab-water-drives-reliable-pharma-research/) - Standardizing lab water quality in pharma R&D improves data accuracy, regulatory compliance and reproducibility across global labs and drug development.
- [High Purity Water as a Pillar of Pharma Quality System](https://www.pharmaadvancement.com/manufacturing/high-purity-water-as-a-pillar-of-pharma-quality-system/) - High purity water as a pillar of pharma quality ensures reliable results, reducing contamination and supports regulatory standards in research and manufacturing
- [Immune Modulation Advances Through Nutraceutical Bioactives](https://www.pharmaadvancement.com/nutraceutical/immune-modulation-advances-through-nutraceutical-bioactives/) - Immune modulation through nutraceuticals like fucoidan supports balanced immunity reduces inflammation and enhances long term health resilience worldwide.
- [How Lab Water Standards Drive Reliable Pharma Testing](https://www.pharmaadvancement.com/facilities-operation/how-lab-water-standards-drive-reliable-pharma-testing/) - Lab water standards ensure reliable pharma testing by maintaining consistency, reducing contamination risks and supporting regulatory compliance in global labs.
- [Fucoidan in Gut Health Driving Microbiome Innovation](https://www.pharmaadvancement.com/nutraceutical/fucoidan-in-gut-health-driving-microbiome-innovation/) - Fucoidan supports gut health by modulating microbiome balance boosting SCFA production and reducing inflammation for better digestive health outcomes.
- [Fucoidan in Nutraceuticals Driving Clinical Innovation](https://www.pharmaadvancement.com/nutraceutical/fucoidan-in-nutraceuticals-driving-clinical-innovation/) - Fucoidan in nutraceuticals offers immune anti-inflammatory and antioxidant benefits supported by clinical research driving new therapeutic applications.
- [Marine-Derived Nutraceuticals Transform Modern Healthcare](https://www.pharmaadvancement.com/nutraceutical/marine-derived-nutraceuticals-transform-modern-healthcare/) - Marine-derived nutraceutical ingredients offer clinically backed health benefits driving innovation in preventive healthcare and sustainable solutions globally
- [Importance of Ingredient Sourcing in Dietary Supplements](https://www.pharmaadvancement.com/nutraceutical/importance-of-ingredient-sourcing-in-dietary-supplements/) - Ingredient sourcing in dietary supplements ensures quality safety and traceability while supporting compliance sustainability and reliable global supply chains.
- [Fucoidan Market Growth Opportunities for Pharma Brands](https://www.pharmaadvancement.com/nutraceutical/fucoidan-market-growth-opportunities-for-pharma-brands/) - Fucoidan market growth driven by rising demand for natural ingredients creates new opportunities for pharma nutraceutical and cosmetic companies worldwide.
- [Marine Nutraceuticals Driving Future Pharma Innovation](https://www.pharmaadvancement.com/nutraceutical/marine-nutraceuticals-driving-future-pharma-innovation/) - Marine nutraceuticals from algae and sea sources drive pharma innovation with sustainable bioactives supporting immunity cardiovascular and therapeutic health.
- [Eli Lilly GLP-1 Diabetes and Obesity Drug Drive China Pledge](https://www.pharmaadvancement.com/manufacturing/eli-lilly-glp-1-diabetes-and-obesity-drug-drive-china-pledge/) - GLP-1 diabetes and obesity drug from Eli Lilly are real reason why company is betting on $3bn investment in China which is a thriving market in this domain.
- [Women’s HealthX 2026 Event Launches in Boston this December](https://www.pharmaadvancement.com/press-statements/womens-healthx-2026-event-launches-in-boston-this-december/) - Women’s HealthX 2026(WoHX) in Boston gathers 750 global leaders with 150+ speakers, AI demos, policy talks and networking to advance women’s health innovation.
- [Next Generation Lipids Redefine LNP Formulation Strategies](https://www.pharmaadvancement.com/drug-development/next-generation-lipids-redefine-lnp-formulation-strategies/) - Next generation lipids in LNP formulation redefine delivery efficiency, improve safety profiles, enhance tissue targeting and support innovative RNA therapies.
- [Quality by Design Drives Robust LNP Manufacturing](https://www.pharmaadvancement.com/drug-development/quality-by-design-drives-robust-lnp-manufacturing/) - Quality by Design in LNP manufacturing strengthens risk management, ensures process consistency and supports scalable, compliant RNA drug production globally.
- [Targeted Delivery Advances Transform LNP Platforms](https://www.pharmaadvancement.com/drug-development/targeted-delivery-advances-transform-lnp-platforms/) - Targeted delivery advances in LNP platforms improve tissue specificity, biodistribution control and enhance therapeutic performance in precision medicine.
- [Navigating Regulatory Pathways for LNP Drug Products](https://www.pharmaadvancement.com/drug-development/navigating-regulatory-pathways-for-lnp-drug-products/) - Regulatory pathways for LNP drug products define quality standards, safety data, CMC requirements and global approval strategies for RNA-based therapeutics.
- [LNP Stability Studies Strengthens RNA Therapeutics](https://www.pharmaadvancement.com/drug-development/research-development/lnp-stability-studies-strengthens-rna-therapeutics/) - LNP stability testing for RNA therapeutics enhance shelf life, strengthen cold chain performance, and improve formulation robustness for global distribution.
- [LNP Formulation Strategies Advancing mRNA Drug Delivery](https://www.pharmaadvancement.com/drug-development/lnp-formulation-strategies-advancing-mrna-drug-delivery/) - LNP formulation strategies for mRNA drug delivery improve stability, enhance encapsulation efficiency, enable scale-up and support regulatory readiness.
- [Microfluidics Technologies in Lipid Nanoparticle Production](https://www.pharmaadvancement.com/drug-development/microfluidics-technologies-in-lipid-nanoparticle-production/) - Microfluidics technologies in lipid nanoparticle production enables precise mixing control, reproducible particle size and scalable process development.
- [Advanced Analytics Transform LNP Characterization](https://www.pharmaadvancement.com/drug-development/research-development/advanced-analytics-transform-lnp-characterization/) - Advanced analytics in LNP characterization strengthen particle profiling, encapsulation analysis and regulatory data integrity for RNA drug approval.
- [Scalable mRNA Manufacturing Enabled by LNP Platforms](https://www.pharmaadvancement.com/manufacturing/scalable-mrna-manufacturing-enabled-by-lnp-platforms/) - Scalable mRNA manufacturing enabled by LNP platforms supports robust formulation, controlled particle size distribution and commercial production efficiency.
- [Optimizing Lipid Nanoparticle Process Development Strategies](https://www.pharmaadvancement.com/manufacturing/optimizing-lipid-nanoparticle-process-development-strategies/) - Optimizing lipid nanoparticle process development improves particle size control, reproducibility, scalable production and quality compliance in RNA therapies.
- [Advanced Separation and Filtration Systems Drive Efficiency](https://www.pharmaadvancement.com/drug-development/advanced-separation-and-filtration-systems-drive-efficiency/) - Advanced separation and filtration systems enhance product purity, contamination control, solvent recovery and high-efficiency drug processing performance.
- [Innovating Bioprocesses for Modular Pharma Facilities](https://www.pharmaadvancement.com/drug-development/innovating-bioprocesses-for-modular-pharma-facilities/) - Innovations of bioprocess for modular pharma facilities are boosting biologics production with flexible cleanrooms, single-use systems and scalable designs.
- [Driving Digital Transformation in Pharma Operations 2026](https://www.pharmaadvancement.com/drug-development/driving-digital-transformation-in-pharma-operations-2026/) - Digital transformation in pharma operations enables data integrity, AI driven analytics, smart quality systems and connected pharma manufacturing workflows.
- [Process Analytical Technology Driving Pharma Innovation](https://www.pharmaadvancement.com/drug-development/process-analytical-technology-driving-pharma-innovation/) - Process analytical technology in pharma enhances real-time monitoring, quality control, regulatory compliance and risk-based manufacturing efficiency today.
- [Future-Ready GMP Strengthens Regulatory Compliance](https://www.pharmaadvancement.com/drug-development/future-ready-gmp-strengthens-regulatory-compliance/) - Future-ready GMP and regulatory compliance strengthen data integrity, inspection readiness, quality assurance and alignment with global pharma standards.
- [Hydrogen and Clean Energy Transforming Pharma Industry](https://www.pharmaadvancement.com/drug-development/hydrogen-and-clean-energy-transforming-pharma-industry/) - Hydrogen and clean energy in pharma enable decarbonization, sustainable utilities, green steam generation and low-emission operations across facilities globally
- [Smart Pharma Plants are Leading the Industry 4.0 Era](https://www.pharmaadvancement.com/drug-development/smart-pharma-plants-are-leading-the-industry-4-0-era/) - Smart pharma plants and Industry 4.0 integrate IoT sensors, robotics, predictive maintenance and advanced data analytics to enable efficient production now.
- [Continuous Manufacturing Transforming Drug Production 2026](https://www.pharmaadvancement.com/drug-development/continuous-manufacturing-transforming-drug-production-2026/) - Continuous manufacturing in drug production enhances efficiency, product quality, regulatory compliance and cost control across modern pharma facilities.
- [Sustainable Manufacturing Strategies Shaping Pharma Future](https://www.pharmaadvancement.com/drug-development/sustainable-manufacturing-strategies-shaping-pharma-future/) - Sustainable pharma manufacturing strategies cut carbon emissions, energy use, solvent waste and water consumption across global drug production facilities.
- [Future of Advanced Pharma Manufacturing Technologies 2026](https://www.pharmaadvancement.com/drug-development/future-of-advanced-pharma-manufacturing-technologies-2026/) - Advanced pharma manufacturing technologies in 2026 are enabling smart factories, automation, digital twins and continuous processing across drug production.
- [The 5th LNP Summit: Featuring End-to-End Tracks, Pre-Conference Workshops and Team Discounts](https://www.pharmaadvancement.com/press-statements/the-5th-lnp-summit-featuring-end-to-end-tracks-pre-conference-workshops-and-team-discounts/) - LNP Summit 2026 is featuring global end-to-end LNP development insights, expert tracks, practical hands-on workshops, scale-up strategies and group discounts.
- [ACHEMA Middle East Sets the Stage for the Next Era of Process Industry Growth](https://www.pharmaadvancement.com/press-statements/achema-middle-east-sets-the-stage-for-the-next-era-of-process-industry-growth/) - ACHEMA Middle East 2026 debuts in Riyadh, connecting global process, pharma, lab, digital and energy leaders across the MEASA industrial ecosystem.
- [TrumpRx Direct-To-Consumer Drug Site Launches in the US](https://www.pharmaadvancement.com/pharma-news/trumprx-direct-to-consumer-drug-site-launches-in-the-us/) - The TrumpRx direct-to-consumer drug site launches in the US, linking patients to cash-pay discounts while raising questions over savings for insured Americans.
- [Supply Chain Considerations for Single-Use Bioprocess Systems](https://www.pharmaadvancement.com/packaging-logistic/supply-chain-considerations-for-single-use-bioprocess-systems/) - Supply chain planning for single-use bioprocess systems focuses on material availability, supplier qualification and resilience for critical manufacturing needs
- [Automation Readiness of Single-Use Fluid Handling Platforms](https://www.pharmaadvancement.com/pharma-trends/automation-readiness-of-single-use-fluid-handling-platforms/) - Automation readiness of single-use fluid handling platforms is enabling better process control, data integration and repeatability in modern manufacturing lines
- [Sustainability Progress in Disposable Bioprocess Technologies](https://www.pharmaadvancement.com/pharma-trends/sustainability-progress-in-disposable-bioprocess-technologies/) - Regulatory expectations for single-use bioprocess equipment focus on extractables testing, strong validation and consistent quality across production runs.
- [Regulatory Expectations for Single-Use Bioprocess Equipment](https://www.pharmaadvancement.com/manufacturing/regulatory-expectations-for-single-use-bioprocess-equipment/) - Regulatory expectations for single-use bioprocess equipment emphasize extractables testing, validation documentation and consistent quality across production.
- [Customization Strategies in Single-Use Bag Manifold Design](https://www.pharmaadvancement.com/pharma-trends/customization-strategies-in-single-use-bag-manifold-design/) - Customization strategies in single-use bag manifold design allow manufacturers to align fluid paths, volumes and connectors with specific process requirements.
- [Single-Use Bag Manifolds Shaping Bioprocess Operations](https://www.pharmaadvancement.com/pharma-trends/single-use-bag-manifolds-shaping-bioprocess-operations/) - Single-use bag manifolds are transforming bioprocess operations by improving flexibility, sterility assurance and scalable fluid handling in drug manufacturing.
- [Sterility and Risk Control in Disposable Bioprocess Assemblies](https://www.pharmaadvancement.com/pharma-trends/sterility-and-risk-control-in-disposable-bioprocess-assemblies/) - Sterility and risk control in disposable bioprocess assemblies help manufacturers reduce contamination events while meeting stringent regulatory expectations.
- [Scaling Biologics with Single-Use Fluid Handling Systems](https://www.pharmaadvancement.com/manufacturing/scaling-biologics-with-single-use-fluid-handling-systems/) - Scaling biologics with single-use fluid handling supports flexible manufacturing, reduces validation burden and enables faster capacity expansion in facilities.
- [Design Trends Driving Next-Generation Bag Manifold Systems](https://www.pharmaadvancement.com/pharma-trends/design-trends-driving-next-generation-bag-manifold-systems/) - Design trends driving next-generation bag manifold systems focus on modularity, automation readiness and improved flow control for advanced bioprocess workflows
- [Fluid Transfer Innovation in Single-Use Biomanufacturing](https://www.pharmaadvancement.com/manufacturing/fluid-transfer-innovation-in-single-use-biomanufacturing/) - Fluid transfer innovation in single use biomanufacturing enables faster changeovers, contamination control and operational efficiency in biologics production.
- [DHL Health Logistics Singapore Invests in €10m Pharma Hub](https://www.pharmaadvancement.com/pharma-news/dhl-health-logistics-singapore-invests-in-e10m-pharma-hub/) - DHL Health Logistics Singapore expands operations with a new pharma hub, boosting life sciences infrastructure and healthcare logistics across Asia-Pacific.
- [Lupin and TB Alliance Partner to Advance Telacebec Treatment](https://www.pharmaadvancement.com/drug-development/lupin-and-tb-alliance-partner-to-advance-telacebec-treatment/) - Lupin and TB Alliance announce a tie up to advance Telacebec for tuberculosis and mycobacterial diseases, focusing on clinical development and global access.
- [AI Enabled Forecasting in Pharmaceutical Supply Chains](https://www.pharmaadvancement.com/packaging-logistic/ai-enabled-forecasting-in-pharmaceutical-supply-chains/) - Discover how AI-enabled forecasting in pharma supply chains uses machine learning and predictive analytics to improve demand accuracy and optimize inventory.
- [Digital Transformation Redefining Pharma Logistics Operations](https://www.pharmaadvancement.com/packaging-logistic/digital-transformation-redefining-pharma-logistics-operations/) - Explore how digital transformation in pharma logistics improves visibility, predictive planning, automation and decision-making across complex supply networks.
- [Sustainability Strategies Across Pharma Logistics and Packaging](https://www.pharmaadvancement.com/packaging-logistic/sustainability-strategies-across-pharma-logistics-and-packaging/) - Explore sustainability strategies in pharma logistics reshaping packaging and transport to reduce emissions and improve ESG performance across the supply chain.
- [Data Driven Planning in Pharmaceutical Supply Networks](https://www.pharmaadvancement.com/packaging-logistic/data-driven-planning-in-pharmaceutical-supply-networks/) - Explore how data driven planning enables pharmaceutical supply networks to improve demand forecasting, inventory optimization, risk visibility and performance.
- [Cold Chain Innovation for Temperature Sensitive Medicines](https://www.pharmaadvancement.com/packaging-logistic/cold-chain-innovation-for-temperature-sensitive-medicines/) - Discover Cold chain innovation strengthening temperature control, monitoring and compliance for sensitive medicines across pharma manufacturing networks.
- [Pharma Supply Chain Resilience in a Volatile Global Market](https://www.pharmaadvancement.com/manufacturing/pharma-supply-chain-resilience-in-a-volatile-global-market/) - Explore how pharma supply chain resilience strategies evolve to manage volatility, sourcing disruptions and ensure operational continuity across global markets.
- [NVIDIA and Lilly AI Lab All Set to Transform Drug Discovery](https://www.pharmaadvancement.com/pharma-news/nvidia-and-lilly-ai-lab-all-set-to-transform-drug-discovery/) - NVIDIA and Lilly AI lab launches in the Bay Area, with up to $1billion investment to apply AI, computing and data to accelerate drug discovery and development.
- [Abalone and Pfizer Partner on Rare Activating Antibodies](https://www.pharmaadvancement.com/pharma-news/abalone-and-pfizer-partner-on-rare-activating-antibodies/) - Abalone and Pfizer are getting into a research collaboration to work on rare activating antibodies where the former is going to apply its FAST platform.
- [Samsung Bioepis Starts Direct Commercialization of Byooviz](https://www.pharmaadvancement.com/pharma-news/samsung-bioepis-starts-direct-commercialization-of-byooviz/) - Samsung Bioepis has gone on to initiate the direct commercialization of Byooviz which is a single-use vial for intravitreal administration throughout Europe.
- [Daiichi Sankyo Plans to Boost Its Antibody-Drug Conjugate](https://www.pharmaadvancement.com/manufacturing/daiichi-sankyo-plans-to-boost-its-antibody-drug-conjugate/) - Daiichi Sankyo is planning to invest around $1.9bn in expanding its antibody-drug conjugate Enhertu with a view to penetrate it across many countries.
- [Hengrui Pharma Inks 20-Year Licensing Agreement with Hansoh](https://www.pharmaadvancement.com/pharma-news/hengrui-pharma-inks-20-year-licensing-agreement-with-hansoh/) - Hengrui Pharma has signed a 20-year licensing agreement with Hansoh Pharma for development, commercialization of specific drug products in mainland China.
- [U.S. FDA Approves Weight Loss Pill from Novo Nordisk](https://www.pharmaadvancement.com/pharma-news/u-s-fda-approves-weight-loss-pill-from-novo-nordisk/) - FDA approval of the Weight Loss Pill from Novo Nordisk marks a milestone for oral obesity treatment, expanding access and strengthening current market position
- [U.S. FDA Approves Bispecific Lunsumio VELO™ by Roche](https://www.pharmaadvancement.com/pharma-news/u-s-fda-approves-bispecific-lunsumio-velo-by-roche/) - Bispecific Lunsumio VELO by Roche has got U.S. FDA approval as a subcutaneous (SC) formulation for adult patients with refractory R/R follicular lymphoma.
- [Boehringer Ingelheim Moves to Lower Costs for Medicines in the U.S.](https://www.pharmaadvancement.com/pharma-news/boehringer-ingelheim-moves-to-lower-costs-for-medicines-in-the-u-s/) - Boehringer Ingelheim has announced a broad agreement with the U.S. government to offer lower costs for medicines and also expand its U.S. footprint.
- [Samsung Biologics Acquires GSK’s Human Genome Sciences Site in U.S.](https://www.pharmaadvancement.com/pharma-news/samsung-biologics-acquires-gsks-human-genome-sciences-site-in-u-s/) - Samsung Biologics HGS Acquisition strengthens US manufacturing after agreeing to acquire 100% of Human Genome Sciences from GSK, adding cGMP biologics capacity.
- [Cytokinetics Secures First FDA Approval With Myqorzo Heart Drug](https://www.pharmaadvancement.com/pharma-news/cytokinetics-secures-first-fda-approval-with-myqorzo-heart-drug/) - Cytokinetics Myqorzo FDA approval gives the biotech its first approved therapy, positioning Myqorzo against Camzyos in obstructive hypertrophic cardiomyopathy
- [Thermo Fisher launches Alzheimers Disease Registry](https://www.pharmaadvancement.com/pharma-news/thermo-fisher-launches-alzheimers-disease-registry/) - Thermo Fisher Scientific has launched the Alzheimers Disease Registry with an intent to generate strong, real-time data to assess drug safety, effectiveness.
- [Meiji Seika Pharma, MBC BioLabs Drug Discovery Partnership](https://www.pharmaadvancement.com/pharma-news/meiji-seika-pharma-mbc-biolabs-drug-discovery-partnership/) - Meiji Seika Pharma, MBC BioLabs partnership strengthens drug discovery collaboration, expands access to biotech startups, and supports R&D engagement globally
- [Astellas Pharma, Autobahn Labs Partnership Strengthens R&D](https://www.pharmaadvancement.com/pharma-news/astellas-pharma-autobahn-labs-partnership-strengthens-rd/) - Astellas Pharma and Autobahn Labs partnership gives Astellas visibility, investment access and licensing options for early academic drug discovery programs
- [Zealand Pharma, OTR Therapeutics Sign Collaboration Deal](https://www.pharmaadvancement.com/pharma-news/zealand-pharma-otr-therapeutics-sign-collaboration-deal/) - Zealand Pharma, OTR Therapeutics sign collaboration to develop metabolic disease therapies, combining obesity expertise with proprietary discovery platforms
- [FDA Approves Inebilizumab-cdon for gMG Treatment in Adults](https://www.pharmaadvancement.com/pharma-news/fda-approves-inebilizumab-cdon-for-gmg-treatment-in-adults/) - FDA approves inebilizumab-cdon for Generalized Myasthenia Gravis following MINT trial results showing reduced disease activity and twice-yearly dosing regimen
- [Risk-Based Quality Management Strengthened by Predictive Digital Tools](https://www.pharmaadvancement.com/market-moves/risk-based-quality-management-strengthened-by-predictive-digital-tools/) - Explore risk-based quality management using predictive digital tools, shifting from reactive to proactive assurance with real-time dashboards and automation.
- [Emerging Paradigms Reshaping Pharma Manufacturing Efficiency](https://www.pharmaadvancement.com/manufacturing/emerging-paradigms-reshaping-pharma-manufacturing-efficiency/) - Explore efficient pharma manufacturing via automation, human–machine collaboration and continuous processing, modernizing facilities with compliance.
- [Building a Future-Ready Digital Workforce for the Next Era of Pharma Innovation](https://www.pharmaadvancement.com/market-moves/building-a-future-ready-digital-workforce-for-the-next-era-of-pharma-innovation/) - Explore how pharmaceutical companies build future-ready digital workforces, enhancing digital literacy, data skills and leadership for Industry 4.0 innovation.
- [Advanced Process Equipment Enhancing Manufacturing Consistency](https://www.pharmaadvancement.com/manufacturing/advanced-process-equipment-enhancing-manufacturing-consistency/) - Explore advanced pharmaceutical equipment innovations, exploring mixing, filtration and separation technologies that boost consistency and reduce variability.
- [Green Chemistry Applications Driving Sustainable Process Development](https://www.pharmaadvancement.com/drug-development/green-chemistry-applications-driving-sustainable-process-development/) - Discover sustainable pharmaceutical manufacturing using green chemistry to reduce solvents, minimize waste and optimize reactions while ensuring compliance.
- [Digital Twins Enabling Predictive Control in Pharma Manufacturing](https://www.pharmaadvancement.com/market-moves/digital-twins-enabling-predictive-control-in-pharma-manufacturing/) - Explore how digital twins transform pharma manufacturing through real-time simulation and predictive control, enhancing reliability and optimizing operations.
- [Artificial Intelligence Advancing Process Optimization in Drug Production](https://www.pharmaadvancement.com/market-moves/artificial-intelligence-advancing-process-optimization-in-drug-production/) - Explore how AI and machine learning optimize pharmaceutical production, improving yields, detecting anomalies and enabling predictive modeling in manufacturing.
- [Smart Factory Architectures Driving Efficiency in Pharma Plants](https://www.pharmaadvancement.com/facilities-operation/smart-factory-architectures-driving-efficiency-in-pharma-plants/) - Discover how smart factory architectures optimize pharmaceutical manufacturing with IoT sensors, automation and real-time monitoring to boost efficiency.
- [FDA Approval of Gonorrhea Medications Broadens Oral Options](https://www.pharmaadvancement.com/pharma-news/fda-approval-of-gonorrhea-medications-broadens-oral-options/) - FDA approval of gonorrhea medications covers two oral therapies for uncomplicated urogenital infection, offering alternatives to injectable treatment regimens
- [Sustainable Manufacturing Strategies Driving the Pharma Sector Toward Net-Zero](https://www.pharmaadvancement.com/drug-development/sustainable-manufacturing-strategies-driving-the-pharma-sector-toward-net-zero/) - Discover how pharmaceutical manufacturers achieve net-zero goals through energy optimization, waste reduction, and solvent recovery. Balance sustainability with
- [FDA Takes Steps to Decrease Animal Testing of New Medicines](https://www.pharmaadvancement.com/pharma-news/fda-takes-steps-to-decrease-animal-testing-of-new-medicines/) - To stop or decrease animal testing of new medicines targeted at stopping toxicity studies of monoclonal antibody-based drugs, FDA has published guidance.
- [FDA to Move Towards Single Clinical Study for Approvals](https://www.pharmaadvancement.com/pharma-news/fda-to-move-towards-single-clinical-study-for-approvals/) - FDA is looking to move towards single clinical study for drugs and other medical products for approvals and looks to establish a fresh default benchmark.
- [Cencora Continues Its Investment in Third-Party Logistics](https://www.pharmaadvancement.com/pharma-news/cencora-continues-its-investment-in-third-party-logistics/) - Cencora is continuing with its investment in third-party logistics across the U.S. and Europe to grow into specialty logistics offerings for pharma companies.
- [Lilly, IU Deepen Work on Clinical Trial Innovation Ecosystem](https://www.pharmaadvancement.com/facilities-operation/lilly-iu-deepen-work-on-clinical-trial-innovation-ecosystem/) - A five-year partnership between Lilly and IU aims to expand trial access, boost Alzheimer’s research and strengthen the clinical trial innovation ecosystem.
- [IQVIA Names AWS as Preferred Agentic Cloud Provider](https://www.pharmaadvancement.com/drug-development/iqvia-names-aws-as-preferred-agentic-cloud-provider/) - IQVIA has announced strategic collaboration with AWS naming it as the Preferred Agentic Cloud Provider thereby leading to digital transformation of healthcare.
- [CDMO-CRDO Partner For Requirements of the Biologics Market](https://www.pharmaadvancement.com/manufacturing/cdmo-crdo-partner-for-requirements-of-the-biologics-market/) - In order to cater to the requirements of the biologics market, Rentschler Biopharma and Coriolis Pharma have gone on to announce a strategic collaboration.
- [US-UK Zero Tariff Deal Reshapes Pharmaceutical Trade Landscape](https://www.pharmaadvancement.com/pharma-news/us-uk-zero-tariff-deal-reshapes-pharmaceutical-trade-landscape/) - The US and UK Zero Tariff Deal lifts duties on UK pharmaceutical exports for three years as the UK adjusts NHS pricing thresholds to boost access to medicines.
- [PLI Incentives Aim to Accelerate API Manufacturing in India](https://www.pharmaadvancement.com/manufacturing/pli-incentives-aim-to-accelerate-api-manufacturing-in-india/) - API manufacturing in India gains momentum as the PLI scheme opens for Meropenem and Ritonavir to cut import dependence and boost domestic drug supply security.
- [Researchers target HER1 receptor for peptide cancer vaccine, therapeutic agents](https://www.pharmaadvancement.com/pharma-news/researchers-target-her1-receptor-for-peptide-cancer-vaccine-therapeutic-agents/) - Small proteins called peptides that consist of 10 to 50 amino acids are being studied as cancer vaccines and as possibly safer, more effective and less costly alternatives to the monoclonal-antibody-based drugs and small-molecule inhibitors now used to treat many malignancies. Researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer
- [Studies suggest new key to 'switching off' hypertension](https://www.pharmaadvancement.com/pharma-news/studies-suggest-new-key-to-switching-off-hypertension/) - A team of University of California, San Diego researchers has designed new compounds that mimic those naturally used by the body to regulate blood pressure. The most promising of them may literally be the key to controlling hypertension, switching off the signaling pathways that lead to the deadly condition. Published online this month in Bioorganic
- [New plan of attack in cancer fight](https://www.pharmaadvancement.com/pharma-news/new-plan-of-attack-in-cancer-fight/) - New research conducted by Harvard scientists is laying out a road map to one of the holy grails of modern medicine: a cure for cancer. As described in a paper recently published in eLife, Martin Nowak, a professor of mathematics and of biology and director of the Program for Evolutionary Dynamics, and co-author Ivana Bozic,
- [Uncovering a healthier remedy for chronic pain](https://www.pharmaadvancement.com/pharma-news/uncovering-a-healthier-remedy-for-chronic-pain/) - Physicians and patients who are wary of addiction to pain medication and opioids may soon have a healthier and more natural alternative. A Duke University study revealed that a derivative of DHA (docosahexaenoic acid), a main ingredient of over-the-counter fish oil supplements, can sooth and prevent neuropathic pain caused by injuries to the sensory system.
- [FDA takes action to protect consumers from dangerous medicines sold by illegal online pharmacies](https://www.pharmaadvancement.com/pharma-news/fda-takes-action-to-protect-consumers-from-dangerous-medicines-sold-by-illegal-online-pharmacies/) - The U.S. Food and Drug Administration, in partnership with international regulatory and law enforcement agencies, took action this week against more than 9,600 websites that illegally sell potentially dangerous, unapproved prescription medicines to consumers. These actions include the issuance of regulatory warnings, and seizure of offending websites and $41,104,386 worth of illegal medicines worldwide. The
- [FDA obtains waiver from European Commission to facilitate export for U.S. pharmaceutical manufacturers](https://www.pharmaadvancement.com/pharma-news/fda-obtains-waiver-from-european-commission-to-facilitate-export-for-u-s-pharmaceutical-manufacturers/) - The U.S. Food and Drug Administration announced that the U.S. is now a "listed" countrydisclaimer icon with the European Commission (EC) so that U.S. companies need not obtain an export certificate from the FDA before shipping certain pharmaceutical products to Europe. Without the waiver, all U.S. companies shipping active pharmaceutical ingredients (APIs) to Europe after
- [Aspirin may fight cancer by slowing DNA damage](https://www.pharmaadvancement.com/pharma-news/aspirin-may-fight-cancer-by-slowing-dna-damage/) - Aspirin is known to lower risk for some cancers, and a new study led by a UC San Francisco scientist points to a possible explanation, with the discovery that aspirin slows the accumulation of DNA mutations in abnormal cells in at least one pre-cancerous condition. "Aspirin and other non-steroidal anti-inflammatory drugs, which are commonly available
- [Big multiple sclerosis breakthrough](https://www.pharmaadvancement.com/pharma-news/big-multiple-sclerosis-breakthrough/) - A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent, according to new Northwestern Medicine research. In MS, the immune system attacks and destroys myelin, the insulating
- [Nanotechnology could help fight diabetes](https://www.pharmaadvancement.com/pharma-news/nanotechnology-could-help-fight-diabetes/) - Injectable nanoparticles developed at Massachusetts Institute of Technology (MIT) may someday eliminate the need for patients with Type 1 diabetes to constantly monitor their blood-sugar levels and inject themselves with insulin. The nanoparticles were designed to sense glucose levels in the body and respond by secreting the appropriate amount of insulin, thereby replacing the function
- [Breakthrough in how pancreatic cancer cells ingest nutrients points to new drug target](https://www.pharmaadvancement.com/pharma-news/breakthrough-in-how-pancreatic-cancer-cells-ingest-nutrients-points-to-new-drug-target/) - In a landmark cancer study published online in Nature, researchers at NYU School of Medicine have unraveled a longstanding mystery about how pancreatic tumor cells feed themselves, opening up new therapeutic possibilities for a notoriously lethal disease with few treatment options. Pancreatic cancer kills nearly 38,000 Americans annually, making it a leading cause of cancer
- [US nets biggest penalties for fraud from pharma](https://www.pharmaadvancement.com/pharma-news/us-nets-biggest-penalties-for-fraud-from-pharma/) - The US crackdown on healthcare fraud is paying huge dividends to the exchequer, accounting for three quarters of the money recovered as penalties in fraud cases exposed by whistleblowers between 1987 and 2013-over $21 billion of the total $27 billion. Over half the whistleblower cases registered under the False Claims Act since 1987 were related
- [James C. Smith elected to Pfizer's Board of Directors](https://www.pharmaadvancement.com/pharma-news/james-c-smith-elected-to-pfizer-s-board-of-directors/) - Pfizer Inc. has announced the election of James C. Smith to its Board of Directors, effective immediately. Mr. Smith also was appointed to the Corporate Governance and Science and Technology Committees of Pfizer's Board. Mr. Smith, 54, is the President and Chief Executive Officer (CEO) of Thomson Reuters and serves on its Board of Directors.
- [Immune Design starts dosing patients in Phase I study of LV305 immuno-oncology agent](https://www.pharmaadvancement.com/drug-development/clinical-trials/immune-design-starts-dosing-patients-in-phase-i-study-of-lv305-immuno-oncology-agent/) - US-based Immune Design has started dosing patients in a Phase I clinical study of LV305, an immuno-oncology investigational agent from its DCVex lentiviral vector platform to treat patients with locally advanced, relapsed, or metastatic breast cancer, melanoma, non-small cell lung cancer, ovarian cancer or sarcoma. The company is focused on the development of novel immune-based
- [Edge Therapeutics begins enrolment in second cohort of EG-1962 Phase I/II trial for aSAH](https://www.pharmaadvancement.com/drug-development/clinical-trials/edge-therapeutics-begins-enrolment-in-second-cohort-of-eg-1962-phase-i-ii-trial-for-asah/) - US-based biotechnology firm Edge Therapeutics has started enrolling patients in the second group of a multicenter, randomised, controlled, open-label, Phase I/II NEWTON trial of its lead product candidate, EG-1962, for the treatment of patients with aneurysmal subarachnoid hemorrhage (aSAH). The NEWTON (Nimodipine microparticles to Enhance recovery While reducing TOxicity after subarachNoid hemorrhage) trial is designed
- [Arena begins Phase Ib trial of APD334 to treat autoimmune diseases](https://www.pharmaadvancement.com/drug-development/clinical-trials/arena-begins-phase-ib-trial-of-apd334-to-treat-autoimmune-diseases/) - US-based Arena Pharmaceuticals has started dosing patients in an investigational Phase Ib clinical trial of APD334, an oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor, to treat a number of autoimmune diseases. The randomised, double-blind and placebo-controlled trial is designed to evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of
- [Boston Therapeutics begins Phase IIb Sugardown trial for type 2 diabetes patients](https://www.pharmaadvancement.com/drug-development/clinical-trials/boston-therapeutics-begins-phase-iib-sugardown-trial-for-type-2-diabetes-patients/) - US-based Boston Therapeutics (BTI) has started a Phase IIb clinical trial SD-002 to evaluate the efficacy and safety of Sugardown in patients with type 2 diabetes taking metformin. Accumed Research Associates is conducting the 24-patient five-week, randomised, double-blind Phase IIb trial under the direction of principal investigator, Mitchell Efros. Sugardown is the company's currently marketed
- [Alexion begins multinational registration trials of eculizumab to treat NMO and MG](https://www.pharmaadvancement.com/pharma-news/alexion-begins-multinational-registration-trials-of-eculizumab-to-treat-nmo-and-mg/) - US-based Alexion Pharmaceuticals has started a single, multinational, placebo-controlled trial designed to assess the safety and efficacy of eculizumab (Soliris) in patients with relapsing neuromyelitis optica (NMO), a life-threatening, ultra-rare neurologic disorder. Primary objective of the multinational, double-blind, placebo-controlled trial is to evaluate the efficacy of eculizumab compared to placebo in patients with relapsing NMO,
- [Pfizer confirms £60bn bid interest in AstraZeneca](https://www.pharmaadvancement.com/pharma-news/pfizer-confirms-60bn-bid-interest-in-astrazeneca/) - US-based drug maker Pfizer has confirmed that it has contacted AstraZeneca seeking to renew discussions over a possible £60bn takeover. The discussions are regarding developing a proposal by both companies that could be recommended to their shareholders. In January, UK-based AstraZeneca discontinued talks with Pfizer regarding its initial approach over the acquisition. AstraZeneca has again
- [Eli Lilly's Cyramza becomes first FDA-approved gastric cancer drug](https://www.pharmaadvancement.com/drug-development/fda-approvals/eli-lilly-s-cyramza-becomes-first-fda-approved-gastric-cancer-drug/) - Eli Lilly has obtained US Food and Drug Administration approval for its Cyramza (ramucirumab) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine or platinum-containing chemotherapy. According to Lilly, approval of Cyramza (ramucirumab injection 10mg/ml solution) makes the drug the
- [Abbvie starts Phase III trial of lung cancer drug veliparib](https://www.pharmaadvancement.com/drug-development/clinical-trials/abbvie-starts-phase-iii-trial-of-lung-cancer-drug-veliparib/) - US-based biopharmaceutical firm AbbVie has started a global Phase III clinical trial of an investigational oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor 'veliparib (ABT-888)' in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer (NSCLC). The company said that PARP is a naturally occurring enzyme in the body that repairs
- [Roche Signs Licensing Agreement with Sysmex Inostics GmbH for emPCR Patent Portfolio](https://www.pharmaadvancement.com/pharma-news/roche-signs-licensing-agreement-with-sysmex-inostics-gmbh-for-empcr-patent-portfolio/) - Pleasanton, CA, USA, 21 February 2014 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today a licensing agreement with Sysmex Inostics GmbH for its emPCR portfolio of patents. Under the terms of the licensing agreement, Roche grants Sysmex Inostics GmbH a worldwide, non-exclusive, royalty-bearing license. Through emulsion PCR (emPCR), each DNA molecule is individually isolated
- [Clever chemistry and a new class of antibiotics](https://www.pharmaadvancement.com/pharma-news/clever-chemistry-and-a-new-class-of-antibiotics/) - As concerns about bacterial resistance to antibiotics grow, researchers are racing to find new kinds of drugs to replace ones that are no longer effective. One promising new class of molecules called acyldepsipeptides - ADEPs - kills bacteria in a way that no marketed antibacterial drug does - by altering the pathway through which cells
- [Scientists demonstrate method to find new therapies](https://www.pharmaadvancement.com/pharma-news/scientists-demonstrate-method-to-find-new-therapies/) - Scientists at The Scripps Research Institute (TSRI) have demonstrated the power of a new drug discovery technique, which allows them to find - relatively quickly and cheaply - antibodies that have a desired effect on cells. The TSRI scientists used the technique to discover two antibodies that protect human cells from a cold virus. The
- [Tafinlar® receives FDA Breakthrough Therapy designation for non-small cell lung cancer with BRAF mutation](https://www.pharmaadvancement.com/drug-development/fda-approvals/tafinlar-receives-fda-breakthrough-therapy-designation-for-non-small-cell-lung-cancer-with-braf-mutation/) - GlaxoSmithKline plc announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Tafinlar® (dabrafenib) for treatment of patients with metastatic BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) who have received at least one prior line of platinum-containing chemotherapy. Dabrafenib is not approved or licensed anywhere in the world for
- [Some 'healthy' vegetable oils may actually increase risk of heart disease](https://www.pharmaadvancement.com/pharma-news/some-healthy-vegetable-oils-may-actually-increase-risk-of-heart-disease/) - Some vegetable oils that claim to be healthy may actually increase the risk of heart disease, and Health Canada should reconsider cholesterol-lowering claims on food labelling, states an analysis in CMAJ (Canadian Medical Association Journal). Replacing saturated animal fats with polyunsaturated vegetable oils has become common practice because they can reduce serum cholesterol levels and
- [Discovery may lead to new treatments for allergic diseases](https://www.pharmaadvancement.com/pharma-news/discovery-may-lead-to-new-treatments-for-allergic-diseases/) - A collaboration among researchers in Israel and the United States has resulted in the discovery of a new pathway that has broad implications for treating allergic diseases - particularly eosinophil-associated disorders. The researchers from Tel Aviv University and Cincinnati Children's Hospital Medical Center have discovered how this pathway kills eosinophils before they can cause havoc.
- [Breakthrough by researchers could lead to new treatment for heart attack](https://www.pharmaadvancement.com/pharma-news/breakthrough-by-researchers-could-lead-to-new-treatment-for-heart-attack/) - The stop and start of blood flow to the heart during and after a heart attack causes severe damage to heart cells, reducing their capacity to function and potentially causing their death. But a recent study led by researchers at Temple University School of Medicine suggests that it is possible to limit the extent of
- [Stem cell breakthrough could set up future transplant therapies](https://www.pharmaadvancement.com/pharma-news/stem-cell-breakthrough-could-set-up-future-transplant-therapies/) - A new method for creating stem cells for the human liver and pancreas, which could enable both cell types to be grown in sufficient quantities for clinical use, has been developed by scientists. Using the technique, researchers have for the first time been able to grow a pure, self-renewing population of stem cells specific to
- [International collaboration finds 11 new Alzheimer's genes to target for drug discovery](https://www.pharmaadvancement.com/pharma-news/international-collaboration-finds-11-new-alzheimer-s-genes-to-target-for-drug-discovery/) - University of Miami Miller School of Medicine researchers played a key role in the largest international Alzheimer's disease genetics collaboration to date, which identified 11 new regions of the genome that contribute to late-onset Alzheimer's disease, doubling the number of potential genetics-based therapeutic targets to investigate. Published October 27 in Nature Genetics, the study gives
- [Human skin wound dressings to treat cutaneous ulcers](https://www.pharmaadvancement.com/pharma-news/human-skin-wound-dressings-to-treat-cutaneous-ulcers/) - Researchers from Université Laval's Faculty of Medicine and CHU de Québec have shown that it is possible to treat venous ulcers unresponsive to conventional treatment with wound dressings made from human skin grown in vitro. A study published recently in the journal Advances in Skin and Wound Care demonstrates how this approach was successfully used
- [AstraZeneca and Merck enter licence agreement for investigational oral WEE1 kinase inhibitor therapy for cancer](https://www.pharmaadvancement.com/pharma-news/astrazeneca-and-merck-enter-licence-agreement-for-investigational-oral-wee1-kinase-inhibitor-therapy-for-cancer/) - AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune, a privately-held, Maryland, US-based biologics company focused on developing novel therapeutics in cancer immunology. WEE1 helps to regulate the cell-division cycle. The WEE1 inhibitor MK-1775 is designed to cause certain tumour cells to divide without
- [VA’S CONVOLUTED PATIENT SCHEDULING STARTS WITH A ‘HELPLINE’ CALL](https://www.pharmaadvancement.com/pharma-news/va-s-convoluted-patient-scheduling-starts-with-a-helpline-call/) - Veterans trying to schedule medical appointments in the Veterans Affairs Department’s Phoenix Health Care System entered a Kafkaesque world where they had to call a “helpline” to provide demographic information to an official who would type the data into a computer and then take a screenshot and send it to a printer in another department.
- [UF Health successfully implements genomic medicine program](https://www.pharmaadvancement.com/pharma-news/uf-health-successfully-implements-genomic-medicine-program/) - GAINESVILLE, Fla. — At the conclusion of the first year of UF Health’s Personalized Medicine Program, the results are in: The program has successfully implemented a process for genetic testing that helps cardiologists identify which patients may benefit from a switch to an alternate anticlotting medication. The researchers published a review of the program’s first
- [Biotech Stocks Technical Report -- Research on Exact Sciences, Anacor Pharma, Cubist Pharma, and Agenus](https://www.pharmaadvancement.com/drug-development/research-development/biotech-stocks-technical-report-research-on-exact-sciences-anacor-pharma-cubist-pharma-and-agenus/) - On Friday, June 06, 2014, the NASDAQ Composite ended at 4,321.40, up 0.59%, the Dow Jones Industrial Average finished the day 0.52% higher at 16,924.28, and the S&P 500 closed at 1,949.44, up 0.46%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care
- [Statins being overprescribed for growing number of kidney disease patients](https://www.pharmaadvancement.com/pharma-news/statins-being-overprescribed-for-growing-number-of-kidney-disease-patients/) - A new analysis concludes that large numbers of patients in advanced stages of kidney disease are inappropriately being prescribed statins to lower their cholesterol - drugs that offer them no benefit and may increase other health risks such as diabetes, dementia or muscle pain. The findings, which were published in the American Journal of Cardiovascular
- [FDA approves new drug to treat HIV infection](https://www.pharmaadvancement.com/drug-development/fda-approvals/fda-approves-new-drug-to-treat-hiv-infection/) - The U.S. Food and Drug Administration has approved Tivicay (dolutegravir), a new drug to treat HIV-1 infection. Tivicay is an integrase strand transfer inhibitor that interferes with one of the enzymes necessary for HIV to multiply. It is a pill taken daily in combination with other antiretroviral drugs. Tivicay is approved for use in a
- [SAVOR-TIMI 53 sets new standard for cardiovascular outcome trials in diabetes](https://www.pharmaadvancement.com/pharma-news/savor-timi-53-sets-new-standard-for-cardiovascular-outcome-trials-in-diabetes/) - Uncertainty persists regarding whether drugs that lower sugar reduce the risk of heart attack, with some concerns that diabetes drugs may actually raise the risks. The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR-TIMI 53) trial was a large international clinical trial that randomized patients to the diabetes drug saxagliptin (Onglyza),
- [Scientists discover potential new way to treat anxiety](https://www.pharmaadvancement.com/pharma-news/scientists-discover-potential-new-way-to-treat-anxiety/) - Chemically modified inhibitors of the COX-2 enzyme relieve anxiety behaviors in mice by activating natural "endocannabinoids" without gastrointestinal side effects, Vanderbilt University scientists will report next week. Endocannabinoids are natural signaling molecules that activate cannabinoid receptors in the brain, the same receptors turned on by the active ingredient in marijuana. These receptors are also found
- [USFDA raises concerns over production at Cadila Healthcare's Moraiya facility](https://www.pharmaadvancement.com/pharma-news/usfda-raises-concerns-over-production-at-cadila-healthcare-s-moraiya-facility/) - The US Food and Drug Administration (FDA) has expressed concerns over the manufacturing process of at least one product at drugmaker Cadila Healthcare's Moraiya facility, two sources with direct knowledge of the matter said. The FDA has not expressed concerns over the entire facility, said the sources. The US agency communicated its concern to Cadila
- [Bristol-Myers Squibb and Allied Minds form new research enterprise](https://www.pharmaadvancement.com/drug-development/research-development/bristol-myers-squibb-and-allied-minds-form-new-research-enterprise/) - Bristol-Myers Squibb and Allied Minds have formed a new jointly owned enterprise, Allied-Bristol Life Sciences, aimed at advancing discoveries of biopharmaceutical innovations at leading US academic research institutions. Allied-Bristol Life Sciences will work with researchers at US university research institutions to identify discoveries that have therapeutic and commercial potential, and will support the research and
- [FDA approves Jardiance tablets for type 2 diabetes](https://www.pharmaadvancement.com/drug-development/fda-approvals/fda-approves-jardiance-tablets-for-type-2-diabetes/) - The US Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) tablets, developed by Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company, as an addition to diet and exercise to improve glycemic control in adults with type II diabetes. Jardiance is a once-daily, 10mg or 25mg tablet that was approved in the US based on
- [FDA approves Bayer’s Eylea to treat diabetic macular edema](https://www.pharmaadvancement.com/drug-development/fda-approvals/fda-approves-bayer-s-eylea-to-treat-diabetic-macular-edema/) - Bayer has announced the US Food and Drug Administration's (FDA) approval of Eylea, an aflibercept solution for injection into the eye for the treatment of diabetic macular edema (DME). The company said that DME is the third approved application for Eylea. The FDA approval is supported by a positive outcome from the Phase III VISTA-DME
- [Achillion Pharmaceuticals Biotech Facility](https://www.pharmaadvancement.com/pharma-projects/achillion-pharmaceuticals-biotech-facility/) - Achillion Pharmaceuticals, Inc., which was founded in February 2000 as one of the largest biotech start-ups in the USA, occupies a renovated space in the George Street Technology Center in downtown New Haven, Connecticut, across from Yale Medical School. The new facility is dedicated to developing biotechnology products on a commercial basis. The facility is
- [Arzerra (Ofatumumab) for Treatment of Chronic Lymphocytic Leukaemia (CLL)](https://www.pharmaadvancement.com/pharma-projects/arzerra-ofatumumab-for-treatment-of-chronic-lymphocytic-leukaemia-cll/) - Arzerra (ofatumumab) is the first-line drug approved for the treatment of chronic lymphocytic leukaemia (CLL). The drug is developed and marketed by GlaxoSmithKline (GSK) in collaboration with Genmab. In April 2014, supplemental biologic licence application (sBLA) of Arzerra was approved by the US Food and Drug Administration (FDA). Afrezza was approved in combination with chlorambucil
- [Afrezza - Mealtime Insulin Therapy for Diabetes](https://www.pharmaadvancement.com/pharma-projects/afrezza-mealtime-insulin-therapy-for-diabetes/) - Afrezza is a rapid-acting insulin therapy indicated for controlling hyperglycaemia in adult patients with type 1 and type 2 diabetes mellitus. The drug is developed and marketed by ManKind Corporation. MannKind Corporation submitted new drug application (NDA) for Afrezza to the US Food and Drug Administration (FDA) in March 2009. The FDA approved Afrezza to
- [Uceris (Budesonide) for Treating Ulcerative Colitis](https://www.pharmaadvancement.com/pharma-projects/uceris-budesonide-for-treating-ulcerative-colitis/) - Uceris (budesonide) is glucocorticoid receptor that is indicated for the treatment of ulcerative colitis. It is developed by US-based biopharmaceutical company Santarus, in collaboration with Cosmo Technologies. Santarus submitted the new drug application (NDA) for uceris to the US Food and Drug Administration (FDA) in December 2011. In January 2013, the company received approval for
- [Eli Lilly Humalog Manufacturing Facility](https://www.pharmaadvancement.com/pharma-projects/eli-lilly-humalog-manufacturing-facility/) - In April 2001 Eli Lilly announced it was constructing a new biotech bulk manufacturing facility in Carolina, Puerto Rico. Construction started in July 2002 and, following validation and commissioning, the plant was in production by mid-2006. This project was part of an overall $1bn investment into the company's facilities in Puerto Rico, which was completed
- [Boston Strategics begins Phase I trial of anti-cancer agent to treat haematologic malignancies](https://www.pharmaadvancement.com/drug-development/clinical-trials/boston-strategics-begins-phase-i-trial-of-anti-cancer-agent-to-treat-haematologic-malignancies/) - Boston Strategics (BSC) has started a Phase I clinical trial of Fujifilm's anti-cancer agent FF-10501 in the US to treat patients with advanced haematologic malignancies, such as relapsed or refractory high-risk myelodysplastic syndromes (MDS). In MDS, the disorder of blood-forming haematopoietic stem cells causes inefficient production of blood cells triggering cytopenia. It is also a
- [Exelixis' Phase III prostate cancer trial of cabozantinib fails to meet primary endpoint](https://www.pharmaadvancement.com/drug-development/clinical-trials/exelixis-phase-iii-prostate-cancer-trial-of-cabozantinib-fails-to-meet-primary-endpoint/) - US-based biopharmaceutical firm Exelixis has reported disappointing top-line results from the final analysis of COMET-1, the Phase III trial of cabozantinib in men with metastatic castration-resistant prostate cancer (mCRPC). The trial evaluated cabozantinib in mCRPC patients whose disease progressed after treatment with docetaxel as well as abiraterone and/or enzalutamide. The company said that the trial
- [FDA lifts partial clinical hold on OncoMed's vantictumab cancer drug trials](https://www.pharmaadvancement.com/pharma-news/fda-lifts-partial-clinical-hold-on-oncomed-s-vantictumab-cancer-drug-trials/) - The US Food and Drug Administration (FDA) has lifted a partial hold on patient enrolments for three Phase Ib clinical trials evaluating OncoMed Pharmaceuticals' experimental cancer drug, vantictumab. In these trials, vantictumab is being evaluated in combination with standard-of-care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC), advanced HER2-negative breast cancer and advanced
- [Senesco completes patient enrolment in Phase Ib/IIa SNS01-T trial](https://www.pharmaadvancement.com/pharma-news/senesco-completes-patient-enrolment-in-phase-ib-iia-sns01-t-trial/) - US-based biotech firm Senesco Technologies has completed patient enrolment in its ongoing Phase Ib/IIa clinical trial of SNS01-T to treat patients with relapsed or refractory multiple myeloma, plasma cell leukemia or B cell lymphoma. A first-in-class modulator of eukaryotic translation initiation factor 5A (eIF5A), SNS01-T is a new approach to cancer therapy that is designed
- [Asterias to begin AST-OPC1 Phase I/IIa trial to treat spinal cord injury](https://www.pharmaadvancement.com/drug-development/clinical-trials/asterias-to-begin-ast-opc1-phase-i-iia-trial-to-treat-spinal-cord-injury/) - The US Food and Drug Administration (FDA) has granted clearance to Asterias Biotherapeutics for the initiation of a Phase I/IIa clinical trial of its product, AST-OPC1, to treat patients with complete cervical spinal cord injury. The approved Phase I/IIa trial follows the completion of the Phase I clinical study of the AST-OPC1, which is a
- [Novo Nordisk introduces Ryzodeg in Mexico for type 2 diabetes](https://www.pharmaadvancement.com/pharma-news/novo-nordisk-introduces-ryzodeg-in-mexico-for-type-2-diabetes/) - Denmark-based Novo Nordisk has introduced Ryzodeg (insulin degludec/insulin aspart) in Mexico, which will be used to treat adult patients suffering from type 2 diabetes. The launch makes Mexico the first country in the world where Ryzodeg will be available. Ryzodeg is a combination of insulin degludec and insulin aspart in the ratio of 70% and
- [Mesoblast and NIH partner on 120-patient trial to treat end-stage heart failure](https://www.pharmaadvancement.com/drug-development/clinical-trials/mesoblast-and-nih-partner-on-120-patient-trial-to-treat-end-stage-heart-failure/) - Australia-based regenerative medicine company Mesoblast has signed an agreement with the US National Institutes of Health's (NIH) National Heart, Lung and Blood Institute to carry out a clinical trial using the company's adult stem cell therapy for the treatment of patients with advanced heart failure. The treatment is indicated for patients who require an implantable
- [In US, FedEx faces drug trafficking charges](https://www.pharmaadvancement.com/pharma-news/in-us-fedex-faces-drug-trafficking-charges/) - The courier firm FedEx faces drug-trafficking charges after being indicted by a federal grand jury in California, in a case that highlights the growth in illegal online pharmacies selling dubious medication to people without prescription. The 15-count indictment accuses FedEx of conspiring in the delivery of illicit pharmaceuticals, including the sleep aid Ambien and the
- [AIDS can be brought under control by 2030: UNAIDS](https://www.pharmaadvancement.com/pharma-news/aids-can-be-brought-under-control-by-2030-unaids/) - AIDS can be brought under control by 2030, according to a report by the United Nations Aids agency. It said the number of new HIV infections and deaths from Aids were both falling. At present, that 35 million people around the world were living with HIV. There were 2.1 million new cases in 2013 — 38%
- [Abbott to sell its developed markets branded generics pharma business to Mylan](https://www.pharmaadvancement.com/pharma-news/abbott-to-sell-its-developed-markets-branded-generics-pharma-business-to-mylan/) - The business to be sold operates in Europe, Japan, Canada, Australia and New Zealand and includes approximately 3,800 employees Abbott will sell its developed markets branded generics pharmaceuticals business to Mylan for equity ownership of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharma business, and will be a
- [Glenmark Generics receives final ANDA approval for Telmisartan tablets](https://www.pharmaadvancement.com/pharma-news/glenmark-generics-receives-final-anda-approval-for-telmisartan-tablets/) - Telmisartan is Glenmark’s generic version of Boehringer Ingelheim’s Micardis Glenmark Generics Inc., US a subsidiary of Glenmark Generics Limited has been granted final abbreviated new drug approval (ANDA) from the United States Food and Drug Administration (US FDA) for Telmisartan Tablets. Glenmark will commence distribution of the product immediately. Telmisartan tablets are Glenmark’s
- [Rotavirus Vaccination Decreases Diarrhea Hospitalizations Among Kids](https://www.pharmaadvancement.com/pharma-news/rotavirus-vaccination-decreases-diarrhea-hospitalizations-among-kids/) - Since the introduction of routine rotavirus vaccination in 2006, rates of diarrhea-related hospitalizations in US children have decreased significantly. Diarrhea-related health care use among young children in the United States has dramatically decreased since the implementation of rotavirus vaccines, the results of a recent study indicate. In addition, the study estimates that more than
- [FDA plans to take steps to enhance the collection and availability of clinical trial data on demographic subgroups.](https://www.pharmaadvancement.com/drug-development/clinical-trials/fda-plans-to-take-steps-to-enhance-the-collection-and-availability-of-clinical-trial-data-on-demographic-subgroups/) - By: Margaret A. Hamburg, M.D.Margaret A. Hamburg, M.D., is Commissioner of the U.S. Food and Drug Administration August 20, 2014, Today FDA is announcing important steps that the agency plans to take to enhance the collection and availability of clinical trial data on demographic subgroups – patient populations divided by sex, race/ethnicity or
- [Antares Pharma to Participate at the Morgan Stanley Healthcare Conference](https://www.pharmaadvancement.com/pharma-news/antares-pharma-to-participate-at-the-morgan-stanley-healthcare-conference/) - Antares Pharma, Inc. today announced that Eamonn P. Hobbs, President and Chief Executive Officer and Robert F. Apple, Chief Financial Officer and President of the Parenteral Products Group, will participate at the Morgan Stanley Healthcare Conference in New York on Wednesday September 10, 2014 at 8:35 am Eastern Time. A live webcast of their participation
- [InnoPharma Announces FDA Approval of Decitabine for Injection, a Generic Version of DACOGEN®](https://www.pharmaadvancement.com/drug-development/fda-approvals/innopharma-announces-fda-approval-of-decitabine-for-injection-a-generic-version-of-dacogen/) - InnoPharma, Inc. today announced the approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for decitabine for injection, a generic version of Eisai Inc.’s DACOGEN®. InnoPharma developed the generic formulation of decitabine for injection and entered into an agreement with Sandoz, Inc., pursuant to which Sandoz will sell,
- [Eisai and Arena Pharmaceuticals Announce BELVIQ(R) (lorcaserin HCl) CIV Nominated a Second Time for the Prix Galien Award in the Best Pharmaceutical Agent Category](https://www.pharmaadvancement.com/pharma-news/eisai-and-arena-pharmaceuticals-announce-belviq-r-lorcaserin-hcl-civ-nominated-a-second-time-for-the-prix-galien-award-in-the-best-pharmaceutical-agent-category/) - Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that BELVIQ(R) (lorcaserin HCl) has been nominated by the Galien Foundation and Awards Committee for the 2014 Prix Galien USA Award in the Best Pharmaceutical Agent category. BELVIQ was previously nominated for this award in 2013. "Eisai's commitment to patient care is the driving force
- [STALLERGENES Expands Latin American Presence with Acquisition of ALERGO PHARMA S.R.L. in Argentina](https://www.pharmaadvancement.com/pharma-news/stallergenes-expands-latin-american-presence-with-acquisition-of-alergo-pharma-s-r-l-in-argentina/) - STALLERGENES (Paris:GENP), a global healthcare company specialized in the diagnosis and treatment of allergies through allergen immunotherapy-based solutions, announced today the acquisition of the entire share capital of ALERGO PHARMA S.R.L., an Argentinean allergen immunotherapy (AIT) company. “With its excellent market knowledge, an extensive distribution network and long standing relationships with allergy specialists, ALERGO PHARMA
- [Takeda and Orexigen receive FDA approval for new weight-loss pill called Contrave](https://www.pharmaadvancement.com/drug-development/fda-approvals/takeda-and-orexigen-receive-fda-approval-for-new-weight-loss-pill-called-contrave/) - Takeda Pharmaceuticals USA and Orexigen Therapeutics have received approval from the US Food and Drug Administration (FDA) for a new weight-loss pill called Contrave (naltrexone HCI and bupropion HCI). The approval allows the tablets to be used for chronic weight management in adults with an initial body mass index (BMI) of 30kg/m2 or
- [INDUSTRY NEWS Hayat Pharmacy to open Greenfield location](https://www.pharmaadvancement.com/pharma-news/industry-news-hayat-pharmacy-to-open-greenfield-location/) - Milwaukee-based pharmacy chain Hayat Pharmacy will open its sixth location Tuesday at its first site in southern Milwaukee County: 4931 S. 27th St. in Greenfield. The new pharmacy will be located within the clinic of independent physicians Dr. Hector Lopez and Dr. Mauricio Tovar, said Hashim Zaibak, majority owner of Hayat Pharmacy. Also at the
- [Hayat Pharmacy to open Greenfield location](https://www.pharmaadvancement.com/pharma-news/hayat-pharmacy-to-open-greenfield-location/) - Milwaukee-based pharmacy chain Hayat Pharmacy will open its sixth location Tuesday at its first site in southern Milwaukee County: 4931 S. 27th St. in Greenfield. The new pharmacy will be located within the clinic of independent physicians Dr. Hector Lopez and Dr. Mauricio Tovar, said Hashim Zaibak, majority owner of Hayat Pharmacy. Also at the
- [Rock Creek Pharmaceuticals receives new Dietary Ingredient Notification (NDIN) Response](https://www.pharmaadvancement.com/pharma-news/rock-creek-pharmaceuticals-receives-new-dietary-ingredient-notification-ndin-response/) - Rock Creek Pharmaceuticals, Inc., a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today it has received a written response from the U.S. Food and Drug Administration (FDA) in response to the New Dietary Ingredient Notification (NDIN) for the formulations of Anatabloc® and CigRx® submitted by the Company in June 2014.
- [Takeda and Orexigen Announce FDA Approval of Contrave ® (naltrexone HCI and bupropion HCI) Extended - release Tablets for Chronic Weight Management](https://www.pharmaadvancement.com/drug-development/fda-approvals/takeda-and-orexigen-announce-fda-approval-of-contrave-naltrexone-hci-and-bupropion-hci-extended-release-tablets-for-chronic-weight-management/) - Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration (FDA) has approved Contrave® (naltrexone HCI and bupropion HCI) extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30
- [New Pharmaceutical Solid Dosage Form Development Collaboration from Mettler Toledo](https://www.pharmaadvancement.com/pharma-news/new-pharmaceutical-solid-dosage-form-development-collaboration-from-mettler-toledo/) - Mettler Toledo has initiated a collaboration with Actera Pharmaceuticals, San Francisco, to expand the applications of Focused Beam Reflectance Measurement (FBRM) probes into pharmaceutical solid dosage form development. An FBRM in situ particle size tracking instrument is located in Actera's product innovation labs at the California Institute for Quantitative Biosciences (QB3@953) in San Francisco. Mark
- [US Pharma now developing 44 drugs/vaccines for HIV/AIDS](https://www.pharmaadvancement.com/pharma-news/us-pharma-now-developing-44-drugs-vaccines-for-hiv-aids/) - The USA’s biopharmaceutical research companies are currently developing 44 medicines and vaccines for HIV/AIDS treatment and prevention, according to the latest Medicines in Development report by the trade group Pharmaceutical Research and Manufacturers of America (PhRMA). A second report, a PhRMA-sponsored white paper by Boston Healthcare Associates (BHA), The Value of Innovation in HIV/AIDS Therapy,
- [Mylan to Acquire U.S. Rights to Arixtra® (fondaparinux sodium) Injection from Aspen](https://www.pharmaadvancement.com/pharma-news/mylan-to-acquire-u-s-rights-to-arixtra-fondaparinux-sodium-injection-from-aspen/) - Mylan Inc. today announced that its subsidiary Mylan Ireland Limited has entered into an agreement to acquire the U.S. commercialization, marketing and intellectual property rights relating to Arixtra® (fondaparinux sodium) Injection and the authorized generic (AG) of Arixtra from Aspen Global Incorporated. Arixtra is indicated for the prophylaxis of deep vein thrombosis (DVT), which may
- [FDA Advisory Committee recommends against approval of Actavis' Nebivolol/Valsartan Fixed-Dose combination NDA for Treatment of Hypertension](https://www.pharmaadvancement.com/pharma-news/fda-advisory-committee-recommends-against-approval-of-actavis-nebivolol-valsartan-fixed-dose-combination-nda-for-treatment-of-hypertension/) - Actavis plc today confirmed that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has voted to recommend against approval of Actavis' New Drug Application (NDA) for the fixed-dose combination of nebivolol and valsartan for the treatment of hypertension. The committee vote was six to four recommending against approval. The
- [Baxter Announces Baxalta as the Name of the New Global Biopharmaceutical Company](https://www.pharmaadvancement.com/pharma-news/baxter-announces-baxalta-as-the-name-of-the-new-global-biopharmaceutical-company/) - Baxter International Inc. announced today that Baxalta Incorporated will be the name of the new, publicly traded biopharmaceutical company that is expected to launch in mid-2015. Upon completion of the separation, Baxalta plans to trade on the New York Stock Exchange (NYSE) under the symbol BXLT. Baxter International will continue trading on the NYSE under
- [Spectrum Pharmaceuticals to Advance Neutropenia Drug](https://www.pharmaadvancement.com/pharma-news/spectrum-pharmaceuticals-to-advance-neutropenia-drug/) - Spectrum Pharmaceuticals ( SPPI ) announced its intention to initiate a phase III study on SPI-2012 next year. SPI-2012, Spectrum Pharma's long acting granulocyte stimulating factor, is being developed for the treatment of neutropenia utilizing the proprietary Lapscovery technology of its partner Hanmi Pharmaceutical Company. Spectrum Pharma plans to meet with the U.S. regulatory authorities
- [Kinex completes acquisition of QuaDPharma](https://www.pharmaadvancement.com/pharma-news/kinex-completes-acquisition-of-quadpharma/) - Kinex Pharmaceuticals Inc. today announced that it has completed the acquisition of QuaDPharma, LLC., a Western New York based privately-held company specializing in pharmaceutical manufacturing, analytical and support services to the pharmaceutical and biotech industries. Financial terms of the transaction were not disclosed. “Over the past two years, Kinex has substantially increased its global presence
- [Par Pharmaceutical Resumes Shipment of Generic Precedex® Injection](https://www.pharmaadvancement.com/pharma-news/par-pharmaceutical-resumes-shipment-of-generic-precedex-injection/) - Par Pharmaceutical Companies, Inc. today announced that it has resumed shipping dexmedetomidine hydrochloride (HCl) injection, EQ 100 mcg base/mL, the generic version of Hospira’s Precedex® Injection. Par immediately resumed shipping after a U.S. District Court lifted a temporary restraining order that was issued in August at Hospira’s request. Last month, Par received final approval from
- [FDA Approves Use of Menactra® Vaccine for Booster Immunization Against Potentially Deadly Disease](https://www.pharmaadvancement.com/drug-development/fda-approvals/fda-approves-use-of-menactra-vaccine-for-booster-immunization-against-potentially-deadly-disease/) - Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration (FDA) approved use of Menactra® [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine] for booster vaccination against meningococcal disease in persons 15 years through 55 years of age. Meningococcal disease, which includes meningococcal meningitis, is
- [NeuroVive signs USD 150 m agreement with OnCore BioPharma for the outlicensing of NVP018 for the treatment of chronic Hepatitis B virus infection](https://www.pharmaadvancement.com/pharma-news/neurovive-signs-usd-150-m-agreement-with-oncore-biopharma-for-the-outlicensing-of-nvp018-for-the-treatment-of-chronic-hepatitis-b-virus-infection/) - NeuroVive Pharmaceutial AB, a leading mitochondrial medicine company, has signed an exclusive global outlicensing agreement with the US biotechnology company OnCore BioPharma, Inc. related to the development and commercialization of NeuroVive’s drug candidate NVP018 for oral treatment of chronic Hepatitis B Virus (HBV) infection. The agreement can give NeuroVive in total $150 million in conditional
- [T-Bird Pharma Inc. to be British Columbia's first Health Canada Licensed Publicly Traded Medical Marijuana Company](https://www.pharmaadvancement.com/pharma-news/t-bird-pharma-inc-to-be-british-columbia-s-first-health-canada-licensed-publicly-traded-medical-marijuana-company/) - T-Bird Pharma Inc., a pharmaceutical company focused on developing premium quality medical marijuana products, is pleased to announce that its shares will begin trading on the TSX Venture Exchange on September 9, 2014. The Company's wholly-owned subsidiary, Thunderbird Biomedical Inc. ("Thunderbird"), is licensed under the Marihuana for Medical Purposes Regulations (Canada) ("MMPR") overseen by Health
- [Raleigh awards economic development incentive to Xellia Pharmaceuticals](https://www.pharmaadvancement.com/pharma-news/raleigh-awards-economic-development-incentive-to-xellia-pharmaceuticals/) - The city will award an economic development incentive grant to Xellia Pharmaceuticals to expand its manufacturing plant on Capital Boulevard in North Raleigh. The grant requires Xellia to create 40 permanent full-time jobs with an average annual salary of $45,000 to $70,000 in the next five years as well as maintain 90 existing jobs. The
- [DPT Laboratories acquires Meda Pharmaceuticals’ facilities in Lakewood](https://www.pharmaadvancement.com/pharma-news/dpt-laboratories-acquires-meda-pharmaceuticals-facilities-in-lakewood/) - DPT Laboratories, a contract development and manufacturing organization (CDMO) with a specialized focus on semi-solid and liquid dosage forms, has announced the acquisition of Meda Pharmaceuticals’ Lakewood, New Jersey, facilities. The acquisition reflects the organization's recent growth, allowing DPT to expand its footprint in Lakewood by adding two buildings totaling 90,000 square feet of space.
- [Sigma Pharmaceuticals buys Discount Drug Stores for $26.7m](https://www.pharmaadvancement.com/pharma-news/sigma-pharmaceuticals-buys-discount-drug-stores-for-26-7m/) - SIGMA Pharmaceuticals, one of Australia’s largest listed pharmacy brands, has acquired the Discount Drug Stores portfolio for $26.7 million. The deal will add 121 outlets to Sigma’s existing network of brands including Amcal, Chemist King and Guardian. DDS will become part of Sigma’s subsidiary Central Healthcare Services, which it purchased in March for $24.5m. Mark
- [Mylan Launches Generic Boniva® Injection](https://www.pharmaadvancement.com/pharma-news/mylan-launches-generic-boniva-injection/) - Mylan Inc. (MYL) today announced that it has launched Ibandronate Sodium Injection, 1 mg (base)/mL, packaged in 3 mg (base)/3 mL pre-filled glass syringes, which is the generic version of Hoffmann-La Roche's Boniva® Injection. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this
- [Chicago misses out in AbbVie-Calico pharma deal](https://www.pharmaadvancement.com/pharma-news/chicago-misses-out-in-abbvie-calico-pharma-deal/) - A few days ago, Calico, a Google-backed biotech company, announced that it would build a California-based research and development facility to invent new drugs to combat diseases afflicting the elderly. Half of the initial $500 million investment would be footed by AbbVie, a pharma company based in the Chicago area, for a few more months
- [Advancement of Ascendia Pharmaceutical’s Nano-Emulsion Technology Platform with Its Lead Development Program ASD-002](https://www.pharmaadvancement.com/pharma-news/advancement-of-ascendia-pharmaceutical-s-nano-emulsion-technology-platform-with-its-lead-development-program-asd-002/) - Ascendia Pharmaceuticals, a start-up specialty pharmaceutical company in the business of providing formulation technologies and product development services for poorly soluble molecules, today announced that the company has successfully applied its nano-emulsion technology platform to a novel injectable formulation of clopidogrel - the world’s top-selling blood thinner medicine. Ascendia has advanced the program to pre-IND
- [Chicago misses out in AbbVie-Calico pharma deal](https://www.pharmaadvancement.com/pharma-news/chicago-misses-out-in-abbvie-calico-pharma-deal-1/) - A few days ago, Calico, a Google-backed biotech company, announced that it would build a California-based research and development facility to invent new drugs to combat diseases afflicting the elderly. Half of the initial $500 million investment would be footed by AbbVie, a pharma company based in the Chicago area, for a few more months
- [Beacon Hill Launches New Division - Beacon Hill Pharma](https://www.pharmaadvancement.com/pharma-news/beacon-hill-launches-new-division-beacon-hill-pharma/) - Beacon Hill Staffing Group is proud to announce the addition of Beacon Hill Pharma – providing contract, direct (permanent), FSP/outsourcing and consulting to pharmaceutical, medical device, biotech and contract research organizations. Led by Managing Director Ryan Pirnat and Division Director Maricela Ostrand, Beacon Hill Pharma's dedicated team of recruiting and staffing experts delivers quality professionals on a time-sensitive
- [AbbVie teams with pharma firm to develop cancer drug](https://www.pharmaadvancement.com/pharma-news/abbvie-teams-with-pharma-firm-to-develop-cancer-drug/) - AbbVie Inc. could pay for a pharmaceutical firm in Massachusetts more than $800 million in a collaboration on a potential treatment for cancer. Cambridge, Massachusetts-based Infinity Pharmaceuticals Inc. will receive $275 million upfront and up to $530 million in additional payments if the treatment, duvelisib, reaches certain development and commercial milestones. Infinity is studing duvelisib
- [Knight Therapeutics acquires Orphan Canada](https://www.pharmaadvancement.com/pharma-news/knight-therapeutics-acquires-orphan-canada/) - Knight Therapeutics, a leading Canadian specialty pharmaceutical company, has entered into an agreement of purchase of assets with Orphan Canada (orphan) related to the Canadian rights for ATryn and PHOTOFRIN (porfimer sodium), two innovative pharmaceutical products approved for sale in multiple jurisdictions. Orphan is a Toronto-based specialty pharmaceutical company that in-licenses therapies for rare disorders
- [Luye Pharma Acquired 57.98% Stake of Beijing Jialin Pharmaceutical](https://www.pharmaadvancement.com/pharma-news/luye-pharma-acquired-57-98-stake-of-beijing-jialin-pharmaceutical/) - The board of directors of Luye Pharma Group Ltd., announced yesterday that the Company had entered into an agreement to purchase 57.98% stake of Beijing Jialin Pharmaceutical Co., Ltd. (Jialin Pharmaceutical) for an aggregate consideration of RMB 3.68 billion in cash. The acquisition will add another key product to the Company’s portfolio and enrich product
- [Luye Pharma Acquired 57.98% Stake of Beijing Jialin Pharmaceutical](https://www.pharmaadvancement.com/pharma-news/luye-pharma-acquired-57-98-stake-of-beijing-jialin-pharmaceutical-1/) - The board of directors of Luye Pharma Group Ltd., announced yesterday that the Company had entered into an agreement to purchase 57.98% stake of Beijing Jialin Pharmaceutical Co., Ltd. (Jialin Pharmaceutical) for an aggregate consideration of RMB 3.68 billion in cash. The acquisition will add another key product to the Company’s portfolio and enrich product
- [Salix inks deal with Indian pharma company to sell its drugs in Canada](https://www.pharmaadvancement.com/pharma-news/salix-inks-deal-with-indian-pharma-company-to-sell-its-drugs-in-canada/) - Salix Pharamaceuticals and Indian pharmaceutical company Lupin announced Friday that they have entered into a distribution agreement that grants Lupin the exclusive right to market and sell some Salix drugs in Canada. The drugs included in the deal are Zaxine, a drug used to treat the rare liver condition hepatic encephalopathy, and Relistor, a drug
- [Canada’s Valeant buys Salix for $11bn](https://www.pharmaadvancement.com/pharma-news/canada-s-valeant-buys-salix-for-11bn/) - Canada-based Valeant Pharmaceuticals International has completed the acquisition of US-based Salix Pharmaceuticals for around $11bn. Under the deal, Valeant has acquired all outstanding common stock of Salix for $173.00 per share in cash. Based in Raleigh of North Carolina, Salix develops and markets prescription pharmaceutical products and medical devices to treat gastrointestinal diseases.
- [Novartis's Jadenu receives FDA approval to treat chronic iron overload](https://www.pharmaadvancement.com/drug-development/fda-approvals/novartis-s-jadenu-receives-fda-approval-to-treat-chronic-iron-overload/) - Novartis has received approval from the US Food and Drug Administration (FDA) for its Jadenu (deferasirox) tablets to treat patients with chronic iron overload. Chronic iron overload is a life-threatening cumulative toxicity, which results from blood transfusions required to treat sickle cell disease, myelodysplastic syndromes, thalassemia and other conditions. FDA has approved a
- [Neurocrine, Mitsubishi Tanabe to develop VMAT2 inhibitor NBI-98854 for movement disorders](https://www.pharmaadvancement.com/pharma-news/neurocrine-mitsubishi-tanabe-to-develop-vmat2-inhibitor-nbi-98854-for-movement-disorders/) - US-based Neurocrine Biosciences has entered into an exclusive collaboration and licensing agreement with Japanese firm Mitsubishi Tanabe Pharma to develop and commercialize its VMAT2 inhibitor, NBI-98854, in Japan and other select Asian markets. Initially, the Japanese firm will develop NBI-98854 in Japan for the chorea associated with Huntington's disease (HD) and tardive dyskinesia.
- [BioCryst gets $35m contract for new Ebola treatment](https://www.pharmaadvancement.com/pharma-news/biocryst-gets-35m-contract-for-new-ebola-treatment/) - BioCryst Pharmaceuticals has received a $35m contract to continue developing BCX4430, a drug that has shown early signs of fighting the Ebola virus. BCX4430 is an RNA dependent-RNA polymerase inhibitor that has showed broad-spectrum activity in vitro against more than 20 RNA viruses in nine different families such as filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses,
- [Signum out-licenses SIG990 to Dermata to develop new topical treatment for rosacea](https://www.pharmaadvancement.com/pharma-news/signum-out-licenses-sig990-to-dermata-to-develop-new-topical-treatment-for-rosacea/) - US-based biotechnology firm Signum Dermalogix has out-licensed SIG990, a new anti-inflammatory compound, to Dermata Therapeutics for the development of a topical product to treat patients with rosacea, a chronic skin condition. SIG990 is claimed to have the potential to both reduce erythema and decrease the papules and pustules associated with the disease. The
- [Omega-3 fatty acids and vitamin D may control brain serotonin](https://www.pharmaadvancement.com/pharma-news/omega-3-fatty-acids-and-vitamin-d-may-control-brain-serotonin/) - Although essential marine omega-3 fatty acids and vitamin D have been shown to improve cognitive function and behavior in the context of certain brain disorders, the underlying mechanism has been unclear. In a new paper published in FASEB Journal by Rhonda Patrick, PhD and Bruce Ames, PhD of Children's Hospital Oakland Research Institute (CHORI), serotonin
- [Graphene shows potential as novel anti-cancer therapeutic strategy](https://www.pharmaadvancement.com/pharma-news/graphene-shows-potential-as-novel-anti-cancer-therapeutic-strategy/) - University of Manchester scientists have used graphene to target and neutralise cancer stem cells while not harming other cells. This new development opens up the possibility of preventing or treating a broad range of cancers, using a non-toxic material. Writing in the journal Oncotarget, the team of researchers led by Professor Michael Lisanti and Dr
- [Cipher Pharma buys Canadian rights to novel treatment for psoriasis and RA from Can-Fite Biopharma](https://www.pharmaadvancement.com/pharma-news/cipher-pharma-buys-canadian-rights-to-novel-treatment-for-psoriasis-and-ra-from-can-fite-biopharma/) - Cipher Pharmaceuticals Inc., a rapidly growing specialty pharmaceutical dermatology company, has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by Can-Fite Biopharma (Can-Fite) for moderate to severe plaque psoriasis and rheumatoid arthritis. CF101 recently completed a phase II/III double-blind, placebo-controlled study, which was designed to test the efficacy of CF101
- [Bristol-Myers Squibb to Present at Bank of America Merrill Lynch 2015 Health Care Conference](https://www.pharmaadvancement.com/drug-development/research-development/bristol-myers-squibb-to-present-at-bank-of-america-merrill-lynch-2015-health-care-conference/) - The Bank of America Merrill Lynch 2015 Health Care Conference on Tuesday, May 12, 2015, in Las Vegas. Doug Manion, head, Specialty Development, will make a formal presentation about the company at 2:20 p.m. EDT (11:20 a.m. PDT). Investors and the general public are invited to listen to a live webcast of the presentation at
- [Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC/ICC 2015](https://www.pharmaadvancement.com/drug-development/clinical-trials/results-of-phase-2-study-of-merck-s-investigational-beta-lactamase-inhibitor-relebactam-presented-at-icaac-icc-2015/) - Company Initiates Pivotal Phase 3 Studies Evaluating Relebactam in Combination with Imipenem/Cilastatin for Treatment of Serious Bacterial Infections known as MSD outside the United States and Canada, today announced that a Phase 2 study of relebactam, the company’s investigational beta-lactamase inhibitor for the treatment, in combination with imipenem/cilastatin (an approved carbapenem antibiotic), of complicated intra-abdominal
- [Merck Provides Diabetes Portfolio Update and Underscores Comprehensive, Long-Term Commitment to Patients with Diabetes](https://www.pharmaadvancement.com/pharma-news/merck-provides-diabetes-portfolio-update-and-underscores-comprehensive-long-term-commitment-to-patients-with-diabetes/) - Presents Pivotal Data for Omarigliptin, Merck’s Investigational Once-Weekly DPP-4 Inhibitor, and Additional Data from the TECOS CV Safety Trial, at European Association for the Study of Diabetes Annual Meeting known as MSD outside the United States and Canada, provided an update today on its diabetes portfolio and re-affirmed the company’s comprehensive, long-term commitment to patients
- [ABBVIE ANNOUNCES SUBMISSION OF A SUPPLEMENTAL NEW DRUG APPLICATION FOR IMBRUVICA® (IBRUTINIB) FOR TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA](https://www.pharmaadvancement.com/pharma-news/abbvie-announces-submission-of-a-supplemental-new-drug-application-for-imbruvica-ibrutinib-for-treatment-naive-chronic-lymphocytic-leukemia/) - a global biopharmaceutical company, announced today that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) based on the randomized, multi- center, open-label Phase III RESONATETM-2 (PCYC-1115) trial assessing the use of IMBRUVICA® (ibrutinib) versus chlorambucil in treatment-naive chronic lymphocytic leukemia (CLL) patients aged 65 years or older.
- [Study Links Early Infections to Celiac Risk](https://www.pharmaadvancement.com/pharma-news/study-links-early-infections-to-celiac-risk/) - Children who have a lot of infections in the first 18 months of life may have an increased risk for celiac disease, a new study from Norway suggests. The study found that children with 10 or more respiratory and gastrointestinal infections during the first 18 months of life were 30 percent more likely to develop
- [Expert Offers Car Seat Safety Tips](https://www.pharmaadvancement.com/pharma-news/expert-offers-car-seat-safety-tips/) - Although it can sometimes be a challenge to get a cranky, wriggling toddler into a child car seat, those safety devices can protect youngsters from serious injuries in an accident. But only when they're used properly, an expert advised. "We know from our work with thousands of families across the country over the past decade
- [FDA Approves Keytruda (pembrolizumab) for Advanced Non-Small Cell Lung Cancer](https://www.pharmaadvancement.com/drug-development/fda-approvals/fda-approves-keytruda-pembrolizumab-for-advanced-non-small-cell-lung-cancer/) - The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test,
- [Allergan to Present New Data for VIBERZI™ (eluxadoline) at the American College of Gastroenterology 2015 Annual Scientific Meeting](https://www.pharmaadvancement.com/pharma-news/allergan-to-present-new-data-for-viberzi-eluxadoline-at-the-american-college-of-gastroenterology-2015-annual-scientific-meeting/) - Allergan plc today announced that three data posters/presentations for eluxadoline will be presented during the American College of Gastroenterology 2015 Annual Scientific Meeting in Honolulu, HI, October 16-21, 2015. The presentations will feature data from eluxadoline's Phase III clinical trials in irritable bowel syndrome with diarrhea (IBS-D). VIBERZI™ (eluxadoline) was approved by the FDA on
- [Drugs Used in Cancer, Arthritis May Help Fight Hair Loss](https://www.pharmaadvancement.com/pharma-news/drugs-used-in-cancer-arthritis-may-help-fight-hair-loss/) - one approved for use in arthritis and the other approved for cancer -- may also hold potential for boosting hair growth, new animal research suggests. "The ultimate potential is a very effective topical product to rub on the scalp to help with all types of hair loss," said Dr. Luis Garza, an associate professor of
- [FDA Approves Dyanavel XR](https://www.pharmaadvancement.com/drug-development/fda-approvals/fda-approves-dyanavel-xr/) - Tris Pharma Receives FDA Approval of Dyanavel XR (amphetamine) Once-Daily Liquid for ADHD in Children ("Tris") announced that the U.S. Food and Drug Administration ("FDA") has approved Dyanavel XR (amphetamine), extended-release oral suspension, CII, for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children 6 years and older. With this approval, Dyanavel XR becomes the only
- [Shire Receives FDA Complete Response Letter for Lifitegrast NDA and Plans to Respond with OPUS-3 Trial](https://www.pharmaadvancement.com/drug-development/fda-approvals/shire-receives-fda-complete-response-letter-for-lifitegrast-nda-and-plans-to-respond-with-opus-3-trial/) - Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the U.S. Food and Drug Administration (FDA) requested an additional clinical study as part of a complete response letter (CRL) to the company’s new drug application for lifitegrast for the signs and symptoms of dry eye disease in adults. Shire has recently completed a Phase 3
- [Collegium Provides Update on FDA Review of Xtampza ER, an Abuse-Deterrent Analgesic for the Treatment of Chronic Pain](https://www.pharmaadvancement.com/pharma-news/collegium-provides-update-on-fda-review-of-xtampza-er-an-abuse-deterrent-analgesic-for-the-treatment-of-chronic-pain/) - Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the U.S. Food and Drug Administration (FDA) has advised Collegium that it will not be able to complete its review of the New Drug Application (NDA) for Xtampza™ ER (oxycodone) extended-release capsules by the Prescription Drug User Fee Act (PDUFA) action date of October 12, 2015. "We are
- [Jazz Pharmaceuticals Announces FDA Acceptance for Filing with Priority Review of NDA for Defibrotide](https://www.pharmaadvancement.com/drug-development/fda-approvals/jazz-pharmaceuticals-announces-fda-acceptance-for-filing-with-priority-review-of-nda-for-defibrotide/) - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted for filing with Priority Review its recently submitted New Drug Application (NDA) for defibrotide. Defibrotide is an investigational agent proposed for the treatment of patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome
- [Sun Pharmaceutical wins US approval to buy Ranbaxy](https://www.pharmaadvancement.com/pharma-news/sun-pharmaceutical-wins-us-approval-to-buy-ranbaxy/) - Sun Pharmaceutical Industries LtdBSE -0.35 % has won US approval to buy Ranbaxy Laboratories LtdBSE -0.61 % on condition that it sell its interest in a generic antibacterial medicine, the US Federal Trade Commission said on Friday. Sun Pharmaceutical said in April that it had agreed to Ranbaxy from its current owner, Japan's Daiichi Sankyo
- [We would like to make one plus one more than two: Uday Baldota](https://www.pharmaadvancement.com/pharma-news/we-would-like-to-make-one-plus-one-more-than-two-uday-baldota/) - Sun Pharmaceutical Industries is in the process of closing its merger with Ranbaxy. The former's chief financial officer (CFO), Uday Baldota, talks to Digbijay Mishra on what's ahead. Edited excerpts:The US Federal Trade Commission's nod for the Sun-Ranbaxy merger has come. How are you approaching the integration? Till the merger closes, we cannot integrate. What
- [Sun Seals Ranbaxy Deal, To Invest $300 MN in R&D](https://www.pharmaadvancement.com/pharma-news/sun-seals-ranbaxy-deal-to-invest-300-mn-in-r-d/) - Sun Pharmaceutical Industries, India’s largest drugmaker, on Wednesday announced the closure of its merger with Ranbaxy Laboratories and said the integration would deliver synergies worth $250 million (about Rs 1,500 crore) in three years. Announcing an operational blueprint to achieve synergies through value-creation across functions, Sun Pharma Managing Director Dilip Shanghvi told reporters here the
- [Post-Merger with Ranbaxy, Sun Pharma Becomes 5th Largest Generic Company](https://www.pharmaadvancement.com/pharma-news/post-merger-with-ranbaxy-sun-pharma-becomes-5th-largest-generic-company/) - Following the successful closure of the merger with drug maker Ranbaxy, Dilip Shanghvi-led Sun Pharma said on Wednesday that it is initiating the integration process, which will make the combined entity the fifth largest generic company in the world with revenues of over $4.5 billion. Post this transaction, Ranbaxy will be delisted from the Indian
- [MacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination with KEYTRUDA® (pembrolizumab) for Advanced Gastric Cancer](https://www.pharmaadvancement.com/pharma-news/macrogenics-and-merck-to-collaborate-on-immuno-oncology-study-evaluating-margetuximab-in-combination-with-keytruda-pembrolizumab-for-advanced-gastric-cancer/) - Clinical trial to evaluate MacroGenics' Fc-optimized anti-HER2 antibody with Merck's anti-PD-1 therapy in patients with advanced HER2-positive gastric cancer MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, autoimmune disorders and infectious diseases, and Merck (NYSE: MRK), known as MSD outside the
- [Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda® (pembrolizumab) as First-line Treatment for Advanced Melanoma](https://www.pharmaadvancement.com/pharma-news/incyte-and-merck-expand-clinical-collaboration-to-include-phase-3-study-investigating-the-combination-of-epacadostat-with-keytruda-pembrolizumab-as-first-line-treatment-for-advanced-melanoma-1/) - Pivotal study to evaluate Incyte’s IDO1 inhibitor in combination with Merck’s anti-PD-1 therapy in patients with advanced or metastatic melanoma .Incyte Corporation (Nasdaq: INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the expansion of the companies’ ongoing clinical collaboration to include a Phase 3 study evaluating the combination
- [Bionomics Announces Extension of Strategic Collaboration with Merck & Co., Inc. for the Discovery and Development of Novel Pain Medications](https://www.pharmaadvancement.com/pharma-news/bionomics-announces-extension-of-strategic-collaboration-with-merck-co-inc-for-the-discovery-and-development-of-novel-pain-medications/) - Merck & Co., Inc. to make US$9 million investment in Bionomics Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today announced that it has extended its strategic collaboration with Merck & Co., Inc., Kenilworth
- [Proteros signs new oncology collaboration with Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA on epigenetic target](https://www.pharmaadvancement.com/pharma-news/proteros-signs-new-oncology-collaboration-with-merck-sharp-dohme-corp-whitehouse-station-nj-usa-on-epigenetic-target/) - Proteros to receive upfront and research funding plus milestone payments of up to $126 million plus royalties Proteros biostructures GmbH today announced that it has signed an agreement with Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA (“MSD”) to discover and develop small molecule compounds against an epigenetic target for the potential treatment of
- [International Institute for Integrative Sleep Medicine (WPI-IIIS, University of Tsukuba, Japan) announces drug discovery collaboration agreement with Merck](https://www.pharmaadvancement.com/pharma-news/international-institute-for-integrative-sleep-medicine-wpi-iiis-university-of-tsukuba-japan-announces-drug-discovery-collaboration-agreement-with-merck/) - International Institute for Integrative Sleep Medicine, University of Tsukuba (“WPI-IIIS”) today announced a research collaboration agreement with Merck & Co., Inc., Kenilworth, N.J., U.S.A., known as MSD outside the United States and Canada. Under the agreement, WPI-IIIS and Merck will perform collaborative research aimed at discovering new medicines for disorders of the central nervous system.
- [Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer](https://www.pharmaadvancement.com/drug-development/clinical-trials/merck-and-dnatrix-announce-phase-2-immuno-oncology-collaboration-in-patients-with-aggressive-form-of-brain-cancer/) - Merck (NYSE:MRK), known as MSD outside the United States and Canada, and DNAtrix today announced they have entered into an oncology clinical study collaboration to evaluate the efficacy and safety of DNX-2401, DNAtrix’s oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in a Phase 2, multi-centered study of patients with recurrent glioblastoma, the
- [Syndax and Merck Announce First Patients Dosed in Phase 1b/2 Clinical Trial of Entinostat and KEYTRUDA®](https://www.pharmaadvancement.com/drug-development/clinical-trials/syndax-and-merck-announce-first-patients-dosed-in-phase-1b-2-clinical-trial-of-entinostat-and-keytruda/) - Clinical trial to assess safety and efficacy of immuno-oncology combination in patients with advanced NSCLC or melanoma Syndax Pharmaceuticals, Inc. and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the dosing of the first patients in the Phase 1b/2 clinical trial of Syndax’s entinostat in combination with Merck’s anti-PD-1
- [Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus](https://www.pharmaadvancement.com/pharma-news/daktari-enters-collaboration-agreement-with-merck-to-develop-test-for-hepatitis-c-virus/) - Daktari Diagnostics today announced a collaboration with Merck, known as MSD outside the United States and Canada, to develop Daktari’s rapid hepatitis C virus (HCV) screening test. The deal, worth up to $8.5 million over the next 3.5 years, will support an accelerated development timeline for the clinical validation and regulatory approval of Daktari’s HCV
- [Merck and MD Anderson Cancer Center Announce Strategic Immuno-Oncology Research Collaboration in Solid Tumors](https://www.pharmaadvancement.com/drug-development/research-development/merck-and-md-anderson-cancer-center-announce-strategic-immuno-oncology-research-collaboration-in-solid-tumors/) - Clinical Trials to Evaluate Merck’s KEYTRUDA® (pembrolizumab) in Combination with Other Medicines and Treatments Across Multiple Tumor Types Merck (NYSE:MRK), known as MSD outside the United States and Canada, and The University of Texas MD, Anderson Cancer Center today announced that they have entered into a strategic clinical research collaboration to evaluate Merck’s anti-PD-1 therapy, KEYTRUDA®
- [Unilateral Pricing Policy](https://www.pharmaadvancement.com/pharma-news/unilateral-pricing-policy/) - Alcon’s limited unilateral pricing policy applies only to new and innovative brands of contact lens and was introduced to encourage eye care professionals to educate their patients about the benefits of these breakthrough technologies. Alcon strongly believes that the UPP generates significant procompetitive benefits for consumers, eye care professionals, and the market for vision care
- [Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering RAVICTI(R) (glycerol phenylbutyrate) Oral Liquid](https://www.pharmaadvancement.com/pharma-news/horizon-pharma-plc-announces-the-u-s-patent-and-trademark-office-issuance-of-an-additional-notice-of-allowance-with-claims-covering-ravicti-r-glycerol-phenylbutyrate-oral-liquid/) - Will Represent Sixth U.S. Patent to Be Listed in the Orange Book for RAVICTI Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has received a Notice of Allowance from the United
- [AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds](https://www.pharmaadvancement.com/pharma-news/abbvie-and-boehringer-ingelheim-announce-global-collaboration-on-promising-immunology-compounds/) - AbbVie and Boehringer Ingelheim announced a global collaboration to develop and commercialize BI 655066, an anti-IL-23 monoclonal biologic antibody in Phase 3 development for psoriasis. AbbVie and Boehringer Ingelheim also are evaluating the potential of this biologic therapy in Crohn’s disease, psoriatic arthritis and asthma. In addition to the anti-IL-23 antibody, AbbVie gains rights to
- [ALMAC GROUP LAUNCHES US SERIALISATION SOLUTION](https://www.pharmaadvancement.com/pharma-news/almac-group-launches-us-serialisation-solution/) - Almac Group, the global contract development and manufacturing organisation, is pleased to announce an expansion to its serialisation capabilities to include its US commercial packaging facility in Audubon, PA. Building upon Almac’s in-house expertise and proprietary serialisation / track and trace solution developed at its UK headquarters, this technology expansion will address FDA regulations
- [Merck & Co Inc Final overall survival (OS) dataData from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma To Be Presented at 2016 ASCO Annual Meeting](https://www.pharmaadvancement.com/pharma-news/merck-co-inc-final-overall-survival-os-datadata-from-keynote-006-and-keynote-001-in-advanced-melanoma-to-be-presented-at-2016-asco-annual-meeting/) - Final Overall Survival Data from KEYNOTE-006 To Be Presented at ASCO; KEYTRUDA, the First Anti-PD-1 Monotherapy to Demonstrate Overall Survival Compared to Ipilimumab, Shows Continued Benefit with Longer Follow-UpKEYNOTE-001 Findings Show Continued Benefit in Response Rates, Duration of Response, and Include New Three-Year Overall Survival Data for KEYTRUDA Merck known as MSD outside the United
- [AbbVies Showcased at Digestive Disease Week with New HUMIRA ,Real-World Research and Promising Anti-IL-23 Antibody Late-Breaking Data](https://www.pharmaadvancement.com/drug-development/research-development/abbvies-showcased-at-digestive-disease-week-with-new-humira-real-world-research-and-promising-anti-il-23-antibody-late-breaking-data/) - Data presentations further evaluate HUMIRA® (adalimumab) for the treatment of inflammatory bowel diseases including moderate to severe Crohn's disease in adult and pediatric patients Late-breaking Phase 2 data evaluates risankizumab, an anti-IL-23 monoclonal biologic antibody for the treatment of moderate to severe Crohn's disease, in collaboration with Boehringer Ingelheim AbbVie a global biopharmaceutical company,
- [AbbVie Inc to participate at the UBS Global Health Care Conference](https://www.pharmaadvancement.com/pharma-news/abbvie-inc-to-participate-at-the-ubs-global-health-care-conference/) - AbbVie will participate in the UBS Global Healthcare Conference on Monday, May 23, 2016. Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 1:00 p.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at www.abbvieinvestor.com. An
- [Pharma Giant Eli Lilly Wants to Launch 20 New Drugs by 2023](https://www.pharmaadvancement.com/pharma-news/pharma-giant-eli-lilly-wants-to-launch-20-new-drugs-by-2023/) - Indianapolis-based pharmaceutical giant Eli Lilly LLY -0.64% laid out an ambitious R&D agenda for launching up to 20 new drugs by 2023 during an investor presentation on Tuesday. The company also said it hopes to add a significant number of uses for its existing therapies in order to bolster those drugs’ market strength.
- [Dr Reddy's drops as US agency charges firm for packaging lapses](https://www.pharmaadvancement.com/pharma-news/dr-reddy-s-drops-as-us-agency-charges-firm-for-packaging-lapses/) - The US CPSC, which is tasked with protecting children and families from risks of injuries or death associated with consumer products, had taken issue with the company’s compliance norms. The US Consumer Product Safety Commission, a federal regulatory body, has pleaded to the US Department of Justice, seeking civil penalty
- [Merck, Pfizer double size of diabetes study to catch rivals](https://www.pharmaadvancement.com/pharma-news/merck-pfizer-double-size-of-diabetes-study-to-catch-rivals/) - Merck in partnership with Pfizer Inc. announced that two Phase 3 studies (VERTIS Mono and VERTIS Factorial) of ertugliflozin, an investigational oral SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, met their primary endpoints. The study results showed statistically significant reductions in A1C (a measure of average blood glucose) for both
- [FDA Panel To Review the Amgen’s ABP 501, Biosimilar Candidate To Adalimumab](https://www.pharmaadvancement.com/pharma-news/fda-panel-to-review-the-amgen-s-abp-501-biosimilar-candidate-to-adalimumab/) - Amgen announced that the Arthritis Advisory Committee of the U.S. FDA will review data supporting the Company's Biologics License Application (BLA) for ABP 501, a biosimilar candidate to Humira® (adalimumab). "With our heritage in both rheumatology and dermatology, we are committed to providing physicians and patients a variety of biologic options, which are critical
- [Biogen tanks as opicinumab misses Phase II endpoints in MS trial](https://www.pharmaadvancement.com/drug-development/clinical-trials/biogen-tanks-as-opicinumab-misses-phase-ii-endpoints-in-ms-trial/) - Biogen reported top-line results from the Phase 2 SYNERGY study evaluating opicinumab (anti-LINGO-1), an investigational, fully human monoclonal antibody being developed as a potential neuroreparative therapy in people with relapsing forms of multiple sclerosis (RMS). In the study, opicinumab missed the primary endpoint, a multicomponent measure evaluating improvement of physical function, cognitive function, and
- [Eisai presents data on its anti-fractalkine monoclonal antibody E6011](https://www.pharmaadvancement.com/pharma-news/eisai-presents-data-on-its-anti-fractalkine-monoclonal-antibody-e6011/) - Eisai Co Ltd. announced that interim analyses on the latest data for the world's first anti-fractalkine monoclonal antibody E6011, discovered by Eisai's research subsidiary KAN Research Institute Inc. from two respective Phase I/II clinical studies in Crohn's disease and rheumatoid arthritis (Study 101 and Study 103) showed positive results for safety and tolerability, and exploratory
- [Cepheid Announces WHO Prequalification Of Xpert HIV-1 Qualitative Test](https://www.pharmaadvancement.com/pharma-news/cepheid-announces-who-prequalification-of-xpert-hiv-1-qualitative-test/) - Cepheid announced that its Xpert® HIV-1 Qual test has been awarded WHO prequalification, making it one of the first molecular point of care tests designed for HIV to be given this designation. The test can detect HIV-1 in whole blood and dried blood spots from individuals suspected of HIV infection, including infants. Inclusion in
- [Advanced Clinical Receives Silver Award From Pro Unlimited Annual Global Supplier Awards](https://www.pharmaadvancement.com/pharma-news/advanced-clinical-receives-silver-award-from-pro-unlimited-annual-global-supplier-awards/) - Advanced Clinical has been recognized as a Silver Award recipient of PRO Unlimited’s Annual Global Supplier Awards. Recipients of this award consistently deliver the highest standard of excellence , meeting the talent and project requirements of PRO's global Fortune 1000 customers. Recipients are chosen based on customer service rankings, which are determined by a
- [Spark Therapeutics and Pfizer receives FDA Designation for SPK-9001](https://www.pharmaadvancement.com/drug-development/fda-approvals/spark-therapeutics-and-pfizer-receives-fda-designation-for-spk-9001/) - Spark Therapeutics and Pfizer Inc announced that the U.S. FDA has granted breakthrough therapy designation to SPK-9001, the lead investigational candidate in the companies’ SPK-FIX program, in development for the treatment of hemophilia B. SPK-9001, a novel bio-engineered adeno-associated virus (AAV) capsid expressing a codon-optimized, high-activity human factor IX variant, is being investigated in
- [U.S. FDA Grants Priority Review to Janssen’s New Drug Application for Chewable Mebendazole Tablets](https://www.pharmaadvancement.com/drug-development/fda-approvals/u-s-fda-grants-priority-review-to-janssen-s-new-drug-application-for-chewable-mebendazole-tablets/) - Janssen Pharmaceuticals, Inc one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for the New Drug Application (NDA) for a 500mg chewable tablet formulation of mebendazole. If approved, the chewable mebendazole tablet will provide a treatment and prevention
- [Allergan Plc Files Application to FDA for Approval of Oculeve Intranasal Tear Neurostimulator](https://www.pharmaadvancement.com/pharma-news/allergan-plc-files-application-to-fda-for-approval-of-oculeve-intranasal-tear-neurostimulator/) - Allergan plc announced that it has filed with the U.S. FDA the de novo application for the Oculeve Intranasal Tear Neurostimulator device. According to the FDA, this process provides a pathway for medical devices for which general and/or special controls provide a reasonable assurance of safety and effectiveness, but for which there is no legally
- [Egalet Announces OXAYDO Receives Pharmaceutical Composition Patent Protection Through 2024](https://www.pharmaadvancement.com/pharma-news/egalet-announces-oxaydo-receives-pharmaceutical-composition-patent-protection-through-2024/) - Egalet Corporation a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions announced the issuance of a United States patent covering OXAYDO® (oxycodone HCI, USP) tablets for oral use only–CII. Egalet licensed OXAYDO from Acura Pharmaceuticals and launched the product in the United States in September
- [Biogen Inc. Renews License with Absorption Systems for Testing Platform](https://www.pharmaadvancement.com/pharma-news/biogen-inc-renews-license-with-absorption-systems-for-testing-platform/) - Absorption Systems, a world leader in novel test systems for drug transporters, announces the renewal of a technology licensing deal with Biogen. After years of contract testing by Absorption Systems using MDR1-MDCK cells, Biogen licensed the technology associated with the test system from Absorption Systems in October 2015 and is renewing the license for another
- [FDA approves Novo Nordisk's diabetes drug](https://www.pharmaadvancement.com/drug-development/fda-approvals/fda-approves-novo-nordisk-s-diabetes-drug/) - Novo Nordisk A/S said the U.S. FDA approved on Monday its diabetes drug, Xultophy.The Danish drug maker said it planned to launch the drug in the United States in the first half of 2017. Xultophy, approved in Europe since 2014, combines Novo's
- [Sandoz’s Erelzi receives FDA Approval making it the First US Enbrel Biosimilar](https://www.pharmaadvancement.com/drug-development/fda-approvals/sandoz-s-erelzi-receives-fda-approval-making-it-the-first-us-enbrel-biosimilar/) - Sandoz, a Novartis company, has announced its drug, Erelzi, has been approved by the FDA, in a significant development.
- [Shire to Establish Rare Disease Innovation Hub in Cambridge, Mass.](https://www.pharmaadvancement.com/pharma-projects/shire-to-establish-rare-disease-innovation-hub-in-cambridge-mass/) - Shire plc announced that it will expand its operations in Cambridge, Massachusetts, establishing a rare disease innovation hub and increasing its footprint in the heart of Kendall Square. Shire and BioMed Realty have signed a lease for a 343,000-square-foot building
- [PCI Services Expanding of Cryogenic Storage Facilities at our Rockford, IL Site](https://www.pharmaadvancement.com/pharma-projects/pci-services-expanding-of-cryogenic-storage-facilities-at-our-rockford-il-site/) - PCI Services are pleased to announce that we are extending our current Cryogenic storage capabilities to our Rockford , Illinois operations, complementing the specialized capability currently offered at our Bridgend, UK center of excellence for Clinical Trial Services. This investment was made in support of the changing needs of the pharmaceutical and biotech market and
- [WUXI BIOLOGICS and PRIMA sign MOU and Announce Strategic Development and Manufacturing Partnership](https://www.pharmaadvancement.com/pharma-projects/wuxi-biologics-and-prima-sign-mou-and-announce-strategic-development-and-manufacturing-partnership/) - Prima BioMed Ltd and WuXi Biologics ,a WuXi AppTec group company, and a leading open-access R&D capability and technology platform company dedicated to expedite global biologics development, announced that a non-binding MOU was signed to form a strategic biologics development and manufacturing partnership. Under the partnership, WuXi Biologics will be the exclusive clinical and commercial
- [Dr Reddy's launches anti-fungal ointment in the US](https://www.pharmaadvancement.com/pharma-news/dr-reddy-s-launches-anti-fungal-ointment-in-the-us/) - Dr. Reddy’s Laboratories Ltd announced that it has launched Nystatin and Triamcinolone Acetonide Cream, USP, in the United States market, approved by the U.S. Food & Drug Administration (USFDA). Nystatin and Triamcinolone Acetonide Cream, USP is the generic equivanent of Nystatin and Triamcinolone Acetonide Cream, USP
- [DNA2.0 Inc Becomes ATUM](https://www.pharmaadvancement.com/pharma-news/dna2-0-inc-becomes-atum/) - Now combining DNA synthesis, protein expression and protein engineering capabilities, ATUM delivers full suite of service to speed discovery Founded in 2003 to marry computational design and gene synthesis, DNA2.0 was a pioneer in the application of machine learning (or artificial intelligence) to biology. The company is building on that legacy of invention with a new
- [VistaGen Licenses Stem Cell Technology to New Firm Backed by Big Pharma](https://www.pharmaadvancement.com/pharma-news/vistagen-licenses-stem-cell-technology-to-new-firm-backed-by-big-pharma/) - VistaGen Therapeutics Inc , a clinical-stage biopharmaceutical company focused on developing new generation therapies for depression and other central nervous system (CNS) disorders announced it has signed an exclusive sublicense agreement with BlueRock Therapeutics, a stem cell research company established by Bayer AG and Versant Ventures, for VistaGen's rights to certain proprietary technologies relating to
- [AMRA announces $9 million investment from Pfizer Venture Investments, Novo Seeds and Industrifonden](https://www.pharmaadvancement.com/pharma-news/amra-announces-9-million-investment-from-pfizer-venture-investments-novo-seeds-and-industrifonden/) - Swedish-based digital health company AMRA has announced a $9 million funding round co-led by US-based Pfizer Venture Investments and leading Nordic VC Novo Seeds. Industrifonden, another leading Nordic VC and current
- [Irvine Scientific Introduces PRIME-XV T Cell CDM for Immunotherapy Applications](https://www.pharmaadvancement.com/pharma-news/irvine-scientific-introduces-prime-xv-t-cell-cdm-for-immunotherapy-applications/) - Irvine Scientific, a worldwide leader in cell culture media development and manufacturing announced the introduction of PRIME-XV T Cell CDM, the first commercially available chemically-defined, animal component-free medium for T cell culture. The new medium has been developed to maximize consistent growth of T cells while maintaining their functionality and therapeutic potential.An increasingly important trend
- [Amri Announces Strategic Alliance To Advance Mass Spectrometry Capabilities For Drug Discovery](https://www.pharmaadvancement.com/pharma-projects/amri-announces-strategic-alliance-to-advance-mass-spectrometry-capabilities-for-drug-discovery/) - AMRI , a global contract research and manufacturing organization working to improve patient outcomes and quality of life, has entered an alliance with Bruker Daltonics and HighRes Biosolutions to develop new applications for using high throughput mass spectrometry (MS) for drug discovery. AMRI has acquired the new MALDI PharmaPulse system from Bruker Daltonics and HighRes
- [Epinomics to Collaborate with the Parker Institute for Cancer Immunotherapy at Stanford University](https://www.pharmaadvancement.com/pharma-news/epinomics-to-collaborate-with-the-parker-institute-for-cancer-immunotherapy-at-stanford-university/) - Researchers from Epinomics will collaborate with the research team led by Crystal Mackall, MD, director of the Parker Institute for Cancer Immunotherapy at Stanford, to utilize biomarkers defined by Epinomics’ immune intelligence framework to improve outcome and reduce adverse events in immunotherapy clinical trials. "The insights from this work will serve to direct further improvements
- [FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review](https://www.pharmaadvancement.com/drug-development/fda-approvals/fda-accepts-the-biologics-license-application-for-avelumab-for-the-treatment-of-metastatic-urothelial-carcinoma-for-priority-review/) - EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada, and Pfizer Inc. announced that the US FDA has accepted for Priority Review EMD Serono's Biologics License Application (BLA) for avelumab* as a treatment for patients with locally advanced or metastatic urothelial carcinoma (mUC) with disease progression on or after
- [ANI Pharmaceuticals Announces Launch of Pindolol Tablets](https://www.pharmaadvancement.com/pharma-news/ani-pharmaceuticals-announces-launch-of-pindolol-tablets/) - ANI Pharmaceuticals, Inc. announced the launch of Pindolol Tablets, 5mg and 10mg, which is used in the treatment of hypertension. The annual U.S. market for Pindolol Tablets is approximately $10 million, per IMS Health. Arthur S. Przybyl, ANI’s President and CEO stated, “We are excited to launch the first product from our partnership with IDT
- [LEO Pharma appoints Chris Posner to lead US business](https://www.pharmaadvancement.com/pharma-news/leo-pharma-appoints-chris-posner-to-lead-us-business/) - LEO Pharma announced that it appointed Chris Posner Executive Vice President Region US and President & CEO, LEO Pharma, Inc. President Region US and President & CEO, LEO Pharma, Inc. From July 15, 2017, he will be responsible for the US business of LEO Pharma, a global healthcare company dedicated to helping people achieve
- [Lexicon Collaborator Ipsen Receives Positive Chmp Opinion For Xermelo](https://www.pharmaadvancement.com/pharma-news/lexicon-collaborator-ipsen-receives-positive-chmp-opinion-for-xermelo/) - Lexicon Pharmaceuticals, Inc. , announced that the Committee for Medicinal Products for Human Use (CHMP), the committee of the European Medicines Agency (EMA) responsible for human medicines, has adopted a positive opinion for the Marketing Authorization Application (MAA) filed by Lexicon collaborator Ipsen for XERMELO® (telotristat ethyl) 250 mg to treat carcinoid syndrome diarrhea in
- [First FDA-Approved Treatment for ALS in 22 Years Now Available in U.S](https://www.pharmaadvancement.com/drug-development/fda-approvals/first-fda-approved-treatment-for-als-in-22-years-now-available-in-u-s/) - Mitsubishi Tanabe Pharma America, Inc. announced RADICAVA ™ (edaravone), an intravenous therapy indicated for all adult patients diagnosed with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is now available for treatment in the United States. RADICAVA, the first FDA-approved ALS treatment option in more than 20 years,has been demonstrated to slow the decline in the
- [Aurobindo Pharma receives FDA approval for Dolutegravir, Lamivudine & Tenofovir Disoproxil tablets](https://www.pharmaadvancement.com/drug-development/fda-approvals/aurobindo-pharma-receives-fda-approval-for-dolutegravir-lamivudine-tenofovir-disoproxil-tablets/) - Aurobindo Pharma Limited is pleased to announce that the company has received tentative approval from the U.S. FDA under the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (TLD) tablets, 50mg/300mg/300mg.The approved product is used for the treatment of HIV-1 infection alone as
- [Aurobindo Pharma receives USFDA Approval for Sevela mer Carbonate tablets](https://www.pharmaadvancement.com/drug-development/fda-approvals/aurobindo-pharma-receives-usfda-approval-for-sevela-mer-carbonate-tablets/) - Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture Sevelamer Carbonate tablets 800mg. Sevelamer Carbonate tablets, a therapeutic equivalent generic version of Genzyme’s Renvela® tablets. The product is being launched immediately. Sevelamer Carbonate tablets is indicated for the control of
- [FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma](https://www.pharmaadvancement.com/drug-development/fda-approvals/fda-grants-priority-review-for-genentech-s-gazyva-in-previously-untreated-follicular-lymphoma/) - Genentech, a member of the Roche Group , announced that the U.S. FDA has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Gazyva® (obinutuzumab) in combination with chemotherapy followed by Gazyva alone for people with previously untreated follicular lymphoma, one of the most common blood cancers among adults. Follicular lymphoma,
- [Sanofi Receives Tentative FDA Approval of Admelog 100 Units/mL](https://www.pharmaadvancement.com/drug-development/fda-approvals/sanofi-receives-tentative-fda-approval-of-admelog-100-units-ml/) - Sanofi announced that the U.S. FDA granted tentative approval for Admelog® (insulin lispro injection) 100 Units/mL, a rapid-acting human insulin analog. Admelog is indicated to improve glycemic control in adults and children with diabetes mellitus. The tentative approval is based on physicochemical, non-clinical and clinical similarity to another insulin lispro 100 Units/mL as currently approved
- [Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Omaveloxolone for the Treatment of Malignant Melanoma](https://www.pharmaadvancement.com/pharma-news/reata-pharmaceuticals-inc-receives-orphan-drug-designation-for-omaveloxolone-for-the-treatment-of-malignant-melanoma/) - Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that the United States Food and Drug Administration (“FDA”) has granted orphan designation to omaveloxolone for the treatment of Stage IIb through IV malignant melanoma. Reata is currently executing a Phase 1b/2 trial evaluating the safety and efficacy of omaveloxolone in combination with nivolumab or
- [2017 Scientist Award For Best New Clinical Laboratory Product received by Agilent](https://www.pharmaadvancement.com/pharma-news/2017-scientist-award-for-best-new-clinical-laboratory-product-received-by-agilent/) - Agilent Technologies Inc. has received a 2017 Scientists' Choice Award for Best New Clinical Laboratory Product: the IQFISH Panel for Lung Cancer. The IQFISH panel for lung cancer makes it easier for pathology labs to integrate fast, high-quality FISH (fluorescent in situ hybridization) into their IHC workflows. The announcement was made during a special ceremony
- [Juno Therapeutics Opens New Headquarters and Research Center](https://www.pharmaadvancement.com/drug-development/research-development/juno-therapeutics-opens-new-headquarters-and-research-center/) - Juno Therapeutics, Inc. a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today unveiled its new headquarters and research facility, located in the heart of South Lake Union in Seattle.The new headquarters brings together Juno’s Seattle employees – previously spread among three locations – enabling the company’s scientists, researchers, technical professionals and
- [New Nymalize Oral Solution 10 mL Unit Dose for the Treatment of Subarachnoid Hemorrhage launched by Arbor Pharma](https://www.pharmaadvancement.com/pharma-news/new-nymalize-oral-solution-10-ml-unit-dose-for-the-treatment-of-subarachnoid-hemorrhage-launched-by-arbor-pharma/) - Arbor Pharmaceuticals, LLC, a U.S.-based specialty pharmaceutical company, announced today that Nymalize® (nimodipine) Oral Solution will now be available in a 10 mL (30 mg) unit dose cup. This new packaging option is designed specifically for patients whom require a dosage that is lower than the standard 20 mL (60 mg) dose. Nymalize provides accurate,
- [UPMC Invests in Private Rome Hospital, Plans Expansion of Specialized Services](https://www.pharmaadvancement.com/pharma-news/upmc-invests-in-private-rome-hospital-plans-expansion-of-specialized-services/) - In a move that will expand advanced cancer services and other specialized treatments to patients in central and southern Italy, UPMC announced today that it is making a strategic investment in Salvator Mundi International Hospital, a well-respected private facility near Rome’s city center. UPMC now owns a 50 percent stake in Salvator Mundi, with the
- [Anti-Blindness Effort Pioneered by NewYork-Presbyterian/Columbia University Medical Center’s Tele-Ophthalmology Unit](https://www.pharmaadvancement.com/pharma-news/anti-blindness-effort-pioneered-by-newyork-presbyterian-columbia-university-medical-center-s-tele-ophthalmology-unit/) - Presbyterian/Columbia University Medical Center (CUMC) recently unveiled a state-of-the-art mobile testing unit in a push to reduce blindness-causing eye diseases across the city. The unit, called The Tele-Ophthalmology Unit, is the first of its kind in the country, targeting communities where residents are most vulnerable to four major sight-threatening conditions: glaucoma, cataracts, macular degeneration and
- [Ilc dover to unveil innovative new xtrakt™ bulk liquid dispensing system at pack expo](https://www.pharmaadvancement.com/pharma-news/ilc-dover-to-unveil-innovative-new-xtrakt-bulk-liquid-dispensing-system-at-pack-expo/) - ILC Dover has announced that it will be conducting live demos of its new Xtrakt™ Bulk Liquid Dispensing System in Booth 6758 at Pack Expo, which will run from 9:00 a.m. to 4:00 p.m.daily, September 25–27, at the Las Vegas Convention Center, Las Vegas, NV. The revolutionary Xtrakt™ System represents the first completely new packaging
- [Zimmer Biomet introduces Avenue T TLIF Cage with integrated VerteBRIDGE plating in US market](https://www.pharmaadvancement.com/pharma-news/zimmer-biomet-introduces-avenue-t-tlif-cage-with-integrated-vertebridge-plating-in-us-market/) - Zimmer Biomet Holdings, a global leader in musculoskeletal healthcare, announced it is officially launching in the United States the Avenue T TLIF Cage. Avenue T advances posterior lumbar cage technology by incorporating VerteBRIDGE plating, which facilitates simplified cage insertion and zero-profile, intradiscal fixation through a direct, minimally invasive surgical (MIS) approach. Avenue T is
- [Heptares founder richard henderson receives nobel prize in chemistry 2017 for pioneering work in cryo-em for visualising biological structures](https://www.pharmaadvancement.com/pharma-news/heptares-founder-richard-henderson-receives-nobel-prize-in-chemistry-2017-for-pioneering-work-in-cryo-em-for-visualising-biological-structures/) - Heptares Therapeutics (“Heptares”), a wholly owned subsidiary of Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), is delighted that one of its founders, Richard Henderson (MRC Laboratory of Molecular Biology, Cambridge, UK), was awarded the Nobel Prize in Chemistry 2017 together with Jacques Dubochet (University of Lausanne, Switzerland) and Joachim Frank (Columbia University, New York,
- [Aushon BioSystems and ABL, Inc. Announce Adoption of the Cira™ Platform for Multiplex and Ultrasensitive Biomarker Testing](https://www.pharmaadvancement.com/pharma-news/aushon-biosystems-and-abl-inc-announce-adoption-of-the-cira-platform-for-multiplex-and-ultrasensitive-biomarker-testing/) - BILLERICA, MASS and Rickville, MD Aushon BioSystems (Aushon) and ABL, Inc. (ABL) today announced that ABL has adopted the Cira platform for multiplex and ultrasensitive biomarker analysis. Effective immediately, ABL will offer this proprietary technology as a new, exciting addition to its service offerings in support of pharmaceutical and clinical research clients. “The adoption
- [AI-Driven Discovery of Novel Predictors of Parkinson’s Disease Progression by GNS Healthcare Appears in The Lancet Neurology](https://www.pharmaadvancement.com/pharma-news/ai-driven-discovery-of-novel-predictors-of-parkinson-s-disease-progression-by-gns-healthcare-appears-in-the-lancet-neurology/) - GNS Healthcare (GNS), a leading precision medicine company, announced today the discovery of genetic and molecular markers of faster motor progression of Parkinson’s Disease (PD) patients, the LINGO2 gene together with a second genetic variant, along with demographic factors. The publication describing the discovery, titled “Large-scale identification of clinical and genetic predictors of Parkinson’s disease
- [Marken Acquires Touchdown International Ltd in Taiwan](https://www.pharmaadvancement.com/market-moves/marken-acquires-touchdown-international-ltd-in-taiwan/) - Marken announced today the acquisition of Touchdown International Ltd, a privately held specialty logistics company in Taiwan, for an undisclosed sum. Touchdown is 100% dedicated to the life sciences industry and complements Marken’s strategy to continue expanding in the Asia Pacific region. Touchdown was founded in 2013 as a specialty courier with specific expertise in
- [Irvine Scientific Increases Production Capacity of Dry Powder Media for Cell Culture](https://www.pharmaadvancement.com/pharma-news/irvine-scientific-increases-production-capacity-of-dry-powder-media-for-cell-culture/) - Irvine Scientific, a world leader in cell culture media development and manufacturing today announced the expansion of its manufacturing facility in Santa Ana, California to increase overall dry-powder production capacity. The expansion was multistep and included: more space dedicated to its animal component free (ACF) dry powder production area, additional impact milling capacity, the addition
- [GE sets new standard for monoclonal antibody purification: Up to 40% increase in capacity](https://www.pharmaadvancement.com/pharma-news/ge-sets-new-standard-for-monoclonal-antibody-purification-up-to-40-increase-in-capacity/) - GE Healthcare introduces a new Protein A chromatography resin, MabSelect PrismA, which will help biopharmaceutical manufacturers improve their monoclonal antibody (mAb) purification capacity by up to 40 percent (1). The resin is also significantly more alkaline-stable (2), meaning that MabSelect PrismA can be cleaned with a higher concentration of sodium hydroxide to better control cross-contamination
- [Piramal Pharma Solutions Announces Large scale Expansion of API Manufacturing Facilities](https://www.pharmaadvancement.com/pharma-news/piramal-pharma-solutions-announces-large-scale-expansion-of-api-manufacturing-facilities/) - Piramal Pharma Solutions (PPS), a leading Contract Development and Manufacturing Organisation (CDMO) and part of Piramal Enterprises Ltd. (PEL), announced investments of $55 million across its sites in North America & Asia, to expand its APImanufacturing capabilities and capacities.A part of this investment will go into new state-of-the-art, multi-purpose plants, with over 270kL of total capacity, to support
- [Arctic™ Sperm Cryopreservation Medium introduced by Irvine Scientific](https://www.pharmaadvancement.com/pharma-news/arctic-sperm-cryopreservation-medium-introduced-by-irvine-scientific/) - Irvine Scientific, a world leader in the development and manufacture of cell culture media and Assisted Reproductive Technologies (ART), today announced the introduction of Arctic™ Sperm Cryopreservation Medium. This new medium is formulated to improve the post-thaw performance of frozen sperm samples and reduce the cost of sperm cryopreservation.Increasing numbers of infertility cases are found
- [CordenPharma Acquires Pfizer API Manufacturing Facility in Boulder Colorado](https://www.pharmaadvancement.com/market-moves/cordenpharma-acquires-pfizer-api-manufacturing-facility-in-boulder-colorado/) - CordenPharma, a leading Contract Development & Manufacturing Organization (CDMO), has entered into definite agreements to acquire the former Hospira Boulder (Colorado) high containment API site from Pfizer, Inc. The closing of the transaction is anticipated to occur in November 2017. Located in proximity to the existing CordenPharma Colorado facility, Hospira Boulder produces Active Pharmaceutical
- [FDA Approval And Launch Of Generic Renvela® (Sevelamer Carbonate) Tablets, 800 Mg announces impax](https://www.pharmaadvancement.com/drug-development/fda-approvals/fda-approval-and-launch-of-generic-renvela-sevelamer-carbonate-tablets-800-mg-announces-impax/) - Impax Laboratories, Inc., a specialty pharmaceutical company, announced it has received final U.S. FDA approval on its ANDA for a generic version of Renvela® (sevelamer carbonate) tablets, 800 mg. Impax has immediately initiated commercialization activities. "We are pleased to receive approval of our generic version of Renvela," said Paul Bisaro, President and Chief Executive Officer
- [BrainStorm Expands Its Patent Portfolio to Include a New US Patent For Its NurOwn Technology for Parkinson's Disease And ALS](https://www.pharmaadvancement.com/pharma-news/brainstorm-expands-its-patent-portfolio-to-include-a-new-us-patent-for-its-nurown-technology-for-parkinson-s-disease-and-als/) - BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that it has received Notice of Allowance from the United States Patent Office for US Patent Application No.: 14/173,846 titled "ISOLATED CELLS AND POPULATIONS COMPRISING SAME FOR THE TREATMENT OF CNS DISEASES". The allowed claims cover methods of
- [AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix](https://www.pharmaadvancement.com/drug-development/fda-approvals/abbvie-receives-u-s-fda-priority-review-for-investigational-oral-treatment-elagolix/) - AbbVie , a research and development based global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc.announced that the U.S. FDA has granted priority review for elagolix, an investigational, orally administered GnRH antagonist, being investigated for the management of endometriosis with associated pain. The FDA grants priority review to medicines that it determines have potential to
- [Astellas Partners with CNBC for its Global Branding Campaign](https://www.pharmaadvancement.com/pharma-news/astellas-partners-with-cnbc-for-its-global-branding-campaign/) - Astellas Pharma Inc. announced the next installment of its global corporate branding initiative, which it is conducting in collaboration with CNBC, the world's number one business and financial news network. The integrated campaign launches on November 1 and will run on CNBC's platforms in the United States, EMEA and Asia. Astellas initiated its global corporate
- [Eisai To Present Latest Data At 10th Clinical Trials On Alzheimer’s Diesase](https://www.pharmaadvancement.com/drug-development/clinical-trials/eisai-to-present-latest-data-at-10th-clinical-trials-on-alzheimer-s-diesase/) - Eisai Co., Ltd. announced that the latest data on its oral dual orexin receptor antagonist lemborexant and its oral beta secretase cleaving enzyme (BACE) inhibitor elenbecestat* will be presented at the 10th Clinical Trials on Alzheimer's Disease (CTAD), taking place in Boston, the United States, from November 1 to 4. At the CTAD meeting, there
- [Cerus And Kedrion Biopharma Enter Distribution Agreement For The Full INTERCEPT Blood System Portfolio In Italy](https://www.pharmaadvancement.com/pharma-news/cerus-and-kedrion-biopharma-enter-distribution-agreement-for-the-full-intercept-blood-system-portfolio-in-italy/) - Cerus Corporation announced that it has entered into an agreement with Kedrion Biopharma to distribute the full complement of INTERCEPT Blood System products in Italy. Kedrion Biopharma will initially distribute INTERCEPT for platelets and plasma and will have the right to distribute INTERCEPT red blood cells following CE mark approval. Under the terms of the
- [Merrimack Receives Orphan Drug Designation For MM-121 For The Treatment Of Heregulin Positive Non-Small Cell Lung Cancer](https://www.pharmaadvancement.com/pharma-news/merrimack-receives-orphan-drug-designation-for-mm-121-for-the-treatment-of-heregulin-positive-non-small-cell-lung-cancer/) - Merrimack Pharmaceuticals, Inc. announced that the U.S. FDA has granted orphan drug designation to MM-121, its investigational drug candidate, for the treatment of heregulin positive non-small cell lung cancer. MM-121 (seribantumab) is a fully human monoclonal antibody designed to block tumor survival signals and enhance the anti-tumor effect of combination therapies by targeting the cell
- [Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront](https://www.pharmaadvancement.com/drug-development/novartis-bolsters-late-stage-cardiovascular-pipeline-with-agreement-to-acquire-anthos-therapeutics-for-usd-925-million-upfront/) - Novartis acquires Anthos Therapeutics for $925M, strengthening its late-stage cardiovascular pipeline and advancing innovative heart health treatments.
- [Thermo Fisher to acquire Solventum’s Purification & Filtration business for US$4.1bn](https://www.pharmaadvancement.com/press-statements/thermo-fisher-to-acquire-solventums-purification-filtration-business-for-us4-1bn/) - Thermo Fisher acquires Solventum\'s Purification & Filtration division for $4.1 billion, enhancing its bioprocessing portfolio and global capabilities.
- [Global Biopharma Market to Hit $566B by 2032](https://www.pharmaadvancement.com/drug-development/global-biopharma-market-to-hit-566b-by-2032/) - Innovation, increased disease cases, and strategic industry collaborations will drive biopharma market growth at 8% CAGR to $566B by 2032 despite hurdles.
- [CDMO Growth and Biotechnology Outsourcing Trends](https://www.pharmaadvancement.com/market-moves/cdmo-growth-and-biotechnology-outsourcing-trends/) - Biotech CMOs drive innovation with expanded CDMO services, new facilities, and global outreach, supporting drug development, manufacturing, and market growth.
- [Pharmaceutical Chemicals Market Booms with Rising API Demand](https://www.pharmaadvancement.com/market-moves/pharmaceutical-chemicals-market-booms-with-rising-api-demand/) - Explore how the pharmaceutical chemicals market is growing globally fueled by API demand, specialty chemical innovations and sustainable manufacturing practices
- [FDA Approves Brain Tumour Treatment Modeyso by Jazz Pharma](https://www.pharmaadvancement.com/pharma-news/fda-approves-brain-tumour-treatment-modeyso-by-jazz-pharma/) - The U.S. FDA has approved Modeyso, a once-weekly oral capsule and the first FDA-approved brain tumour treatment for diffuse midline glioma in all age groups.
- [FDA PreCheck Programme to Boost U.S. Drug Manufacturing](https://www.pharmaadvancement.com/manufacturing/fda-precheck-programme-to-boost-u-s-drug-manufacturing/) - The FDA PreCheck programme will streamline regulations, boost U.S. drug manufacturing, and strengthen resilience in the domestic pharmaceutical supply chain.
- [FDA Approves Brinsupri by Insmed for Chronic Lung Condition](https://www.pharmaadvancement.com/pharma-news/fda-approves-brinsupri-by-insmed-for-chronic-lung-condition/) - The U.S. Food and Drug Administration, FDA approves Brinsupri developed by Insmed, as the first treatment for non-cystic fibrosis bronchiectasis lung condition
- [Trump Signs Executive Order to Boost US Pharma Supply Chain](https://www.pharmaadvancement.com/pharma-news/trump-signs-executive-order-to-boost-us-pharma-supply-chain/) - US President Trump directs stockpiling of APIs for 26 critical drugs, reinforcing domestic pharma manufacturing and strengthening the US pharma supply chain.
- [The U.S. FDA Approved Papzimeos for RRP Treatment in Adults](https://www.pharmaadvancement.com/pharma-news/the-u-s-fda-approved-papzimeos-for-rrp-treatment-in-adults/) - FDA Approved Papzimeos offers first-of-its-kind immunotherapy for adults with recurrent respiratory papillomatosis, providing a new, effective treatment option.
- [Pharmaceutical Tariff Agreed at 15% Under US-EU Trade Deal](https://www.pharmaadvancement.com/pharma-news/pharmaceutical-tariff-agreed-at-15-under-us-eu-trade-deal/) - Pharmaceutical tariff capped at 15% in the US-EU trade deal, easing pressure on exporters and ensuring greater stability for global pharmaceutical supply chains
- [AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline](https://www.pharmaadvancement.com/press-statements/abbvie-to-acquire-gilgamesh-pharmaceuticals-bretisilocin-a-novel-investigational-therapy-for-major-depressive-disorder-expanding-psychiatry-pipeline/) - AbbVie acquires Gilgamesh\'s bretisilocin to advance treatment of major depressive disorder, expanding its psychiatry pipeline with next-generation therapies.
- [Roche's Genentech Launches New Manufacturing Facility in USA](https://www.pharmaadvancement.com/pharma-news/roches-genentech-launches-new-manufacturing-facility-in-usa/) - Roche breaks ground on a Genentech Manufacturing Facility in USA\'s North Carolina, expanding production of metabolic medicines and creating new jobs in USA.
- [FDA Approves Sanofi’s Wayrilz for Immune Thrombocytopenia](https://www.pharmaadvancement.com/pharma-news/fda-approves-sanofis-wayrilz-for-immune-thrombocytopenia/) - FDA Approves Sanofi’s Wayrilz for adults with immune thrombocytopenia, providing a new therapy after trail showed sustained platelet and symptom improvement.
- [GSK to Invest $30B in Drug Manufacturing and R&D in the US](https://www.pharmaadvancement.com/pharma-news/gsk-to-invest-30b-in-drug-manufacturing-and-rd-in-the-us/) - GSK commits $30 billion to U.S. R&D and drug manufacturing, including $1.2 billion for new facilities, AI technologies, and expanded clinical trial operations.
- [Lilly to Build $6.5B API Manufacturing Facility in Houston](https://www.pharmaadvancement.com/manufacturing/lilly-to-build-6-5b-api-manufacturing-facility-in-houston/) - Eli Lilly will build a $6.5B API manufacturing facility in Houston, Texas, creating 615 jobs and boosting U.S. medicine production with advanced technologies.
- [Amgen to Expand U.S. Manufacturing with $650M Investment](https://www.pharmaadvancement.com/manufacturing/amgen-to-expand-u-s-manufacturing-with-650m-investment/) - Amgen is investing $650 M to expand U.S. manufacturing, creating nearly 750 jobs and boosting production with advanced technologies at its Juncos facility.
- [AbbVie Launches New API Manufacturing Facility in Illinois](https://www.pharmaadvancement.com/facilities-operation/abbvie-launches-new-api-manufacturing-facility-in-illinois/) - AbbVie begins construction of a new API Manufacturing Facility in North Chicago, expanding U.S. production of immunology, oncology, and neuroscience medicines.
- [US FDA Launches Fast-Track Review Scheme for Generic Drugs](https://www.pharmaadvancement.com/manufacturing/us-fda-launches-fast-track-review-scheme-for-generic-drugs/) - The US FDA launches a fast-track review programme for generics made and tested in the US, aiming to boost domestic production and reduce reliance on imports.
- [FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials](https://www.pharmaadvancement.com/drug-development/fda-clears-tissue-repair-drug-ad-np1-for-clinical-trials/) - FDA approves clinical trials for UCLA’s tissue repair drug AD-NP1, a first-in-class therapy that enhances organ regeneration by targeting cellular metabolism.
- [US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis](https://www.pharmaadvancement.com/drug-development/us-fda-approves-jascayd-for-idiopathic-pulmonary-fibrosis/) - US FDA approves Jascayd for idiopathic pulmonary fibrosis (IPF), providing the first new treatment in more than ten years for this rare, serious lung disease.
- [FDA Clears UZEDY Injection for Bipolar I Disorder in Adults](https://www.pharmaadvancement.com/drug-development/fda-clears-uzedy-injection-for-bipolar-i-disorder-in-adults/) - FDA approves UZEDY, a once-monthly risperidone injection for adults with Bipolar I Disorder, introducing new long-acting treatment and flexible dosing options.
- [FDA Approves Celltrion’s EYDENZELT for Retinal Diseases](https://www.pharmaadvancement.com/drug-development/fda-approves-celltrions-eydenzelt-for-retinal-diseases/) - FDA has approved EYDENZELT for Retinal Diseases, including wAMD, DME, DR, and RVO, providing new treatment options and expanding patient access in ophthalmology
- [FDA Clears Genentech’s Gazyva for Lupus Nephritis in Adults](https://www.pharmaadvancement.com/drug-development/fda-clears-genentechs-gazyva-for-lupus-nephritis-in-adults/) - FDA approves Genentech’s Gazyva for adults with active lupus nephritis, offering shorter infusions and a twice-yearly dosing schedule for eligible patients.
- [FDA Approves Amgen and AstraZeneca’s TEZSPIRE for CRSwNP](https://www.pharmaadvancement.com/drug-development/fda-approves-amgen-and-astrazenecas-tezspire-for-crswnp/) - FDA approves TEZSPIRE for CRSwNP, offering a new biologic option by Amgen and AstraZeneca to treat chronic nasal polyps and improve long-term symptom control.
- [FDA Approves Novo Nordisk’s Rybelsus Oral GLP-1 Therapy](https://www.pharmaadvancement.com/pharma-news/fda-approves-novo-nordisks-rybelsus-oral-glp-1-therapy/) - The US FDA approves Novo Nordisk’s Rybelsus®, the only oral GLP-1 therapy, to reduce the risk of major cardiovascular events in adults with type 2 diabetes.
- [AstraZeneca Unveils Expanded Manufacturing Facility in Texas](https://www.pharmaadvancement.com/manufacturing/astrazeneca-unveils-expanded-manufacturing-facility-in-texas/) - AstraZeneca has expanded its manufacturing facility in Coppell, Texas, investing $445m to boost Lokelma production and strengthen its US manufacturing footprint
- [Novartis to Acquire Avidity Biosciences in $12 Billion Deal](https://www.pharmaadvancement.com/facilities-operation/novartis-to-acquire-avidity-biosciences-in-12-billion-deal/) - Novartis will acquire U.S.-based Avidity Biosciences in a $12B cash deal to expand its rare muscle disorder therapies and strengthen its rare disease portfolio.
- [FDA Approves Omvoh by Eli Lilly for Ulcerative Colitis](https://www.pharmaadvancement.com/drug-development/fda-approves-omvoh-by-eli-lilly-for-ulcerative-colitis/) - US FDA approves Eli Lilly’s Omvoh single-injection treatment for adults with moderately to severely active ulcerative colitis, enhancing patient convenience.
- [FDA Unveils Initiative for Faster Biosimilar Development](https://www.pharmaadvancement.com/drug-development/fda-unveils-initiative-for-faster-biosimilar-development/) - The FDA has introduced new guidance to streamline biosimilar development, reducing costly trials and enabling faster access to affordable biologic alternatives.
- [Lilly, NVIDIA Partner on AI Supercomputer for Drug Research](https://www.pharmaadvancement.com/drug-development/lilly-nvidia-partner-on-ai-supercomputer-for-drug-research/) - Eli Lilly and NVIDIA are building a powerful supercomputer for drug research, creating an AI factory to accelerate medicine discovery and development worldwide.
- [FDA Approves UCB’s KYGEVVI for Thymidine Kinase 2 Deficiency](https://www.pharmaadvancement.com/drug-development/fda-approves-ucbs-kygevvi-for-thymidine-kinase-2-deficiency/) - The US FDA approves UCB’s KYGEVVI for thymidine kinase 2 deficiency, offering the first therapy for patients with symptom onset at or before 12 years of age.
- [FDA Approves J&J’s DARZALEX FASPRO for HR-SMM in Adults](https://www.pharmaadvancement.com/drug-development/fda-approves-jjs-darzalex-faspro-for-hr-smm-in-adults/) - FDA approves DARZALEX FASPRO® as the first and only treatment for adults with high-risk smoldering multiple myeloma, allowing earlier and proactive intervention
- [FDA Grants Approval for CAPLYTA for MDD Treatment in Adults](https://www.pharmaadvancement.com/drug-development/fda-grants-approval-for-caplyta-for-mdd-treatment-in-adults/) - FDA has granted Approval for CAPLYTA as a therapy for major depressive disorder in adults, expanding Johnson & Johnson’s treatment options for mental health.
- [Novartis Opens Radioligand Therapy Manufacturing Plant in US](https://www.pharmaadvancement.com/manufacturing/novartis-opens-radioligand-therapy-manufacturing-plant-in-us/) - Novartis opens a 10,000-sq-ft radioligand therapy manufacturing facility in Carlsbad, California, expanding US infrastructure and boosting production capacity.
- [Merck Announces Acquisition of Cidara Therapeutics at $9.2 B](https://www.pharmaadvancement.com/manufacturing/merck-announces-acquisition-of-cidara-therapeutics-at-9-2-b/) - Merck’s acquisition of Cidara Therapeutics advances its antiviral strategy, adding CD388 to its pipeline as a late-phase candidate for influenza prevention.
- [FDA Announces Removal of Black Box Warnings on HRT Products](https://www.pharmaadvancement.com/manufacturing/fda-announces-removal-of-black-box-warnings-on-hrt-products/) - HHS and the FDA move to lift broad Black Box Warnings from menopause-related HRT products, updating labels after new reviews to expand safe treatment options.
- [Henlius, Organon Secure FDA Approval for PERJETA Biosimilar](https://www.pharmaadvancement.com/drug-development/henlius-organon-secure-fda-approval-for-perjeta-biosimilar/) - FDA approves POHERDY as the first PERJETA biosimilar in the US, expanding options for HER2-positive breast cancer and improving access to quality biologics.
- [FDA Unveils Plausible Mechanism Pathway for Custom Therapies](https://www.pharmaadvancement.com/drug-development/fda-unveils-plausible-mechanism-pathway-for-custom-therapies/) - The plausible mechanism pathway accelerates bespoke gene treatment approvals by easing requirements and supporting personalised therapies for rare conditions.
- [FDA Clears Merck’s Keytruda with Padcev for Bladder Cancer](https://www.pharmaadvancement.com/drug-development/fda-clears-mercks-keytruda-with-padcev-for-bladder-cancer/) - FDA approves Merck’s Keytruda, Keytruda Qlex and Padcev perioperative regimen for cisplatin-ineligible muscle-invasive Bladder Cancer, backed by trial data.
- [FDA Clears Novartis Itvisma Gene Replacement Therapy for SMA](https://www.pharmaadvancement.com/drug-development/fda-clears-novartis-itvisma-gene-replacement-therapy-for-sma/) - FDA clears Novartis’ Itvisma gene replacement therapy for SMA, expanding access to one-time treatment designed to help address the genetic cause of the disease
- [AI-Assisted Fetal Screening Sets New Standard at Mount Sinai](https://www.pharmaadvancement.com/pharma-news/ai-assisted-fetal-screening-sets-new-standard-at-mount-sinai/) - Mount Sinai uses AI-assisted fetal screening to improve detection of congenital heart defects, raising accuracy, shortening read times, and boosting confidence
- [Advanced Clinical Trial Support Hub Launched in South Korea](https://www.pharmaadvancement.com/facilities-operation/advanced-clinical-trial-support-hub-launched-in-south-korea/) - Zuellig Pharma, the leading Asian healthcare solutions company has launched a state-of-the-art Clinical Trial Support innovation centre in South Korea.
- [New Clinical Data on Breast Cancer Detection Technology](https://www.pharmaadvancement.com/drug-development/new-clinical-data-on-breast-cancer-detection-technology/) - New clinical data on breast cancer detection tech is going to be presented by Hologic at RSNA with results coming from its 3DQuorum imaging technology.
- [A Possible New US Manufacturing Hub from Novartis](https://www.pharmaadvancement.com/pharma-news/a-possible-new-us-manufacturing-hub-from-novartis/) - The plans of a new US manufacturing hub from Novartis in Durham is a part of the $23bn investment which it has in store for the forthcoming five years.
- [Nigeria, Brazil Ink MoU to Push Local Pharma Manufacturing](https://www.pharmaadvancement.com/pharma-news/nigeria-brazil-ink-mou-to-push-local-pharma-manufacturing/) - Nigeria and Brazil have signed an MoU which will lead to push local pharma manufacturing so as to attain global competitiveness and be self-reliant.
- [Alvotech and Advanz Pharma Secure EC Approval for Gobivaz](https://www.pharmaadvancement.com/drug-development/alvotech-and-advanz-pharma-secure-ec-approval-for-gobivaz/) - EC approval for Gobivaz strengthens Alvotech and Advanz Pharma’s biosimilar presence, expanding access to immune-mediated disease treatments across Europe.
- [Aylward Showcases Advanced Bulk Handling Solutions: BPC and BPC Sorter](https://www.pharmaadvancement.com/press-statements/aylward-showcases-advanced-bulk-handling-solutions-bpc-and-bpc-sorter/) - Aylward’s Bulk Product Conveyor and BPC Sorter improve tablet handling, inspection and flow, helping solid dose manufacturers boost automation and quality.
- [Growth of Clinical Trials in Emerging Markets and its Impact on Pharma Supply Chains](https://www.pharmaadvancement.com/drug-development/growth-of-clinical-trials-in-emerging-markets-and-its-impact-on-pharma-supply-chains/) - Discover how growing clinical trials in emerging markets are transforming pharma supply chains, strengthening logistics and influencing global study planning.
- [Singapore’s Emergence as a Pharma Manufacturing & Logistics Powerhouse](https://www.pharmaadvancement.com/packaging-logistic/singapores-emergence-as-a-pharma-manufacturing-logistics-powerhouse/) - Discover why Singapore is becoming a leading pharma manufacturing and logistics hub, backed by strong regulation, world-class infrastructure and skilled talent.
- [The Pharmaceutical Industry’s Shift Toward Advanced Clinical Supply Solutions](https://www.pharmaadvancement.com/market-moves/the-pharmaceutical-industrys-shift-toward-advanced-clinical-supply-solutions/) - Explore how advanced clinical supply solutions, from adaptive packaging and labeling to smarter sourcing are transforming efficiency of modern trial operations.
- [The Next Wave of Biomanufacturing Facilities: Automation, Digitization and Sustainability](https://www.pharmaadvancement.com/market-moves/the-next-wave-of-biomanufacturing-facilities-automation-digitization-and-sustainability/) - Explore how automation, robotics, digitization and sustainable practices are shaping the next generation of efficient and resilient biomanufacturing facilities
- [Surge in CDMO Expansion: Why Pharma Companies are Increasing Outsourcing](https://www.pharmaadvancement.com/market-moves/surge-in-cdmo-expansion-why-pharma-companies-are-increasing-outsourcing/) - Explore why pharma companies are expanding outsourcing to CDMOs, driven by complex molecules, scalability demands and the push for faster market entry today.
- [Biopharmaceutical Manufacturing Growth: Capacity, Technology and Workforce Trends](https://www.pharmaadvancement.com/market-moves/biopharmaceutical-manufacturing-growth-capacity-technology-and-workforce-trends/) - Explore major trends defining biopharma manufacturing in 2025, from capacity expansion and advanced technologies to evolving workforce skills and demands.
- [Clinical Trial Material (CTM) Packaging Innovations Transforming Global Studies](https://www.pharmaadvancement.com/market-moves/clinical-trial-material-ctm-packaging-innovations-transforming-global-studies/) - Explore key innovations in CTM packaging, from smart labeling to temperature-controlled systems that protect products and support global clinical studies.
- [Bayer Secures EU Approval for Lynkuet Menopause Treatment](https://www.pharmaadvancement.com/drug-development/bayer-secures-eu-approval-for-lynkuet-menopause-treatment/) - Bayer secures EU approval for Lynkuet menopause treatment, expanding its non-hormonal VMS portfolio amid global rollout advances across major pharma markets.
- [Almac Announces Major Investment to Expand Singapore Facility](https://www.pharmaadvancement.com/press-statements/almac-announces-major-investment-to-expand-singapore-facility/) - Almac Singapore clinical supply expansion boosts warehouse capacity, cold chain packaging, and -20°C storage to meet rising APAC clinical trial demand.
- [Amgen Announces Phase 3 VESALIUS-CV Clinical Trial Results](https://www.pharmaadvancement.com/drug-development/amgen-announces-phase-3-vesalius-cv-clinical-trial-results/) - Amgen’s Phase 3 VESALIUS-CV Clinical Trial shows Repatha significantly reduces major cardiovascular risks, marking a significant advance in LDL-C management.
- [GENFIT and LabCorp Sign a Licensing Agreement to Expand Access to a Diagnostic Assay for Non-Alcoholic Steatohepatitis](https://www.pharmaadvancement.com/drug-development/genfit-and-labcorp-sign-a-licensing-agreement-to-expand-access-to-a-diagnostic-assay-for-non-alcoholic-steatohepatitis/) - LabCorp, a leading global life sciences company, and GENFIT, a biopharmaceutical company sign LabCorp's drug development business licensing agreement
- [Building the Right Team and Resource Model to Support Quality System and Validation Activities](https://www.pharmaadvancement.com/market-moves/building-the-right-team-and-resource-model-to-support-quality-system-and-validation-activities/) - Life Sciences CQV and CSA success starts with a multi-disciplinary team, risk-based CSV, paperless validation and managed services to scale compliance.
- [Merck and Blackstone Enter R&D Funding Agreement for sac-TMT](https://www.pharmaadvancement.com/drug-development/merck-and-blackstone-enter-rd-funding-agreement-for-sac-tmt/) - Merck partners with Blackstone Life Sciences in a $700M funding agreement for sac-TMT, supporting development across six cancer types in global Phase 3 trials
- [Lilly to Expand its Manufacturing Facility in Puerto Rico](https://www.pharmaadvancement.com/manufacturing/lilly-to-expand-its-manufacturing-facility-in-puerto-rico/) - Eli Lilly plans a $1.2 billion expansion of its Lilly del Caribe manufacturing facility in Puerto Rico, adding advanced technology and boosting production.
- [Lilly to Build $3B Manufacturing Facility in Netherlands](https://www.pharmaadvancement.com/manufacturing/lilly-to-build-3b-manufacturing-facility-in-netherlands/) - Eli Lilly is investing $3 billion in a new manufacturing facility in the Netherlands to expand oral medicine production and strengthen its global supply chain.
- [Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials](https://www.pharmaadvancement.com/press-statements/novartis-ianalumab-first-drug-to-reduce-disease-activity-and-patient-burden-in-sjogrens-disease-phase-iii-trials/) - Novartis reports positive Phase III results for ianalumab in Sjögren’s disease, showing reduced disease activity and potential as the first targeted therapy.
- [AstraZeneca Secures EU Approval for Koselugo to Treat NF1 PN](https://www.pharmaadvancement.com/drug-development/astrazeneca-secures-eu-approval-for-koselugo-to-treat-nf1-pn/) - AstraZeneca gains EU Approval for Koselugo to treat adults with NF1 PN, following KOMET Phase III results showing strong efficacy and consistent safety profile.
- [Guardant Health, Zephyr AI Collab to Advance Cancer Research](https://www.pharmaadvancement.com/drug-development/guardant-health-zephyr-ai-collab-to-advance-cancer-research/) - Guardant Health and Zephyr AI partnered to advance cancer research, combining AI-driven molecular data and analytics to accelerate precision oncology innovation
- [Biobeat Report: CDMO Growth in China and USA for 2026](https://www.pharmaadvancement.com/market-moves/biobeat-report-cdmo-growth-in-china-and-usa-for-2026/) - De Facto\'s new Biobeat Report analyzes CDMO market resilience, predicting growth for mAbs, PROTACs, and ADCs, despite AI\'s impact on biotech VC funding.
- [Digital Validation and Compliance in Pharma](https://www.pharmaadvancement.com/market-moves/digital-validation-and-compliance-in-pharma/) - Explore how digital validation tools and paperless systems transforming pharma compliance, enhancing accuracy, transparency and operational efficiency.
- [Pharma Manufacturing Hubs in the Middle East](https://www.pharmaadvancement.com/facilities-operation/pharma-manufacturing-hubs-in-the-middle-east/) - Discover how Middle East is building world-class pharmaceutical manufacturing hubs, boosting global competitiveness, innovation and regional healthcare growth.
- [Pharma Cold Chain 4.0 and Smart Logistics](https://www.pharmaadvancement.com/market-moves/pharma-cold-chain-4-0-and-smart-logistics/) - Discover how IoT and AI innovations are transforming temperature-controlled logistics, ensuring safety, traceability and quality for biopharmaceutical products.
- [Carbon-Neutral Bioprocessing in Pharmaceuticals](https://www.pharmaadvancement.com/manufacturing/carbon-neutral-bioprocessing-in-pharmaceuticals/) - Explore how green bioprocessing and energy-efficient systems enhance sustainability, reduce emissions and accelerate carbon neutrality in the pharma industry.
- [Precision Fermentation and the Future of Biomanufacturing](https://www.pharmaadvancement.com/manufacturing/precision-fermentation-and-the-future-of-biomanufacturing/) - Explore how precision fermentation technologies are transforming production of medicines, enzymes, and proteins driving innovation in modern biomanufacturing.
- [Pharma 5.0 Human-Centric Automation Trends](https://www.pharmaadvancement.com/market-moves/pharma-5-0-human-centric-automation-trends/) - Understand how Pharma 5.0 combines human intelligence and smart automation to enhance efficiency, innovation and sustainability across the pharma industry.
- [Regenerative Medicine and Cell Therapy Innovations](https://www.pharmaadvancement.com/drug-development/regenerative-medicine-and-cell-therapy-innovations/) - Discover how regenerative medicine and cell therapies are reshaping healthcare delivery, driving innovation and redefining biotech investment priorities.
- [Digital Transformation of Smart Pharma R&D Labs](https://www.pharmaadvancement.com/facilities-operation/digital-transformation-of-smart-pharma-rd-labs/) - How smart lab technologies and digital twin innovations are revolutionizing pharmaceutical research, development and innovation across the Middle East.
- [Strengthening Biotech Supply Chains in the Middle East](https://www.pharmaadvancement.com/market-moves/strengthening-biotech-supply-chains-in-the-middle-east/) - Explore how resilient, localized biotech supply chains accelerate commercialization, strengthen regional capabilities and drive life sciences innovation forward
- [AI in Drug Discovery Accelerates Pharma Innovation](https://www.pharmaadvancement.com/market-moves/ai-in-drug-discovery-accelerates-pharma-innovation/) - Explore how artificial intelligence is transforming drug discovery and development, accelerating innovation and growth across the Middle East pharma industry.
- [Continuous Manufacturing Transforming Formulation](https://www.pharmaadvancement.com/manufacturing/continuous-manufacturing-transforming-formulation/) - Discover how continuous manufacturing transforms drug formulation efficiency, scalability and quality for consistent performance and faster development.
- [Designing Effective Rare Disease Drug Formulations](https://www.pharmaadvancement.com/market-moves/designing-effective-rare-disease-drug-formulations/) - Patient-centric strategies to design stable rare disease formulations, spanning gene/enzyme therapies, pediatric dosing, CNS delivery, and expedited pathways.
- [Sustainable Formulation and Green Chemistry in Pharma](https://www.pharmaadvancement.com/market-moves/sustainable-formulation-and-green-chemistry-in-pharma/) - Explore how green chemistry, sustainable excipients, flow synthesis, biocatalysis, analytics and eco-friendly packaging cut waste and emissions in pharma.
- [Building Regulatory Readiness in Biologics Formulation](https://www.pharmaadvancement.com/market-moves/building-regulatory-readiness-in-biologics-formulation/) - Build regulatory readiness for biologics with QbD, robust CMC, analytics, process control, stability data, comparability and lifecycle plan to speed approvals
- [Smart Materials for Controlled Release Systems](https://www.pharmaadvancement.com/market-moves/smart-materials-for-controlled-release-systems/) - Explore stimuli-responsive polymers, hydrogels, liposomes, and nanoplatforms using pH, heat, enzymes, light, or magnets to deliver drugs and cut side effects.
- [Formulation Challenges in Biosimilars Development](https://www.pharmaadvancement.com/market-moves/formulation-challenges-in-biosimilars-development/) - Biosimilars face complex formulation, regulatory, and manufacturing challenges. Overcoming these barriers ensures safety, efficacy, and global accessibility.
- [Enhancing Stability in Biologics Formulation](https://www.pharmaadvancement.com/market-moves/enhancing-stability-in-biologics-formulation/) - Explore cutting-edge excipients, drying methods, and real-time analytics that enhance stability, extend shelf life, and ensure quality of modern biologics.
- [FDA Clears Elecsys pTau181 Alzheimer’s Test by Roche, Lilly](https://www.pharmaadvancement.com/drug-development/fda-clears-elecsys-ptau181-alzheimers-test-by-roche-lilly/) - The FDA has cleared Roche and Lilly’s Elecsys pTau181 test, allowing primary care doctors to assess Alzheimer’s risk in adults 55 and older more accurately.
- [EIB, EC to Finance BioNTech’s Kigali mRNA Vaccine Facility](https://www.pharmaadvancement.com/manufacturing/eib-ec-to-finance-biontechs-kigali-mrna-vaccine-facility/) - The EIB and EC back BioNTech’s Kigali mRNA vaccine facility with €95M financing, aiming to produce vaccines for malaria, HIV, tuberculosis, and mpox in Africa.
- [UK Grants Pharma Firms Early Access to Aligned Pathway](https://www.pharmaadvancement.com/drug-development/uk-grants-pharma-firms-early-access-to-aligned-pathway/) - MHRA and NICE have invited early adopters for the Aligned Pathway which will accelerate licensing and approvals for medicines, boosting UK’s life science sector
- [Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery](https://www.pharmaadvancement.com/drug-development/bristol-myers-takeda-astex-to-back-ai-based-drug-discovery/) - Bristol Myers, Takeda and Astex join AbbVie and J&J in a global consortium to strengthen AI Based Drug Discovery by training the OpenFold3 model with data.
- [Overcoming Challenges in High-Volume Injectable Formulations](https://www.pharmaadvancement.com/market-moves/overcoming-challenges-in-high-volume-injectable-formulations/) - Discover how pharmaceutical scientists tackle viscosity, stability, and delivery challenges to advance high-volume injectable formulation development.
- [Wearable Drug Delivery Devices for On-Demand Care](https://www.pharmaadvancement.com/market-moves/wearable-drug-delivery-devices-for-on-demand-care/) - Discover how wearable drug delivery devices are transforming treatment with on-demand therapeutics via smart systems and patient-friendly injection solutions.
- [Breakthroughs in Biologic Drug Formulation Stability](https://www.pharmaadvancement.com/drug-development/breakthroughs-in-biologic-drug-formulation-stability/) - Discover how advanced formulation techniques are enhancing biologic drug stability, extend shelf life, and optimize delivery of biologic drugs worldwide.
- [Lipid Nanoparticles in RNA and Gene Therapies](https://www.pharmaadvancement.com/drug-development/lipid-nanoparticles-in-rna-and-gene-therapies/) - Discover how lipid nanoparticle technology powers RNA drugs and gene therapies, driving the next era of pharma innovation and transformative treatments.
- [Smart Drug Delivery Systems for Patient Care](https://www.pharmaadvancement.com/market-moves/smart-drug-delivery-systems-for-patient-care/) - Explore how smart drug delivery systems revolutionize patient care through precision dosing, enhanced therapeutic results, and improved treatment experiences.
- [US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly](https://www.pharmaadvancement.com/drug-development/us-fda-approves-breast-cancer-therapy-inluriyo-by-eli-lilly/) - Eli Lilly’s Inluriyo oral breast cancer therapy, is US FDA-approved for ER+, HER2–, ESR1-mutated advanced or metastatic patients after prior endocrine therapy
- [Green Chemistry in Sustainable API Manufacturing](https://www.pharmaadvancement.com/market-moves/green-chemistry-in-sustainable-api-manufacturing/) - Discover how green chemistry practices are advancing sustainability in pharmaceutical ingredient production through cleaner, eco-friendly processes worldwide.
- [Future of Active Pharmaceutical Ingredients Supply](https://www.pharmaadvancement.com/market-moves/future-of-active-pharmaceutical-ingredients-supply/) - Discover how global supply chain Shifts and regulations are reshaping the future of active pharmaceutical ingredient production in pharma manufacturing.
- [Advances in Pharmaceutical Excipients for New Therapies](https://www.pharmaadvancement.com/market-moves/advances-in-pharmaceutical-excipients-for-new-therapies/) - Explore how cutting-edge pharmaceutical excipients are enhancing the stability, efficacy and performance in next-generation drug formulations and therapies.
- [Innovative Ingredient Sourcing in Pharma Markets](https://www.pharmaadvancement.com/market-moves/innovative-ingredient-sourcing-in-pharma-markets/) - Explore how pharma companies are adopting innovative sourcing strategies and diversified supply chains to secure critical pharmaceutical ingredients.
- [API Manufacturing Quality and Regulatory Trends](https://www.pharmaadvancement.com/market-moves/api-manufacturing-quality-and-regulatory-trends/) - Explore how evolving GMP standards and regulatory frameworks are transforming quality and compliance in API manufacturing across the pharmaceutical industry.
- [US FDA to Approve Leucovorin for Cerebral Folate Deficiency](https://www.pharmaadvancement.com/drug-development/us-fda-to-approve-leucovorin-for-cerebral-folate-deficiency/) - The FDA has started the approval process for leucovorin calcium tablets to treat cerebral folate deficiency, working with GSK to expand Wellcovorin labeling.
- [Merck and Siemens to Accelerate AI Driven Drug Development](https://www.pharmaadvancement.com/drug-development/merck-and-siemens-to-accelerate-ai-driven-drug-development/) - Merck and Siemens signed a new MoU to merge AI, automation and data-driven tools, advancing digital drug discovery, development and manufacturing worldwide.
- [ABPI Launches Manifesto to Advance Scottish Pharma Sector](https://www.pharmaadvancement.com/manufacturing/abpi-launches-manifesto-to-advance-scottish-pharma-sector/) - ABPI has unveiled its manifesto urging bold policies to strengthen the Scottish pharma sector, improve patient access, boost R&D, and drive health innovation.
- [Generative AI in Pharma Labs Driving Data to Discovery](https://www.pharmaadvancement.com/drug-development/generative-ai-in-pharma-labs-driving-data-to-discovery/) - Generative AI is transforming pharma research by analyzing data, optimizing experiments, and speeding discovery from hypothesis to therapy development.
- [Generative AI for Drug Discovery Accelerating Molecule Design](https://www.pharmaadvancement.com/market-moves/generative-ai-for-drug-discovery-accelerating-molecule-design/) - How generative AI transforming drug discovery by rapidly designing and optimizing molecules, empowering pharma scientists with faster, smarter lab innovations.
- [Automating Experimental Design with Generative AI in Pharma](https://www.pharmaadvancement.com/market-moves/automating-experimental-design-with-generative-ai-in-pharma/) - Discover how generative AI automates experimental design, boosting efficiency and innovation for pharmaceutical scientists in the lab.
- [Generative AI in Genomics, Proteomics and Molecular Research](https://www.pharmaadvancement.com/market-moves/generative-ai-in-genomics-proteomics-and-molecular-research/) - See how generative AI advances genomics, proteomics, and molecular biology, enabling pharma researchers to achieve faster and deeper insights.
- [Generative AI Bridging Wet Lab and Dry Lab Workflows](https://www.pharmaadvancement.com/market-moves/generative-ai-bridging-wet-lab-and-dry-lab-workflows/) - Learn how generative AI unifies wet lab and dry lab workflows, optimizing resources, driving efficiency and accuracy across pharmaceutical research processes.
- [Generative AI Enhancing Reproducibility in Pharma Experiments](https://www.pharmaadvancement.com/market-moves/generative-ai-enhancing-reproducibility-in-pharma-experiments/) - Understand how generative AI strengthens reproducibility in pharma labs, ensuring reliable results and consistent scientific outcomes.
- [FDA Grant Approval for Opzelura Cream for Pediatric Eczema](https://www.pharmaadvancement.com/drug-development/fda-approvals/fda-grant-approval-for-opzelura-cream-for-pediatric-eczema/) - The FDA has approved Incyte’s Opzelura cream for Pediatric Eczema in children aged 2–11, offering a steroid-free treatment option and expanding its market reach
- [Ethical Challenges of Generative AI in Pharma Labs](https://www.pharmaadvancement.com/market-moves/ethical-challenges-of-generative-ai-in-pharma-labs/) - Explore the challenges and ethical issues of generative AI in pharma labs, from responsible research to transparent AI-driven drug discovery.
- [Amneal Secures FDA Approval for Sodium Oxybate Oral Solution](https://www.pharmaadvancement.com/pharma-news/amneal-secures-fda-approval-for-sodium-oxybate-oral-solution/) - Amneal secures FDA approval for Sodium Oxybate Oral Solution, broadening treatment options for narcolepsy patients and reinforcing its medicines portfolio.
- [US FDA Tightens Oversight on Misleading Drug Advertising](https://www.pharmaadvancement.com/pharma-news/us-fda-tightens-oversight-on-misleading-drug-advertising/) - FDA intensifies oversight on misleading drug advertising, enforcing regulations on pharmaceuticals and Bigpharma to ensure safety, accuracy, and transparency.
- [US FDA Approves Bladder Cancer Treatment Inlexzo from J&J](https://www.pharmaadvancement.com/pharma-news/us-fda-approves-bladder-cancer-treatment-inlexzo-from-jj/) - US FDA approves Inlexzo bladder cancer treatment from Johnson & Johnson (J&J), offering a surgery-free option for patients resistant to BCG therapy.
- [Eli Lilly Unveils Lilly TuneLab for AI-driven Drug Discovery](https://www.pharmaadvancement.com/pharma-news/eli-lilly-unveils-lilly-tunelab-for-ai-driven-drug-discovery/) - Eli Lilly unveils Lilly TuneLab, an AI-driven platform providing biotech companies access to advanced drug discovery models built on decades of research data.
- [Enhancing Clinical Research with Advanced Sensor Technology](https://www.pharmaadvancement.com/drug-development/clinical-trials/enhancing-clinical-research-with-advanced-sensor-technology/) - Sensor technology enhances clinical trials with real-time monitoring, accurate data, improved efficiency, and personalized care to optimize research outcomes.
- [FDA Approves Recombinant VWF Treatment in Pediatric Patients](https://www.pharmaadvancement.com/pharma-news/fda-approves-recombinant-vwf-treatment-in-pediatric-patients/) - FDA approves recombinant VWF for pediatric VWD, granting children access to the first non-plasma therapy for acute bleeding episodes and surgical management.
- [Novartis and Argo Signs Deal of up to $5.2b for Heart Drugs](https://www.pharmaadvancement.com/pharma-news/novartis-and-argo-signs-deal-of-up-to-5-2b-for-heart-drugs/) - Novartis and Argo have entered a deal worth up to $5.2b to advance RNAi-based therapies for cardiovascular disease, strengthening their biotech partnership.
- [Mod GRF 1-29 Peptide: Investigating Its Potential in Scientific Research](https://www.pharmaadvancement.com/pharma-news/mod-grf-1-29-peptide-investigating-its-potential-in-scientific-research/) - Explore the role of Mod GRF 1-29 Peptide in scientific research, its mechanisms, and potential applications in biomedical and therapeutic studies.
- [MGI Tech and JCBio Advance Multi-Omics with DCS Lab Project](https://www.pharmaadvancement.com/pharma-news/mgi-tech-and-jcbio-advance-multi-omics-with-dcs-lab-project/) - MGI Tech and JCBio launch DCS Lab Project in South Korea, advancing multi-omics research, sequencing innovation, and progress in biotech and precision medicine.
- [Novartis and Arrowhead Sign Deal to Advance Parkinson's Drug](https://www.pharmaadvancement.com/pharma-news/novartis-and-arrowhead-sign-deal-to-advance-parkinsons-drug/) - Novartis and Arrowhead finalize a strategic deal to advance RNA therapy for Parkinson’s, targeting brain proteins and addressing neurodegenerative diseases.
- [FDA Approves Eisai’s Leqembi IQLIK for Alzheimer’s Treatment](https://www.pharmaadvancement.com/pharma-news/fda-approves-eisais-leqembi-iqlik-for-alzheimers-treatment/) - FDA approves Eisai\'s Leqembi IQLIK, a weekly Alzheimer\'s therapy that simplifies treatment, broadens access for dementia patients, aiding healthcare systems.
- [Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases](https://www.pharmaadvancement.com/market-moves/emerging-oral-small-molecule-drugs-for-ultra-rare-diseases/) - The emerging small-molecule drugs for ultra-rare diseases are revolutionizing treatment with accessible, and innovative therapies driven by medical advancements
- [VarioFill: Rotzinger sets new standards with highly flexible filling and capping platform for OTC products](https://www.pharmaadvancement.com/press-statements/variofill-rotzinger-sets-new-standards-with-highly-flexible-filling-and-capping-platform-for-otc-products/) - Rotzinger Launches Filling and Capping Platform for OTC, delivering modular design, 50% space savings, gentle transport, and flexible product handling.
- [U.S. FDA Approves Ionis’ DAWNZERA for Hereditary Angioedema](https://www.pharmaadvancement.com/pharma-news/u-s-fda-approves-ionis-dawnzera-for-hereditary-angioedema/) - The FDA has approved DAWNZERA for hereditary angioedema patients, offering the first RNA-targeted therapy designed to prevent HAE attacks with durable efficacy.
- [J&J Investment of $2B Boosts US Drug Manufacturing Capacity](https://www.pharmaadvancement.com/pharma-news/jj-investment-of-2b-boosts-us-drug-manufacturing-capacity/) - J&J Investment of $2B expands U.S. drug manufacturing capacity, enhances production of advanced medicines, and strengthens healthcare innovation nationwide.
- [Lupin, Sandoz Collab to Commercialise Biosimilar Ranibizumab](https://www.pharmaadvancement.com/pharma-news/lupin-sandoz-collab-to-commercialise-biosimilar-ranibizumab/) - Lupin partners with Sandoz to commercialise its biosimilar ranibizumab across multiple global markets, while Lupin manages manufacturing and regulatory filings
- [Carbon Reduced Pharmaceutical Glass: SCHOTT Melting Tank Construction Starts and External Certification for FIOLAX® Pro OCF](https://www.pharmaadvancement.com/press-statements/carbon-reduced-pharmaceutical-glass-schott-melting-tank-construction-starts-and-external-certification-for-fiolax-pro-ocf/) - Pharmaceutical Glass Tubing Cuts Carbon Emissions by 50% with SCHOTT\'s innovative electric melting technology and green energy for sustainable drug packaging.
- [Thermo Fisher New HMW Kit Powers Long-Read DNA Sequencing](https://www.pharmaadvancement.com/pharma-news/thermo-fisher-new-hmw-kit-powers-long-read-dna-sequencing/) - Thermo Fisher’s MagMAX HMW DNA Kit enables efficient long-read DNA sequencing with fast, consistent DNA extraction for labs using manual or automated workflows.
- [Taiwan Grants Full Approval for NEFECON IgAN Treatment](https://www.pharmaadvancement.com/drug-development/fda-approvals/taiwan-grants-full-approval-for-nefecon-igan-treatment/) - Taiwan’s TFDA grants full approval for NEFECON® to treat IgAN, removing prior limitations and enabling broader access for patients at risk of kidney decline.
- [Agentic AI in Pharma: Transforming R&D to Commercialisation](https://www.pharmaadvancement.com/pharma-trends/agentic-ai-in-pharma-transforming-rd-to-commercialisation/) - Agentic AI in pharma is revolutionising drug discovery, clinical trials, regulatory compliance, and market access, making processes faster, and efficient
- [Future Trends Shaping Pharma Supply Chain and Logistics](https://www.pharmaadvancement.com/pharma-trends/future-trends-shaping-pharma-supply-chain-and-logistics/) - The future trends in pharma supply chain and logistics, emphasising digitalisation, risk management, cold chain, and data security for resilient healthcare.
- [New Software to Predict Cell Activity for Cancer Research](https://www.pharmaadvancement.com/pharma-news/new-software-to-predict-cell-activity-for-cancer-research/) - Innovative software to predict cell activity combining genomics and computational modeling predicting cell behavior over time enabling cancer treatments.
- [Biosimulation Market Size and Growth Projections: 2025–2030](https://www.pharmaadvancement.com/market-moves/biosimulation-market-size-and-growth-projections-2025-2030/) - The biosimulation market size, market growth, regional insights, and technological advances shaping the future of drug discovery and personalised medicine.
- [The Future of Clinical Trial Data in Decentralisation Models](https://www.pharmaadvancement.com/market-moves/the-future-of-clinical-trial-data-in-decentralisation-models/) - Rethinking clinical trial data in decentralisation enhances data quality, accelerates research, and promotes patient-centric approaches for better healthcare.
- [GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology](https://www.pharmaadvancement.com/press-statements/gsk-and-hengrui-pharma-enter-agreements-to-develop-up-to-12-innovative-medicines-across-respiratory-immunology-inflammation-and-oncology/) - GSK and Hengrui partner on 12 innovative medicines deals including COPD drug, expanding their pipeline and driving global growth through strategic collaboration
- [Aptar Pharma Bolsters Clinical Trial Capabilities with Strategic Materials Manufacturing Acquisition](https://www.pharmaadvancement.com/press-statements/aptar-pharma-bolsters-clinical-trial-capabilities-with-strategic-materials-manufacturing-acquisition/) - Aptar Pharma expands cGMP clinical trial services with Mod3 Pharma acquisition, enhancing drug delivery solutions from early-phase to patient-ready therapies.
- [FDA Accepts BLA for Recommended Biosimilar to Simponi](https://www.pharmaadvancement.com/pharma-news/fda-accepts-bla-for-recommended-biosimilar-to-simponi/) - The FDA accepts BLA for a proposed biosimilar to Simponi, BAT2506 bringing affordable, and offering high-quality treatment options for diseases in the US.
- [Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug](https://www.pharmaadvancement.com/pharma-news/merck-to-acquire-verona-pharma-in-10b-deal-boosts-copd-drug/) - Merck to acquire Verona Pharma in $10B deal to boost COPD drug development, expanding its pipeline with promising therapies ahead of Keytruda patent expiry.
- [ChiRhoClin, LogiCare3PL Partners for Drug Distribution](https://www.pharmaadvancement.com/pharma-news/chirhoclin-logicare3pl-partners-for-drug-distribution/) - ChiRhoClin, LogiCare3PL partners for ChiRhoClin\'s product ChiRhoStim, distribution ensuring the reliable, and timely delivery of critical diagnostic treatments
- [Strategies for the Resilient Perinatal Drug Supply Chain](https://www.pharmaadvancement.com/market-moves/strategies-for-the-resilient-perinatal-drug-supply-chain/) - Building a resilient perinatal drug supply chain through diversification, technology, policy, and digital tools is essential for maternal and neonatal health.
- [Thermo Fisher and Sanofi Partners for US Drug Manufacturing](https://www.pharmaadvancement.com/pharma-news/thermo-fisher-and-sanofi-partners-for-us-drug-manufacturing/) - Thermo Fisher expands US drug manufacturing capacity through acquisition of Sanofi’s Ridgefield site, supporting biotech demand and strengthening manufacturing.
- [EMA Recommendations to Secure Anti-D Immunoglobulins Supply](https://www.pharmaadvancement.com/pharma-news/ema-recommendations-to-secure-anti-d-immunoglobulins-supply/) - EMA urges EU regulators and industry to secure anti-D immunoglobulins supply to prevent RhD immunisation, ensuring pregnancy safety amid donor shortages.
- [FDA Approves Oral Therapy for Treating Hereditary Angioedema](https://www.pharmaadvancement.com/pharma-news/fda-approves-oral-therapy-for-treating-hereditary-angioedema/) - FDA approves Ekterly, an on-demand oral therapy for treating hereditary angioedema attacks, offering faster symptom relief to patients aged 12 years and older
- [Welcome to the Inaugural Operationalize: Expanded Access Programs Summit West](https://www.pharmaadvancement.com/press-statements/welcome-to-the-inaugural-operationalize-expanded-access-programs-summit-west/) - West Coast Summit on Expanded Access Programs 2025 brings global leaders together to share strategies, case studies, and insights to improve patient access.
- [WuXi Biologics and Virogen Bio partner to advance VG712](https://www.pharmaadvancement.com/pharma-news/wuxi-biologics-and-virogen-bio-partner-to-advance-vg712/) - WuXi Biologics is all set to offer comprehensive services like tech transfer, process validation, etc. to advance VG712, the clinical-stage asset of Virogen.
- [Role of CDMOs In Technology Transfer From Molecule To Market](https://www.pharmaadvancement.com/market-moves/role-of-cdmos-in-technology-transfer-from-molecule-to-market/) - With expertise within the manufacturing, compliance and also numerous levels of advancements, role of CDMOs in technology transfer plays a critical role.
- [CDMOs Driving Agile Production Within Intricate Therapies](https://www.pharmaadvancement.com/market-moves/cdmos-driving-agile-production-within-intricate-therapies/) - CDMOs driving agile production when it comes to addressing challenges such as strict quality norms and complex processes is a gamechanger for therapies.
- [Biotech CMOs In Russia and Eurasia – A Growing Spectrum](https://www.pharmaadvancement.com/pharma-trends/biotech-cmos-in-russia-and-eurasia-a-growing-spectrum/) - The biotech CMOs in Russia and Eurasia are seeing a change as economic spectrum, regulatory processes and tech advancements are gaining ground in the region.
- [Digitally Driven Pharma Plants Acing Real-Time Tracking](https://www.pharmaadvancement.com/pharma-trends/digitally-driven-pharma-plants-acing-real-time-tracking/) - As the demand for high-quality medicine grows, digitally driven pharma plants are making their presence felt with their predictive maintenance technologies.
- [Construction of WuXi Biologics Microbial Manufacturing Site](https://www.pharmaadvancement.com/pharma-news/construction-of-wuxi-biologics-microbial-manufacturing-site/) - The construction of microbial manufacturing site at Chengdu by WuXi Biologics will enable the development of 80-110 drug substance batches every year.
- [Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season](https://www.pharmaadvancement.com/pharma-news/beyfortus-from-sanofi-to-make-imprint-in-2025-26-rsv-season/) - For broad availability through 2025-26 RSV Season, Beyfortus from Sanofi is all set to offer confidence to healthcare givers for effective infant immunization.
- [Thermo Fischer Accelerator Drug Development an Ideal Choice](https://www.pharmaadvancement.com/pharma-news/thermo-fischer-accelerator-drug-development-an-ideal-choice/) - The Accelerator drug development CDMO and CRO solutions by Thermo Fischer Scientific offers significant time savings in delivering therapies to the patients.
- [Advantages of Industry 4.0 Technologies in Drug Production](https://www.pharmaadvancement.com/pharma-trends/advantages-of-industry-4-0-technologies-in-drug-production/) - Characterised by smart factories, data-driven decision making, advantages of Industry 4.0 technologies enable pharma companies to hit high level scalability.
- [IQVIA Custom-Built AI Agents for Life Sciences, Healthcare](https://www.pharmaadvancement.com/pharma-news/iqvia-custom-built-ai-agents-for-life-sciences-healthcare/) - The new custom-built AI agents from IQVIA using the technology from NVIDIA would elevate the workflows and enable fast insights for the life sciences.
- [SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges](https://www.pharmaadvancement.com/pharma-news/schott-pharma-invests-eur-100-million-in-rtu-cartridges/) - SCHOTT Pharma invests over EUR 100 million in Hungary to expand RTU cartridges production, enhancing supply security and supporting global growth strategies.
- [Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia](https://www.pharmaadvancement.com/press-statements/avadel-pharmaceuticals-receives-orphan-drug-designation-from-fda-for-lumryz-sodium-oxybate-for-extended-release-oral-suspension-for-the-treatment-of-idiopathic-hypersomnia/) - Avadel Pharmaceuticals announces LUMRYZ\'s Orphan Drug Designation from the FDA for Idiopathic Hypersomnia, highlighting its potential to transform patient care
- [Work Smart: Go for  Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk](https://www.pharmaadvancement.com/drug-development/research-development/work-smart-go-for-hands-free-lab-informatics-at-the-bench-not-scribbled-notes-and-delayed-documentation-at-your-desk/) - Hands-Free Efficiency with Lab Informatics Systems – Enhance productivity and accuracy with real-time data, voice input, and connected lab technologies.
- [Robots and AI in Drug Discovery Are Transforming Medicine](https://www.pharmaadvancement.com/articles/robots-and-ai-in-drug-discovery-are-transforming-medicine/) - Explore how robots and AI in drug discovery accelerate timelines, cut costs, and enhance precision, revolutionizing pharmaceutical research and patient care
- [Stringent Policy around COVID Vaccines Laid by FDA](https://www.pharmaadvancement.com/pharma-news/stringent-policy-around-covid-vaccines-laid-by-fda/) - By amping up the requirement for certain set of approvals, the US FDA is rolling out a strict policy around COVID vaccines to make it varied from the flu ones.
- [Regulatory Trends in Pharma Manufacturing to Watch in 2025](https://www.pharmaadvancement.com/market-moves/regulatory-trends-in-pharma-manufacturing-to-watch-in-2025/) - Explore regulatory trends in pharma manufacturing, from AI integration and digital systems to sustainability and personalized medicine, shaping 2025 and beyond
- [AI-Driven Biomanufacturing Adoption Boosts Pharma Quality](https://www.pharmaadvancement.com/pharma-trends/ai-driven-biomanufacturing-adoption-boosts-pharma-quality/) - AI-driven biomanufacturing adoption is redefining the way the development of drugs and therapies takes place in addition to production efficiency and quality.
- [Drug Delivery Technologies Impacting 2025 and Beyond](https://www.pharmaadvancement.com/pharma-trends/drug-delivery-technologies-impacting-2025-and-beyond/) - Pharmaceutical sector is getting largely impacted by the advent of numerous drug delivery technologies which are paving the way for unmatched breakthroughs.
- [Drugmakers Asked to Strictly Follow the US Pricing Reforms](https://www.pharmaadvancement.com/pharma-news/drugmakers-asked-to-strictly-follow-the-us-pricing-reforms/) - The drugmakers are asked to match with the lowest cost of medicines that they are offering to other countries and hence follow the US pricing reforms.
- [Next in Pharma 2025: Innovations Shaping the Future](https://www.pharmaadvancement.com/drug-development/next-in-pharma-2025-innovations-shaping-the-future/) - Explore what\'s next in pharma 2025, from AI-driven production and precision medicine to sustainable practices and value-based healthcare shaping the industry.
- [ACHEMA Middle East to Debut in Riyadh in 2026 Trade Show](https://www.pharmaadvancement.com/press-statements/achema-middle-east-to-debut-in-riyadh-in-2026-trade-show/) - ACHEMA Middle East to Debut in Riyadh in 2026 Trade Show, uniting global process industry leaders, innovators, and policymakers under Saudi Vision 2030.
- [Digital Twins in Biopharma: Innovation in Manufacturing](https://www.pharmaadvancement.com/articles/digital-twins-in-biopharma-innovation-in-manufacturing/) - Explore how digital twins in biopharmaceutical manufacturing optimize processes, enhance quality, and drive innovation through AI and real-time data.
- [DHL Supply Chain comes up with New Pharma Hub in Singapore](https://www.pharmaadvancement.com/pharma-news/dhl-supply-chain-comes-up-with-new-pharma-hub-in-singapore/) - As part of DHL Groups commitment to enhance life sciences & healthcare infrastructure across its business units, new pharma hub in Singapore has been unveiled.
- [Recombinant DNA Technology Market: A Growth Revolution](https://www.pharmaadvancement.com/articles/recombinant-dna-technology-market-a-growth-revolution/) - Explore the recombinant DNA technology market\'s growth, applications in healthcare, agriculture, and industry, driving innovation and sustainability globally.
- [APM Steam Highlights Comprehensive HVAC Insulation Services for Biopharmaceutical and Pharmaceutical Facilities](https://www.pharmaadvancement.com/press-statements/apm-steam-highlights-comprehensive-hvac-insulation-services-for-biopharmaceutical-and-pharmaceutical-facilities/) - American Plant Maintenance (APM Steam), a leading provider of steam systems maintenance services, highlights its innovative HVAC insulation services, designed to provide significant energy savings and
- [Asia-Pacific Biologics Contract Development Market Growth](https://www.pharmaadvancement.com/articles/asia-pacific-biologics-contract-development-market-growth/) - Explore the growth of the Asia-Pacific biologics contract development market, driven by innovation, cost efficiency, and rising global demand for biologics.
- [AI Revolutionizing Drug Discovery and Clinical Development](https://www.pharmaadvancement.com/articles/ai-revolutionizing-drug-discovery-and-clinical-development/) - Discover how AI in drug discovery and clinical development is revolutionizing precision medicine, optimizing trials and accelerating innovative therapies
- [Asia Pacific Omics-Based Clinical Trials Market Growth](https://www.pharmaadvancement.com/market-moves/asia-pacific-omics-based-clinical-trials-market-growth/) - Asia Pacific Omics-Based Clinical Trials Market to hit USD 10.4B by 2030, driven by population diversity, cost-effectiveness, and regulatory support.
- [China's Super Me-Too Drug Development: A New Pharma Frontier](https://www.pharmaadvancement.com/articles/chinas-super-me-too-drug-development-a-new-pharma-frontier/) - Explore China\'s super me-too drug development strategy, focusing on innovation, affordability, and global expansion in the evolving pharmaceutical landscape.
- [Empty Capsules Market Growth to Reach $4.2B by 2029](https://www.pharmaadvancement.com/market-moves/empty-capsules-market-growth-to-reach-4-2b-by-2029/) - Empty capsules market Growth to Reach $4.2B by 2029, growing at 6.3% CAGR, fueled by nutraceuticals, tech advancements and plant-based capsule demand.
- [Amcor Healthcare Packaging Expansion in Asia Pacific](https://www.pharmaadvancement.com/pharma-news/amcor-healthcare-packaging-expansion-in-asia-pacific/) - Amcor healthcare packaging expansion advances in Asia Pacific with a cutting-edge coating facility, improving healthcare packaging access and efficiency.
- [AstraZeneca Eyes Acquisition To Develop Cell Therapies](https://www.pharmaadvancement.com/market-moves/astrazeneca-eyes-acquisition-to-develop-cell-therapies/) - AstraZeneca pursues acquisition of EsoBiotec for $1 billion to advance cell therapies portfolio, focusing on innovative in vivo therapies via EnaBL platform.
- [AI in Drug Commercialization Market to Grow CAGR 24% by 2032](https://www.pharmaadvancement.com/articles/ai-in-drug-commercialization-market-to-grow-cagr-24-by-2032/) - The global AI drug commercialization market is set to grow at a CAGR of 24% by 2032, revolutionizing drug launches, pricing, and patient engagement worldwide
- [Pharma Sector Seeks Seamless EU Medical Device Rules](https://www.pharmaadvancement.com/pharma-trends/pharma-sector-seeks-seamless-eu-medical-device-rules/) - The pharmaceutical sector is looking to align MDR and IVDR to make the medical device sector in the EU more seamless and filled with immense opportunities.
- [Advanced Instruments All Set To Merge With Nova Biomedical](https://www.pharmaadvancement.com/pharma-news/advanced-instruments-all-set-to-merge-with-nova-biomedical/) - Advanced Instruments to acquire Nova Biomedical to help establishing an analytical instruments platform enhancing biopharma & clinical market capacities.
- [Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million](https://www.pharmaadvancement.com/pharma-news/taiho-pharmaceutical-buys-araris-biotech-ag-for-740-million/) - In order to further expand its portfolio in the field of oncology, Taiho Pharmaceutical from Japan has bought Araris Biotech from Switzerland for $740 million.
- [Biopharmaceutical Manufacturing With Continuous Processing](https://www.pharmaadvancement.com/market-moves/biopharmaceutical-manufacturing-with-continuous-processing/) - Biopharmaceutical manufacturing has to have support of continuous processing as it will enable the much-needed access to life-changing biological treatments.
- [Oracle Wins the Asia Pacific Biopharma Excellence Awards](https://www.pharmaadvancement.com/pharma-news/oracle-wins-the-asia-pacific-biopharma-excellence-awards/) - Second consecutive Best Clinical Trial Supplier Award for Data Management & Analytics for Oracle Life Sciences at the Asia Pacific Biopharma Excellence Awards.
- [Continuous Manufacturing is Improving Biopharma Production](https://www.pharmaadvancement.com/articles/continuous-manufacturing-is-improving-biopharma-production/) - Continuous manufacturing is improving biopharma production, ensuring faster timelines, lower costs, better quality and sustainability in future of healthcare
- [AI Transforming Drug Development & Cutting Costs](https://www.pharmaadvancement.com/articles/ai-transforming-drug-development-cutting-costs/) - Explore how AI is transforming drug development, accelerating discovery, enhancing trials, and cutting costs to save billions for the pharmaceutical industry.
- [Continuous Bioprocessing Market to Surge by 2028](https://www.pharmaadvancement.com/market-moves/continuous-bioprocessing-market-to-surge-by-2028/) - Continuous bioprocessing market to grow at 22.4% CAGR, reaching $599M by 2028, revolutionizing pharma manufacturing with efficiency, quality, and innovation.
- [Advancing Asia-Pacific Healthcare & Biopharma Innovation](https://www.pharmaadvancement.com/market-moves/advancing-asia-pacific-healthcare-biopharma-innovation/) - Asia-Pacific governments promote biopharma growth through R&D, collaborations, and innovation hubs like Singapore, boosting healthcare and entrepreneurs.
- [Generative AI in Pharma: Opportunities & Challenges](https://www.pharmaadvancement.com/market-moves/generative-ai-in-pharma-opportunities-challenges/) - Generative AI shows potential in pharma for R&D, manufacturing, and supply chains, but regulatory compliance, expertise gaps, and adoption hinder progress.
- [Overcoming The Pharma Supply Challenges In Biopharma](https://www.pharmaadvancement.com/articles/overcoming-the-pharma-supply-challenges-in-biopharma/) - Global biopharma logistics are evolving as pharma supply challenges rise. Discover how couriers are tackling the main regulatory and sustainability issues.
- [Biotech Spinouts : Seven Key Startups To Watch In 2025](https://www.pharmaadvancement.com/articles/biotech-spinouts-seven-key-startups-to-watch-in-2025/) - Biotech spinouts are transforming research into innovative treatments. These 7 innovative startups are changing immunology, neurology, and cancer treatment.
- [AI Boosts Small Molecule Therapies for I&I Diseases](https://www.pharmaadvancement.com/articles/ai-boosts-small-molecule-therapies-for-ii-diseases/) - In I&I diseases space, drug development which is powered by artificial intelligence is making small molecules more attractive as compared to biologics.
- [Celonic Group Signs Long-Term Multi-Year Manufacturing Service Agreement with LINDIS Biotech for the Commercial Supply of Catumaxomab](https://www.pharmaadvancement.com/drug-development/celonic-group-signs-long-term-multi-year-manufacturing-service-agreement-with-lindis-biotech-for-the-commercial-supply-of-catumaxomab/) - LINDIS Biotech partners with Celonic Group for GMP manufacturing of catumaxomab, the only EMA-approved targeted therapy for malignant ascites treatment.
- [Bio-Rad to Acquire Stilla Technologies by Q3 2025](https://www.pharmaadvancement.com/drug-development/clinical-trials/bio-rad-to-acquire-stilla-technologies-by-q3-2025/) - Bio-Rad to acquire Stilla Technologies, enhancing its digital PCR portfolio and expanding genomics research and clinical diagnostics capabilities globally.
- [3 ways Pharmaceutical Manufacturers Can Accelerate New Product Time-to-Market](https://www.pharmaadvancement.com/articles/3-ways-pharmaceutical-manufacturers-can-accelerate-new-product-time-to-market/) - Pharmaceutical production is recognized as an important benefit for our modern lives. According to IQVIA Institute for Human Data Science total spending and global demand for medicines will increase to approximately $1.9 trillion by 2027.
- [Vitafoods India 2025 Ignites Powerful Knowledge Exchange, Elevating the Future of Nutraceuticals](https://www.pharmaadvancement.com/health-nutrition/vitafoods-india-2025-ignites-powerful-knowledge-exchange-elevating-the-future-of-nutraceuticals/) - The 3rd edition of Vitafoods India, organised by Informa Markets in India, India's leading B2B exhibition organiser, commenced today at Pavilion 1-2, Jio World Convention Center, Mumbai. Taking place
- [AI and Nanotech Innovations in Advancing Drug Discovery](https://www.pharmaadvancement.com/pharma-news/ai-and-nanotech-innovations-in-advancing-drug-discovery/) - AI, nanotechnology, and organoids are advancing drug discovery, transforming development into a more precise, efficient process with targeted treatments.
- [AI Use To Transform Antibody Discovery & Design In Israel](https://www.pharmaadvancement.com/facilities-operation/ai-use-to-transform-antibody-discovery-design-in-israel/) - The launch of CombinAble.AI goes on to shift the approach to targeted antibody design by making use of AI to make optimise and speed-up the discover process.
- [Types of Pharmaceutical Waste and How to Dispose of Them](https://www.pharmaadvancement.com/pharma-news/types-of-pharmaceutical-waste-and-how-to-dispose-of-them/) - If your facility handles pharmaceuticals, you are likely to produce pharmaceutical waste. Proper disposal is essential to prevent environmental harm and protect human health. By understanding.
- [Saudi Arabia Poised to Expand Domestic Manufacturing Eco-system as 30,000 Attendees join Inaugural CPHI Middle East](https://www.pharmaadvancement.com/press-statements/saudi-arabia-poised-to-expand-domestic-manufacturing-eco-system-as-30000-attendees-join-inaugural-cphi-middle-east/) - Riyadh: Efforts to build a new manufacturing, biomanufacturing and R&D hub in Saudi Arabia and across the wider Middle East are accelerating as more than 30,000 pharma professionals and decision makers to attend the inaugural CPHI Middle East
- [Women Leaders in Biopharma: The Way Forward](https://www.pharmaadvancement.com/pharma-trends/women-leaders-in-biopharma-the-way-forward/) - According to the World Health Organization (WHO), women account for 70% of the global healthcare workforce1, significantly higher than in other industries such as tech at 26%, and financial services a
- [Pharma Contract Manufacturing 2025](https://www.pharmaadvancement.com/press-statements/pharma-contract-manufacturing-2025/) - The pharma contract manufacturing industry is projected to grow substantially, reaching $320 billion by 2029. This growth is linked to rising drug development costs, rapid technological advancements,
- [Scalability and therapeutic potential of induced pluripotent reprogramming and neural induction using small molecules](https://www.pharmaadvancement.com/pharma-trends/scalability-and-therapeutic-potential-of-induced-pluripotent-reprogramming-and-neural-induction-using-small-molecules/) - Although we may disagree about the precise costs of bringing novel therapies to market, and even what factors contribute to those costs, it is clear that they have spiraled out of control. Their spora
- [Asahi Kasei Microdevices Advances AgeTech with Better AI-Ready Data Through New Sensor Technologies - Devices will be demonstrated at CES 2025, showing how aging in place can be safer and more accessible](https://www.pharmaadvancement.com/press-statements/asahi-kasei-microdevices-advances-agetech-with-better-ai-ready-data-through-new-sensor-technologies-devices-will-be-demonstrated-at-ces-2025-showing-how-aging-in-place-can-be-safer-and-more-accessi/) - Düsseldorf, Tokyo and Novi – The desire to age in place is stronger than ever, with 95% of adults 55 and older considering it an important goal, according to U.S. News & World Report, even though health challenges
- [Nutraceuticals 2025 takes position on international trade fair calendar, with fair slated for 5th and 6th March at new venue](https://www.pharmaadvancement.com/press-statements/nutraceuticals-2025-takes-position-on-international-trade-fair-calendar-with-fair-slated-for-5th-and-6th-march-at-new-venue/) - Valencia - The next Nutraceuticals Europe Summit & Expo takes place on 5th and 6th March 2025 and professionals, producers, distributors and customers in the functional ingredients, novel foods and finished
- [UK Medicine Manufacturing Regulatory Framework For Care](https://www.pharmaadvancement.com/pharma-news/uk-medicine-manufacturing-regulatory-framework-for-care/) - The UK medicine manufacturing regulatory framework is set to redefine localized care, enhancing safe, efficient delivery of patient-specific therapies.
- [Nanoemulsion Drug Delivery Enhances Tuberculosis Care](https://www.pharmaadvancement.com/pharma-news/nanoemulsion-drug-delivery-enhances-tuberculosis-care/) - Nanoemulsion-based drug delivery for bedaquiline shows improved release and solubility, supporting pediatric-friendly options for TB treatment efficacy.
- [The Future of Drug Delivery Systems In Modern Medicine](https://www.pharmaadvancement.com/pharma-news/the-future-of-drug-delivery-systems-in-modern-medicine/) - Innovations in drug delivery systems improve targeted treatment by enhancing controlled release and reducing side effects, revolutionizing patient care.
- [The Future of Small Molecule Drug Discovery Market](https://www.pharmaadvancement.com/pharma-news/the-future-of-small-molecule-drug-discovery-market/) - The small molecule drug discovery market is booming, driven by high-throughput screening, personalized medicine, and advances in AI-based drug design.
- [Advancing Drug Delivery With Nanoparticle Technology](https://www.pharmaadvancement.com/pharma-news/advancing-drug-delivery-with-nanoparticle-technology/) - Advancing drug delivery with lipid nanoparticles allows precise immune response control, broadening RNA-based therapeutics for diverse medical applications.
- [Reshaping clinical decisions and development with AI- and data-centric mindset](https://www.pharmaadvancement.com/market-moves/reshaping-clinical-decisions-and-development-with-ai-and-data-centric-mindset/) - Clinical data and processes hold untapped potential for reducing the burden and increasing the probability of success in drug discovery and development. For years, complexity, heterogeneity with unforeseen confounding factors, and legal restrictions
- [The data-driven revolution: How real-time analytics are transforming mRNA manufacturing](https://www.pharmaadvancement.com/market-moves/the-data-driven-revolution-how-real-time-analytics-are-transforming-mrna-manufacturing/) - After slow market growth following the first RNA therapy launch in 1998 [1], recent clinical and commercial successes have propelled RNA therapeutics into the pharmaceutical spotlight.
- [Highlights from AL Ideathon 2024: Transforming the Future of Pharma Through Innovation](https://www.pharmaadvancement.com/market-moves/highlights-from-al-ideathon-2024-transforming-the-future-of-pharma-through-innovation/) - AmpleLogic’s Ideathon 2024 took center stage in Hyderabad on September 28, marking a landmark event for the pharmaceutical and life sciences industries. As the leading platform for discussing advancements in artificial intelligence (AI)
- [Record numbers expected at CPHI & PMEC China 2024 as Asian markets boom](https://www.pharmaadvancement.com/press-statements/record-numbers-expected-at-cphi-pmec-china-2024-as-asian-markets-boom/) - CPHI & PMEC China (June 19-21st) returns to the Shanghai New International Expo Center amid soaring demand across the pharmaceutical supply chain in Asia. China, already the primary source of pharmace
- [swop 2024: Year-End Packaging Roundup - Uncovering Industry Trends and Future Outlook](https://www.pharmaadvancement.com/press-statements/swop-2024-year-end-packaging-roundup-uncovering-industry-trends-and-future-outlook/) - Shanghai World of Packaging (swop) will take center stage from November 18 to 20, 2024, at the Shanghai New International Expo Center. This year, swop will offer packaging professionals a forward-thin
- [New Method of Drug Value: Incorporating Real-World Data](https://www.pharmaadvancement.com/drug-development/new-method-of-drug-value-incorporating-real-world-data/) - The SoLV method incorporates real-world data on health disparities and offers a more equitable way to assess drug value, moving beyond the limitations of QALYs.
- [AI And The Future of Drug Discovery And Manufacturing](https://www.pharmaadvancement.com/drug-development/ai-and-the-future-of-drug-discovery-and-manufacturing/) - AI is reshaping drug discovery, clinical trials, and manufacturing in the pharma industry, reducing costs and speeding up development while enhancing precision.
- [AI Technology Transforming Pharmaceutical Route Scouting](https://www.pharmaadvancement.com/drug-development/ai-technology-transforming-pharmaceutical-route-scouting/) - Lonza is advancing drug development with AI route scouting, reducing costs and optimizing synthetic routes in record time, helping companies submit INDs faster.
- [Advancing Biologics : New Drug Delivery Methods In Focus](https://www.pharmaadvancement.com/drug-development/advancing-biologics-new-drug-delivery-methods-in-focus/) - Biologic drug delivery faces hurdles with injection-based methods. New advancements in inhaled and oral delivery show promise for improving patient compliance.
- [Nanoparticles : Next Frontier In Pharmaceutical Innovations](https://www.pharmaadvancement.com/drug-development/nanoparticles-next-frontier-in-pharmaceutical-innovations/) - The SoLV method incorporates real-world data on health disparities and offers a more equitable way to assess drug value, moving beyond the limitations of QALYs.
- [Nickel Complex Innovations Streamlines Drug Development](https://www.pharmaadvancement.com/drug-development/nickel-complex-innovations-streamlines-drug-development/) - A new nickel complex allows researchers to create drugs faster by simplifying alkyl bond formation, cutting drug development costs and improving efficiency.
- [Overcoming Challenges With ML And AI In Drug Development](https://www.pharmaadvancement.com/manufacturing/overcoming-challenges-with-ml-and-ai-in-drug-development/) - AI and ML offer pharmaceutical firms data-driven insights for R&D but require overcoming challenges in data integration and quality aided by ACD-Labs solutions.
- [Molecular Rotational Resonance Is Improving Drug Development](https://www.pharmaadvancement.com/pharma-news/molecular-rotational-resonance-is-improving-drug-development/) - MRR is changing pharma analysis by offering detailed structural information on complex mixtures, reducing separation time, and improving process efficiency.
- [Streamlining Toxicology Materials For IND And FIH Studies](https://www.pharmaadvancement.com/drug-development/streamlining-toxicology-materials-for-ind-and-fih-studies/) - Accelerating toxicology materials helps meet IND timelines for drug development. Technologies, in-silico tools, and evolving regulations play a pivotal role.
- [The Impact of Polycarbonate On Medical Tools And Safety](https://www.pharmaadvancement.com/pharma-news/the-impact-of-polycarbonate-on-medical-tools-and-safety/) - Polycarbonate is very important for healthcare tools, offering a lot of strength, sterilization ease, and transparency, ensuring durability and patient safety.
- [Managing E&L In Pharma : Important Challenges And Solutions](https://www.pharmaadvancement.com/pharma-news/managing-el-in-pharma-important-challenges-and-solutions/) - Extractables and leachables threaten drug safety. Advancements in AI, testing, and analytics target to manage these risks for better regulatory compliance.
- [5 Future Trends In Pharmaceutical Packaging Sphere Post 2025](https://www.pharmaadvancement.com/pharma-news/5-future-trends-in-pharmaceutical-packaging-sphere-post-2025/) - Post-2025 pharmaceutical packaging will evolve with trends in smart tech, eco-friendly materials, enhanced safety, serialization, and personalized packaging.
- [FDA Grants Breakthrough Status To GSKs Lung Cancer Drug](https://www.pharmaadvancement.com/drug-development/fda-grants-breakthrough-status-to-gsks-lung-cancer-drug/) - Targeting aggressive lung cancer, GSKs $1.7B ADC has been granted FDA breakthrough status, launching a novel therapy for advanced-stage small-cell lung cancer.
- [Booming Radiopharmaceuticals Industry Attracts Investors](https://www.pharmaadvancement.com/drug-development/booming-radiopharmaceuticals-industry-attracts-investors/) - With M&A and partnerships on the rise,the radiopharmaceutical sector is booming, offering significant investment options as it continues to expand swiftly.
- [Bayer, NextRNA Collaborate On $547Million Cancer Drug Deal](https://www.pharmaadvancement.com/drug-development/bayer-nextrna-collaborate-on-547million-cancer-drug-deal/) - In a $547M deal, Bayer and NextRNA collaborate to develop small molecule cancer drugs targeting long non-coding RNA, with a focus on the high-need conditions.
- [Enhancing CLD For Complex Biologics: Important Strategies](https://www.pharmaadvancement.com/drug-development/enhancing-cld-for-complex-biologics-important-strategies/) - Test
- [North American Nuclear Medicine Market Set For Expansion](https://www.pharmaadvancement.com/drug-development/north-american-nuclear-medicine-market-set-for-expansion/) - North American nuclear medicine market, valued at USD 2.05B in 2023, is projected to grow at a 9.90% CAGR, driven by AI, hybrid imaging, and theranostics.
- [Bayer, NextRNA Ink $547Million Deal For Cancer Therapies](https://www.pharmaadvancement.com/drug-development/bayer-nextrna-ink-547million-deal-for-cancer-therapies/) - Bayer partners with NextRNA in a $547Million deal to develop new cancer therapies, focusing on the lncRNA-driven diseases with high unmet need in oncology.
- [New Endometrial Cancer Care Phase II Results Encouraging](https://www.pharmaadvancement.com/pharma-news/new-endometrial-cancer-care-phase-ii-results-encouraging/) - Phase II trial result of sacituzumab govitecan- antibody drug conjugate, conducted by Yale Cancer Center researchers at Yale School of Medicine is encouraging.
- [Duality Keeps An Eye Out For Hong Kong IPO For ADC Trials](https://www.pharmaadvancement.com/pharma-news/duality-keeps-an-eye-out-for-hong-kong-ipo-for-adc-trials/) - In an effort to fund a wide pipeline of antibody-drug conjugates moving toward licensing, Duality Biotherapeutics has submitted paperwork for a Hong Kong IPO.
- [Siemens Healthineers, Novartis Partner To Grow PET Imaging](https://www.pharmaadvancement.com/pharma-news/siemens-healthineers-novartis-partner-to-grow-pet-imaging/) - For $223mn, Siemens has agreed to buy radiopharmaceutical molecular imaging business of Novartis, that comprises of manufacturing and delivery infrastructure.
- [Steady Growth Forecasted For Global Pharma Packaging Market](https://www.pharmaadvancement.com/pharma-news/steady-growth-forecasted-for-global-pharma-packaging-market/) - The global pharma plastic packaging market is projected to grow from $56.6B in 2024 to $74.2B by 2034, with a 3.0% CAGR driven by sustainability and innovation.
- [Cold Chain Optimization For Safe Pharmaceutical Delivery](https://www.pharmaadvancement.com/pharma-news/cold-chain-optimization-for-safe-pharmaceutical-delivery/) - Optimizing cold chain logistics safeguards pharma against summer heat, preserving product integrity, patient safety, and compliance with industry regulations.
- [Effectiveness of Industrial Refrigeration In Pharma Spectrum](https://www.pharmaadvancement.com/pharma-news/effectiveness-of-industrial-refrigeration-in-pharma-spectrum/) - Exact temperature control required to preserve integrity of items during manufacturing, storage, distribution is offered by industrial refrigeration systems.
- [Future of Pharma - A Lot Depends On The Sustainable Steps](https://www.pharmaadvancement.com/pharma-news/future-of-pharma-a-lot-depends-on-the-sustainable-steps/) - If the processes used to produce life-saving medications do not harm the environment, then one can promote health and wellbeing and better outcomes for all.
- [Innovative Packaging Playing Key Role In Rising Med Demand](https://www.pharmaadvancement.com/pharma-news/innovative-packaging-playing-key-role-in-rising-med-demand/) - By way of producing exact, patient-specific medication formulas and also lowering human error, packaging technology facilitates with customized medication.
- [Pharmaceutical Packaging To Witness Unprecedented Growth](https://www.pharmaadvancement.com/pharma-news/pharmaceutical-packaging-to-witness-unprecedented-growth/) - The urgent requirement for creative and practical packaging solutions has increased due to the availability of new medications and improved treatment choices.
- [Pharma New Innovation: AI-Powered, Human-Centered Approach](https://www.pharmaadvancement.com/pharma-news/pharma-new-innovation-ai-powered-human-centered-approach/) - AI is revolutionizing pharma by enabling personalized care, enhancing the HCP support, and improving patient outcomes through human-led, AI-powered solutions.
- [Clario joins forces with Mobilise-D to advance Digital Mobility Outcomes in clinical trials](https://www.pharmaadvancement.com/pharma-news/clario-joins-forces-with-mobilise-d-to-advance-digital-mobility-outcomes-in-clinical-trials/) - Clario, a leading provider of technologies and endpoint data solutions for clinical trials announced the enhancement of its digital capture of patient mobility data through the Mobilise-D consortium partnership. This collaboration integrates the recently validated Mobilise-D Digital Mobility Outcomes (DMOs) with Clario's Opal® wearable sensor system, allowing clinicians to measure the way patients move in
- [Detect-ION and Moffitt Cancer Center Collaborate to Revolutionize Lung Cancer Early Detection](https://www.pharmaadvancement.com/pharma-news/detect-ion-and-moffitt-cancer-center-collaborate-to-revolutionize-lung-cancer-early-detection/) - The pilot project partnership envisions breath diagnostics to be an in-home screening that is fast, inexpensive, and as easy as blowing up a balloon
- [Korea develops micro-structured artificial lung model using bioprinting technology](https://www.pharmaadvancement.com/drug-development/korea-develops-micro-structured-artificial-lung-model-using-bioprinting-technology/) - A team of Korean researchers has made a breakthrough that will greatly enhance the efficiency of respiratory disease research, garnering attention.
- [LSPedia and Pharma Logistics Announce Strategic Partnership to Revolutionize Pharmaceutical Reverse Logistics and Supply Chain Visibility](https://www.pharmaadvancement.com/packaging-logistic/lspedia-and-pharma-logistics-announce-strategic-partnership-to-revolutionize-pharmaceutical-reverse-logistics-and-supply-chain-visibility/) - LSPedia, a SaaS solution leader in global product traceability, proudly announces a strategic partnership with Pharma Logistics, the industry leader in pharmaceutical reverse distribution. This collaboration aims to transform the pharmaceutical supply chain by offering turnkey compliance, unprecedented data visibility, and robust supply chain efficiency. Compliance is at the core of Pharma Logistics' business model,
- [Nanoform and Takeda team up to advance plasma-derived therapy development](https://www.pharmaadvancement.com/drug-development/nanoform-and-takeda-team-up-to-advance-plasma-derived-therapy-development/) - The collaboration will aim to develop plasma-derived therapeutics and accelerate the movement of potential medicines into the clinic
- [Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb](https://www.pharmaadvancement.com/drug-development/evotec-announces-progress-in-strategic-neuroscience-partnership-with-bristol-myers-squibb/) - Evotec SE announced progress within the Company’s strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programmes. Evotec receives a US$ 25 m payment to progress further research. Evotec and Bristol Myers Squibb entered their strategic neuroscience collaboration in December 2016 to identify disease-modifying treatments for a broad range of
- [Hoth Therapeutics Partners with Aronnax for HT-KIT Cancer Therapy](https://www.pharmaadvancement.com/pharma-news/hoth-therapeutics-partners-with-aronnax-for-ht-kit-cancer-therapy/) - Hoth Therapeutics Inc., a patient-focused biopharmaceutical company, has entered into a Master Services Agreement with Aronnax, Inc. for its HT-KIT cancer therapeutic. HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT being developed for the treatment of mast cell-derived cancers and anaphylaxis. It previously received Orphan Drug Designation from FDA. Research conducted at NC
- [Bavarian Nordic Provides Statement on Mpox Vaccine Supply and Collaboration with African and Global Stakeholders](https://www.pharmaadvancement.com/pharma-news/bavarian-nordic-provides-statement-on-mpox-vaccine-supply-and-collaboration-with-african-and-global-stakeholders/) - Bavarian Nordic is working closely with all stakeholders to ensure the equitable access to our mpox vaccine during the current PHECS and PHEIC
- [Absci Collaborates with Global Cancer Center to Discover Novel Therapeutics Using Generative AI](https://www.pharmaadvancement.com/drug-development/absci-collaborates-with-global-cancer-center-to-discover-novel-therapeutics-using-generative-ai/) - The collaboration unites Absci’s Generative AI Drug Creation Platform with leading oncology experts to co-develop up to six novel cancer therapeutics
- [Lilly opens state-of-the-art research and development center in the Boston Seaport](https://www.pharmaadvancement.com/pharma-news/lilly-opens-state-of-the-art-research-and-development-center-in-the-boston-seaport/) - Eli Lilly and Company announced the opening of the Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport dedicated to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration and
- [Daiichi Sankyo And MSD Expand Their ADC Partnership Globally](https://www.pharmaadvancement.com/drug-development/daiichi-sankyo-and-msd-expand-their-adc-partnership-globally/) - Daiichi Sankyo and MSD strengthen their collaboration to globally develop and market three DXd-based ADCs, including MK-6070 for treating neuroendocrine tumors.
- [Ideaya Acquires The B7H3/PTK7 BsADC Rights in $400M Deal](https://www.pharmaadvancement.com/drug-development/ideaya-acquires-the-b7h3-ptk7-bsadc-rights-in-400m-deal/) - Ideaya Biosciences buys Biocytogens B7H3/PTK7 BsADC program for $400 million. The company intends to use it to develop targeted treatments for solid tumors.
- [Eli Lilly Secures Actinium-225 Supply Chain For Radiopharma](https://www.pharmaadvancement.com/drug-development/eli-lilly-secures-actinium-225-supply-chain-for-radiopharma/) - Eli Lilly invests $20M in Ionetix to secure actinium-225, crucial for radiopharma cancer therapies, addressing isotope shortages hindering industry growth.
- [Navigating Regulations For Emerging Life Sciences Therapies](https://www.pharmaadvancement.com/drug-development/navigating-regulations-for-emerging-life-sciences-therapies/) - Life sciences face evolving and new regulations with the rise of CAGT and radiopharmaceuticals, requiring innovation and compliance to advance patient care.
- [Radiopharmaceutical Access Enhanced By New IAEA Database](https://www.pharmaadvancement.com/drug-development/radiopharmaceutical-access-enhanced-by-new-iaea-database/) - New IAEA database will facilitate international access, monitor trends, and foster collaboration in the production and distribution of radiopharmaceuticals.
- [Enhancing Cancer Treatments: The Role of ADCs In Medicine](https://www.pharmaadvancement.com/drug-development/enhancing-cancer-treatments-the-role-of-adcs-in-medicine/) - ADCs, which merge antibodies with toxic drugs, enhance cancer treatment precision. Ongoing advancements improve their effectiveness, safety, and stability.
- [ADCs: From Cancer Treatment To Other Broader Applications](https://www.pharmaadvancement.com/drug-development/adcs-from-cancer-treatment-to-other-broader-applications/) - Antibody drug conjugates show promise beyond oncology and have immense potential when it comes to treating cancer, infectious diseases, allergies, and more.
- [ADCs: Innovations And Market Dynamics In Cancer Therapy](https://www.pharmaadvancement.com/drug-development/adcs-innovations-and-market-dynamics-in-cancer-therapy/) - Antibody-drug conjugates dominate cancer treatment with new targets and linkers. Major investments and innovative therapies shape the competitive landscape.
- [Pharmaceutical Water Market: Expected $96.97B Growth By 2033](https://www.pharmaadvancement.com/drug-development/pharmaceutical-water-market-expected-96-97b-growth-by-2033/) - Advanced filtration methods, strict regulations, and rising demand from the biopharma industry will propel the pharmaceutical water market to $96.97B by 2033.
- [Recursion, Exscientia Unite For $850M, 10 Trials In 18 Months](https://www.pharmaadvancement.com/pharma-news/recursion-exscientia-unite-for-850m-10-trials-in-18-months/) - Recursion and Exscientia merge with $850M in capital, targeting at least 10 clinical readouts over 18 months, combining strengths in AI-driven drug development.
- [AI Revolutionizes Drug Discovery And Development Process](https://www.pharmaadvancement.com/drug-development/ai-revolutionizes-drug-discovery-and-development-process/) - AI is transforming the process of finding new drugs, speeding up procedures, increasing success rates, and opening the doors for ground-breaking therapies.
- [AI In Drug Development: Calls For Straightforward Regulation](https://www.pharmaadvancement.com/drug-development/ai-in-drug-development-calls-for-straightforward-regulation/) - To promote medication research and ensure safety, experts urged for more transparent AI laws and public-private collaborations at a session hosted by the FDA.
- [Scaling Cell And Gene Therapies: Challenges And Solutions](https://www.pharmaadvancement.com/pharma-news/scaling-cell-and-gene-therapies-challenges-and-solutions/) - Upscaling cell and gene therapies faces challenges in manufacturing, regulation, and cost. Overcoming these hurdles is very crucial for broader market access.
- [The Cell & Gene Therapy - From Innovation To Market Growth](https://www.pharmaadvancement.com/pharma-news/the-cell-gene-therapy-from-innovation-to-market-growth/) - By 2032, the cell and gene therapy market will grow from $18.8B in 2023 to $60.1B, with rapid tech advances, regulatory support, and increased investments.
- [Advances And Challenges In The Gene Therapy Manufacturing](https://www.pharmaadvancement.com/pharma-news/advances-and-challenges-in-the-gene-therapy-manufacturing/) - The cell and gene therapy industry is changing as new production challenges and possibilities arise. This is leading to upgrades in efficiency and lower costs.
- [With A CAGR of 4.5%, Global Fluid Handling Sees New Highs](https://www.pharmaadvancement.com/pharma-news/with-a-cagr-of-4-5-global-fluid-handling-sees-new-highs/) - At a 4.5% CAGR, market for fluid handling systems is expected to rise to $108 billion by 2032, mostly due to advancements in automation and valve technology.
- [Impact of AI On Drug Development And Discovery Process](https://www.pharmaadvancement.com/drug-development/impact-of-ai-on-drug-development-and-discovery-process/) - AI integration in the development of drugs accelerates research, reduces costs, and improves accuracy, significantly benefiting the pharmaceutical business.
- [Medical Device Contract Manufacturing Surge To $130 Billion](https://www.pharmaadvancement.com/pharma-news/medical-device-contract-manufacturing-surge-to-130-billion/) - Market growth in medical device contract manufacturing, driven by chronic illnesses and advanced tech, is set to reach $130 bn by 2030 from $65 bn in 2022.
- [New FDA Blueprint For Consistent Drug Delivery Performance](https://www.pharmaadvancement.com/pharma-news/new-fda-blueprint-for-consistent-drug-delivery-performance/) - The FDA guide assists in creating EDDOs to ensure drug-device combinations like syringes and inhalers maintain consistent performance through their lifecycle.
- [Dosing Gets Further Precision With New Drug Delivery Tech](https://www.pharmaadvancement.com/drug-development/dosing-gets-further-precision-with-new-drug-delivery-tech/) - Despite being in its infancy, the new technology happens to have the potential to improve hospital-level precision in domains of medicine and drug delivery.
- [EDMQ Replaces Rabbit Pyrogen Test With In Vitro Methods](https://www.pharmaadvancement.com/pharma-news/edmq-replaces-rabbit-pyrogen-test-with-in-vitro-methods/) - The European Pharmacopoeia confirmed in June 2024 the removal of the rabbit pyrogen test- RPT from its monographs, replacing it with in vitro alternatives.
- [$383.1B M&A Strategies By Biopharma For Patent Expirations](https://www.pharmaadvancement.com/pharma-news/383-1b-ma-strategies-by-biopharma-for-patent-expirations/) - Biopharma giants are gearing up for mergers as $183.5B in annual sales face patent expirations; J&J and Merck lead in dealmaking potential, says Morgan Stanley.
- [Dr. Pascal Piedbois Joins One2Treat To Boost Clinical Trials](https://www.pharmaadvancement.com/press-statements/dr-pascal-piedbois-joins-one2treat-to-boost-clinical-trials/) - One2Treat, under Dr. Pascal Piedbois, innovates clinical trials by integrating patient-centric outcomes early, accelerating market entry for new treatments.
- [Keeping Pharma Packaging Safe While Pushing Sustainability](https://www.pharmaadvancement.com/pharma-news/keeping-pharma-packaging-safe-while-pushing-sustainability/) - As customers and financial institutions push pharmaceutical companies to make use of greener materials, sustainable packaging may greatly decrease emissions.
- [Market for Pharmaceutical Packaging to Grow to $464.4bn](https://www.pharmaadvancement.com/pharma-news/market-for-pharmaceutical-packaging-to-grow-to-464-4bn/) - Powered by advancements, regulatory issues, pharmaceutical packaging sector is projected to rise from US$ 133.6 billion in 2022 to US$ 464.4 billion by 2031.
- [Utilising Contract Packing To Give Greener Pharma Options](https://www.pharmaadvancement.com/pharma-news/utilising-contract-packing-to-give-greener-pharma-options/) - Due to aging populations, innovation, and rising production needs, pharma is facing challenges in reducing emissions while meeting the growing demand for drugs.
- [Cold Chain Packaging Needs Evolving Due To E-Commerce Growth](https://www.pharmaadvancement.com/pharma-news/cold-chain-packaging-needs-evolving-due-to-e-commerce-growth/) - Growing need for cold chain logistics & packaging solutions is being driven by consumer preferences, growth of e-commerce, and stricter rules across industries.
- [Revolutionizing Drug Discovery With AI For A Greener Future](https://www.pharmaadvancement.com/ipr-data-management/revolutionizing-drug-discovery-with-ai-for-a-greener-future/) - Integrating AI in drug discovery enhances efficiency, reduces waste, and boosts development, creating a cost-effective and sustainable way for new therapeutics.
- [Understanding And Addressing Drug Shortage Issues In The EU](https://www.pharmaadvancement.com/drug-development/understanding-and-addressing-drug-shortage-issues-in-the-eu/) - The EU identifies drug supply chain shortages and recommends enhancing supply chain resilience, diversifying manufacturing, and regulatory flexibility measures.
- [Optimizing Operations With Product Management Service By EMA](https://www.pharmaadvancement.com/pharma-news/optimizing-operations-with-product-management-service-by-ema/) - The European Medicines Agency emphasizes PMS benefits for decision-making, regulatory compliance, and operational efficiency in medicinal product management.
- [The Role of Partnerships In Managing Clinical Trial Costs](https://www.pharmaadvancement.com/drug-development/clinical-trials/the-role-of-partnerships-in-managing-clinical-trial-costs/) - Key factors influencing clinical trial outsourcing strategies include cost determinants, operational efficiency, and effective vendor-sponsor partnerships.
- [Insights Into $3.72B Clinical Trial Supplies Market By 2028](https://www.pharmaadvancement.com/pharma-news/insights-into-3-72b-clinical-trial-supplies-market-by-2028/) - With an 8.9 percent CAGR, the clinical trial supplies market grew to USD2.75 billion in 2024, propelled by global expansions and technological integrations.
- [FDA Strategies For Combating Medical Product Misinformation](https://www.pharmaadvancement.com/pharma-news/fda-strategies-for-combating-medical-product-misinformation/) - The FDA updated its guidelines, giving farms strategies to counteract misinformation about medical products, as accurate information for public health is vital.
- [Ensuring Patient Safety Through Innovative Pharma Packaging](https://www.pharmaadvancement.com/pharma-news/ensuring-patient-safety-through-innovative-pharma-packaging/) - In pharmaceuticals, packaging extends shelf-life, ensures safety, and integrates advanced tech, meeting trends in sustainability and user-friendly solutions.
- [Innovative Eco-Friendly Technologies Transforming Pharma](https://www.pharmaadvancement.com/pharma-news/innovative-eco-friendly-technologies-transforming-pharma/) - The pharma sector adopts green chemistry and sustainable technologies to reduce environmental impact, reduce costs, and enhance drug manufacturing processes.
- [New FDA Guidance To Enhance Diversity In Clinical Trials](https://www.pharmaadvancement.com/pharma-news/new-fda-guidance-to-enhance-diversity-in-clinical-trials/) - FDA releases guidance for creating Diversity Action Plans in clinical trials, addressing minority underrepresentation, and requiring detailed recruitment plans.
- [Booming Market For Biodegradable Pharmaceutical Packaging](https://www.pharmaadvancement.com/pharma-news/booming-market-for-biodegradable-pharmaceutical-packaging/) - Projected market size growth from $83.46B in 2023 to $335.82B by 2032 underscores rising demand for sustainable and eco-friendly pharma packaging solutions.
- [How EFPIA Plans To Reduce Carbon Emissions In Pharma Sector](https://www.pharmaadvancement.com/pharma-news/how-efpia-plans-to-reduce-carbon-emissions-in-pharma-sector/) - EFPIA announces science-based decarbonization targets, emphasizing renewable energy, in line with Paris Agreement goals for a sustainable pharmaceutical sector.
- [4% CAGR Till 2030 For Water & Wastewater Treatment Equipment](https://www.pharmaadvancement.com/pharma-news/4-cagr-till-2030-for-water-wastewater-treatment-equipment/) - Along with a boost in government laws for wastewater emissions, expansion is caused by industrial water consumption, release, and the rising world population.
- [Water Unit of DuPont Has Some Potential Buyers Interested](https://www.pharmaadvancement.com/pharma-news/water-unit-of-dupont-has-some-potential-buyers-interested/) - Xylem Inc. and Veralto Corp. happen to be showing separate takeover interest in DuPont Water Solutions, a company that is estimated to be worth $6 billion.
- [The Fauna Pharmaceutical Pollution: Scientists Sound Alarm](https://www.pharmaadvancement.com/pharma-news/the-fauna-pharmaceutical-pollution-scientists-sound-alarm/) - Contamination caused by the manufacturing, usage, and disposal of drugs is damaging the ecosystems globally and also harming both human health and animals.
- [Innovative Strategies For A Greener Pharmaceutical Sector](https://www.pharmaadvancement.com/pharma-news/innovative-strategies-for-a-greener-pharmaceutical-sector/) - The pharmaceutical sector can innovate through renewable energy, land restoration, and circular economies to enhance both the environment and human health.
- [Drug Discharge Seen In NYC As Consequences Of Heavy Rainfall](https://www.pharmaadvancement.com/pharma-news/drug-discharge-seen-in-nyc-as-consequences-of-heavy-rainfall/) - Outdated sewer systems in New York result in drug pollution in rivers after heavy rains, necessitating ongoing monitoring to understand environmental impacts.
- [Harnessing Wastewater For Disease Detection And Management](https://www.pharmaadvancement.com/pharma-news/harnessing-wastewater-for-disease-detection-and-management/) - Sewage impacts environmental and human health, containing pathogens, chemicals, and microplastics, which WBE monitors for effective public health responses.
- [Chronic wounds represent a significant healthcare challenge globally](https://www.pharmaadvancement.com/press-statements/chronic-wounds-represent-a-significant-healthcare-challenge-globally/) - Chronic wounds are defined as wounds that do not follow the normal healing process and remain open for extended periods. These wounds, which include vascular ulcers, diabetic ulcers, and pressure
- [Liquid Biopsy in Cancer Diagnostics: Definition and Advantages](https://www.pharmaadvancement.com/pharma-news/liquid-biopsy-in-cancer-diagnostics-definition-and-advantages/) - Consulting firm Fortune Business Insights reports that the global market of liquid biopsy, the procedure of collecting cancer-related materials from bodily fluids.
- [Current E&L Issues And How Parenteral Packaging Is Evolving](https://www.pharmaadvancement.com/pharma-news/current-el-issues-and-how-parenteral-packaging-is-evolving/) - Improvements in the parenteral packing materials are lowering the possibility of contaminant in modern injectables even while the nitrosamine crisis persists.
- [Great Point Partners Acquires Lyocontract - A German CDMO](https://www.pharmaadvancement.com/drug-development/great-point-partners-acquires-lyocontract-a-german-cdmo/) - Providing injectable medications in liquid and freeze-dried forms for both clinical and commercial usage, Lyocontract ships its products all over the world.
- [Transforming In 2024 & Beyond - Prefilled Syringes Market](https://www.pharmaadvancement.com/drug-development/transforming-in-2024-beyond-prefilled-syringes-market/) - Prefilled syringe sales will rise rapidly due to expanding biologic drug pipelines and advancements in auto-injector technology allowing self-administration.
- [Role of Innovation In The Rise of Prefilled Biologics Space](https://www.pharmaadvancement.com/drug-development/role-of-innovation-in-the-rise-of-prefilled-biologics-space/) - Prefilled biologics meet growing needs of patients in terms of better patient experiences, personal care, and self-administration choices, and customized care.
- [Major Surge Expected In The Injectable Drug Delivery Market](https://www.pharmaadvancement.com/drug-development/major-surge-expected-in-the-injectable-drug-delivery-market/) - Advances in tech and chronic illnesses rise like cancer, that are treated by injectable drugs, are major factors propelling global market for injectable drugs.
- [World-Class Biopharma Production Offered By APAC Bioclusters](https://www.pharmaadvancement.com/drug-development/world-class-biopharma-production-offered-by-apac-bioclusters/) - Biopharma hubs in South Korea and Singapore, two prominent APAC countries, are dedicated to vital research and development in the biopharmaceutical sector.
- [M&A In Biopharmaceuticals Raise To New Levels In 2024 Q1](https://www.pharmaadvancement.com/drug-development/ma-in-biopharmaceuticals-raise-to-new-levels-in-2024-q1/) - Estimates from GlobalData suggest that overall deal value of biopharmaceutical M&A has reached an unprecedented $43.5 billion in the first three months of 2024.
- [Global Biopharma Market - Prominent Growth In Years To Come](https://www.pharmaadvancement.com/drug-development/global-biopharma-market-prominent-growth-in-years-to-come/) - The worldwide biopharma market will be driven by a growing number of chronic diseases, technological improvements, and the growing need for new therapies.
- [Biopharma Manufacturing & Generative AI – A Lot To Look Into](https://www.pharmaadvancement.com/drug-development/biopharma-manufacturing-generative-ai-a-lot-to-look-into/) - In a survey conducted, 79% of those polled expressed the opinion that generative AI has the ability to alter the quality and efficiency of manufacturing drugs.
- [$60bn Valuation For Global Biopharma CMO-CRO Market By 2033](https://www.pharmaadvancement.com/drug-development/60bn-valuation-for-global-biopharma-cmo-cro-market-by-2033/) - Increased outsourcing of manufacturing & research operations by biopharmaceutical companies to CMOs and CROs is one of the factors contributing to this growth.
- [Australia Biomedical Space Drives World Innovation, Research](https://www.pharmaadvancement.com/drug-development/australia-biomedical-space-drives-world-innovation-research/) - To give quick reaction to current and upcoming pandemics, space has been set up to bring together some of the best scientific and medical research brains.
- [Titan Krios G4 – A Biomed Research Advancement In Australia](https://www.pharmaadvancement.com/pharma-news/titan-krios-g4-a-biomed-research-advancement-in-australia/) - Record-breaking resolution and other capabilities of Titan Krios G4 will help scientists to examine molecular architecture of human bodies in greater detail.
- [Hepatitis Screening in Community Pharmacies as a Measure of Reducing the Rate of Infections](https://www.pharmaadvancement.com/press-statements/hepatitis-screening-in-community-pharmacies-as-a-measure-of-reducing-the-rate-of-infections/) - "Hepatitis Screening in Community Pharmacies as a Measure of Reducing the Rate of Infections." This comprehensive journal explores the potential of utilizing community pharmacies for hepatitis B (HBV) and hepatitis C (HCV) screening, aiming to reduce the prevalence and transmission of these infections. Hepatitis B and C continue to pose significant global health challenges, with
- [Parenteral Drug Administration – Shaping Today, Tomorrow](https://www.pharmaadvancement.com/drug-development/parenteral-drug-administration-shaping-today-tomorrow/) - The parenteral drugs market dynamics, patient-centric methods, and technological improvements happen to be driving forces behind the evolution of the industry.
- [Moderna - Respiratory Syncytial Virus Jab Nod Post Spikevax](https://www.pharmaadvancement.com/pharma-news/moderna-respiratory-syncytial-virus-jab-nod-post-spikevax/) - The single-dose prefilled syringe containing this Respiratory Syncytial Virus vaccination will be marketed under the name mRESVIA for people aged 60 and over.
- [Worldwide API Market Could Grow At A CAGR of 6.08% By 2033](https://www.pharmaadvancement.com/market-moves/worldwide-api-market-could-grow-at-a-cagr-of-6-08-by-2033/) - A critical development driver in a number of medical fields happens to be the integration of Active Pharmaceutical Ingredients- APIs which is growing strongly.
- [Huge Investment In Indiana For Tirzepatide API Production](https://www.pharmaadvancement.com/pharma-news/huge-investment-in-indiana-for-tirzepatide-api-production/) - In Indiana, US, Eli Lilly and Company has made the biggest investment ever in the production of synthetic medicine active pharmaceutical ingredients- APIs.
- [Innovative Small Molecule Injectables – Forecast Till 2033](https://www.pharmaadvancement.com/market-moves/innovative-small-molecule-injectables-forecast-till-2033/) - Nod for innovative medication formulations, drug delivery systems, and tech advances will be major trends in global market for small molecule injectable pharma.
- [Germany - A Strong Force For Pharmaceutical Drug Reshoring](https://www.pharmaadvancement.com/drug-development/germany-a-strong-force-for-pharmaceutical-drug-reshoring/) - In order to strengthen domestic pharmaceutical industry, the German government adopted a strategy plan in December 2023 that identified three critical sectors.
- [Pharma Solvents Industry Eyeing A $6bn Valuation By 2033](https://www.pharmaadvancement.com/drug-development/pharma-solvents-industry-eyeing-a-6bn-valuation-by-2033/) - The much growing aging population, rise in chronic illness patients as well as the demand for natural drug formulations happen to influence the market size.
- [Deep Dive Into The Pharmaceutical Fine Chemicals Market](https://www.pharmaadvancement.com/drug-development/deep-dive-into-the-pharmaceutical-fine-chemicals-market/) - Chemicals classified as complex specialized building blocks or intermediates are known as pharmaceutical fine chemicals and are utilized in medicine production.
- [Fine & Speciality Chemicals World at Chemspec Europe 2024](https://www.pharmaadvancement.com/pharma-news/fine-speciality-chemicals-world-at-chemspec-europe-2024/) - The fine and speciality chemicals industry happens to be contributing significantly to the development of new materials and technical solutions across Europe.
- [Study Suggests Consistent Rise In Pharma Chemicals Market](https://www.pharmaadvancement.com/drug-development/study-suggests-consistent-rise-in-pharma-chemicals-market/) - Pharmaceutical chemical growth is driven by chronic illnesses, the demand for novel and personalized treatments, and drug research and discovery technology.
- [Key Trends In European Active Pharma Ingredients Market](https://www.pharmaadvancement.com/drug-development/key-trends-in-european-active-pharma-ingredients-market/) - Europe is home to large number of pharma companies, and APIs are essential to the growth, providing foundation for creation, manufacturing of a range of drugs.
- [Europe API Market To Reach $80bn By 2033 - Study Predicts](https://www.pharmaadvancement.com/drug-development/europe-api-market-to-reach-80bn-by-2033-study-predicts/) - The discovery and manufacturing of a wide variety of pharmaceuticals are made possible by APIs, which are essential to European pharmaceutical sectors growth.
- [Research Leads To Major Advancements In Chemical Synthesis](https://www.pharmaadvancement.com/pharma-news/research-leads-to-major-advancements-in-chemical-synthesis/) - Within the realm of the molecular interactions of positively charged carbon atoms, this ground-breaking discovery goes on to give out quite fresh insights.
- [$1.5bn Manufacturing Plant By AstraZeneca In Singapore Soon](https://www.pharmaadvancement.com/drug-development/1-5bn-manufacturing-plant-by-astrazeneca-in-singapore-soon/) - The company intends to manufacture antibody drug conjugates- ADCs in Singapore which are a next-generation therapy that has the ability to kill cancer cells.
- [Opioid Addiction Management – A Study On Pharmacists Role](https://www.pharmaadvancement.com/press-statements/opioid-addiction-management-a-study-on-pharmacists-role/) - A groundbreaking study titled "The Role of Pharmacists in Addiction Management of Opioids" by Pallav Dave, a regulatory compliance analyst based in Kentucky, has shed light on the critical role that p
- [Growing Market Size - US Clinical Trials Supply & Logistics](https://www.pharmaadvancement.com/pharma-news/growing-market-size-us-clinical-trials-supply-logistics/) - Supply chain technological advances and pharmaceutical & biopharmaceutical companies R&D spending drive US clinical trials supply & logistics industry growth.
- [FDA Solidifies Its Authority Over Laboratory-Developed Tests](https://www.pharmaadvancement.com/facilities-operation/fda-solidifies-its-authority-over-laboratory-developed-tests/) - More rigorous evaluation of newly created tests by labs is on the way, but some worry the adjustments will be costly, time-consuming, and hinder creativity.
- [Robust Supply Chains Are Essential For Affordable Drugs](https://www.pharmaadvancement.com/facilities-operation/robust-supply-chains-are-essential-for-affordable-drugs/) - As Indian pharma sector steps into its next phase of growth, it is important to make sure that the supply chains are resilient that lead to drug affordability.
- [8 Essential Elements of Quality Management In Lab Practices](https://www.pharmaadvancement.com/facilities-operation/8-essential-elements-of-quality-management-in-lab-practices/) - Labs can decrease possible errors, enhance risk management, and increase operational efficiency by putting in place a cloud-based quality management system.
- [Bioinformatics Industry To Reach $31.71 Billion By 2031](https://www.pharmaadvancement.com/market-moves/bioinformatics-industry-to-reach-31-71-billion-by-2031/) - Beginning in 2024, it is anticipated that the market for bioinformatics would go on to expand at a CAGR of 13.4%, reaching $31.71 billion by the year 2031.
- [Influence On Supply Chains of EU Sustainability Directive](https://www.pharmaadvancement.com/pharma-news/influence-on-supply-chains-of-eu-sustainability-directive/) - Pharmaceutical along with the healthcare companies anticipate some operational changes of a much larger extent because of the new EU supply chain regulations.
- [AI-Role In Supply Chain Management In Bio, Pharma Sectors](https://www.pharmaadvancement.com/pharma-news/ai-role-in-supply-chain-management-in-bio-pharma-sectors/) - Bio, pharma sectors are actually making use of AI extensively in crucial areas like drug discovery and as a matter of fact are achieving significant heights.
- [100% Renewable Electricity Record Hit By Charles River Labs](https://www.pharmaadvancement.com/facilities-operation/100-renewable-electricity-record-hit-by-charles-river-labs/) - A major milestone has been reached by Charles River Laboratories, much ahead of the schedule, when it comes to meeting its renewable electricity milestone.
- [All Infinity Laboratories Locations Are Now ISO-Accredited](https://www.pharmaadvancement.com/facilities-operation/all-infinity-laboratories-locations-are-now-iso-accredited/) - The certification of all Infinity Laboratories sites goes on to show its dedication to quality and competence within chemical and microbiological sciences.
- [ESG Sparks Global Trend for Eco-Friendly Packaging: swop 2024's GREEN POWER ZONE Paves the Path to Sustainability!](https://www.pharmaadvancement.com/press-statements/esg-sparks-global-trend-for-eco-friendly-packaging-swop-2024s-green-power-zone-paves-the-path-to-sustainability/) - TestFrom an Environmental, Social and Governance (ESG) perspective, the global green packaging sector has a promising outlook for 2024.
- [Apt Teamwork Holds Key To Successful Lab Design Projects](https://www.pharmaadvancement.com/facilities-operation/apt-teamwork-holds-key-to-successful-lab-design-projects/) - The lab can profit greatly from the creation of expanded space, which will also be an excellent learning opportunity for the staff and the mission of the lab.
- [Lab Automation And Its Role In Global Research Collaboration](https://www.pharmaadvancement.com/facilities-operation/lab-automation-and-its-role-in-global-research-collaboration/) - Application of automation can be a significant boon to international research collaboration, assisting in advancement of research & introducing novel products.
- [Robot-Based Solutions For Lab Automation Making Inroads](https://www.pharmaadvancement.com/facilities-operation/robot-based-solutions-for-lab-automation-making-inroads/) - A growing number of customers are finding that robot systems for laboratory automation are becoming more affordable, which in turn makes them more appealing.
- [Lab Operations And Their Shift Towards A Digital Prowess](https://www.pharmaadvancement.com/facilities-operation/lab-operations-and-their-shift-towards-a-digital-prowess/) - Digitalization uses cloud-connected tech to improve every stage of the process, from samples arriving at door to making results accessible to stakeholders.
- [Sharp Services announces expansion in Pennsylvania to facilitate growth in sterile injectable market](https://www.pharmaadvancement.com/packaging-logistic/sharp-services-announces-expansion-in-pennsylvania-to-facilitate-growth-in-sterile-injectable-market/) - Sharp has announced plans for the expansion of its Macungie, PA site in North America to increase its production capacity for sterile injectables secondary packaging.
- [Pharmaceutical Packaging: The Role of Pre-Consumer Regrind](https://www.pharmaadvancement.com/pharma-news/pharmaceutical-packaging-the-role-of-pre-consumer-regrind/) - Creation of recycled packaging for products through pre-consumer regrind material can help greatly in making sure pharma packaging has less carbon footprint.
- [Sustainable Packaging: A Complete Approach Need Of The Hour](https://www.pharmaadvancement.com/pharma-news/sustainable-packaging-a-complete-approach-need-of-the-hour/) - First step to sustainable packaging with a holistic method is to choose materials based on how harmful they are to environment and how they can be recycled.
- [A Throttling Pharmaceutical Packaging Equipment Scenario](https://www.pharmaadvancement.com/pharma-news/a-throttling-pharmaceutical-packaging-equipment-scenario/) - Biopharmaceutical industry is expected to propel global pharmaceutical packaging equipment market, which is forecast to reach a valuation of US$ 5.6bn by 2023.
- [UK Unveils CiPPPA To Push Pharma Packaging Plans Into Action](https://www.pharmaadvancement.com/pharma-news/uk-unveils-cipppa-to-push-pharma-packaging-plans-into-action/) - The UK launched the CiPPPA initiative to create and implement plans for the end-of-use recycling pertaining to pharmaceutical packaging and medical devices.
- [Sustainable Pharma Packaging Counting On Its Worth Globally](https://www.pharmaadvancement.com/pharma-news/sustainable-pharma-packaging-counting-on-its-worth-globally/) - By reducing harmful environmental effects associated with packaging, global manufacturers hope to offer pharmaceutical packaging options that are sustainable.
- [Packaging Films: Making Their Presence Felt In Pharma Sector](https://www.pharmaadvancement.com/pharma-news/packaging-films-making-their-presence-felt-in-pharma-sector/) - In order to validate the integrity, safety, and efficacy of pharmaceutical products, packaging is essential, and packaging films are an essential part of it.
- [Generics Driving The Pharma Parenteral Packaging Market](https://www.pharmaadvancement.com/pharma-news/generics-driving-the-pharma-parenteral-packaging-market/) - The pharmaceutical parenteral packaging market happens to be growing because of the demand for small molecule as well as diabetic prefilled insulin syringes.
- [Successful Scale-Up of Cell-Gene Therapy With Platform Tech](https://www.pharmaadvancement.com/drug-development/successful-scale-up-of-cell-gene-therapy-with-platform-tech/) - Because of their nature, CGTs need precise control on processing & careful handling to preserve product integrity, which platform technologies make possible.
- [Ideas To Improve Availability of Critical Drugs Made By EMA](https://www.pharmaadvancement.com/drug-development/ideas-to-improve-availability-of-critical-drugs-made-by-ema/) - With a focus on companies authorized to commercialize pharmaceuticals in one or more EU nations, EMA has put up some specific suggestions for improvement.
- [Cell & Gene Therapies: FDA Regulatory Implications For 2024](https://www.pharmaadvancement.com/pharma-news/cell-gene-therapies-fda-regulatory-implications-for-2024/) - With office of therapeutic products- OTPs established as the super office, FDA is now looking to have an increase in the cell and gene therapy applications.
- [Clinical Research Ecosystem Making Utmost Gene Therapy Use?](https://www.pharmaadvancement.com/drug-development/clinical-trials/clinical-research-ecosystem-making-utmost-gene-therapy-use/) - To ensure trial development process complies with clinical requirements & regulatory standards, gene therapy aims to manage risks without slowing progress.
- [US Okays Biosecurity Bill Against Chinese Bio Company Deals](https://www.pharmaadvancement.com/pharma-news/us-okays-biosecurity-bill-against-chinese-bio-company-deals/) - US Congress passed a biosecurity law restricting dealings with Chinese bio firms as bio could be next big thing to target after semiconductors and batteries.
- [Fresh Biologics Clinical Manufacturing CDMO Service Trends](https://www.pharmaadvancement.com/drug-development/fresh-biologics-clinical-manufacturing-cdmo-service-trends/) - Biologics clinical manufacturing CDMO market is composed of a range of products & services tailored to meet needs of different market segments, client groups.
- [CDMOs Using Specialized Solutions To Meet Cold Chain Needs](https://www.pharmaadvancement.com/drug-development/cdmos-using-specialized-solutions-to-meet-cold-chain-needs/) - CDMOs are continually investing in improving their cold chain solutions with new and innovative technology so as to meet the increasing need for CGT products.
- [The After-Effects of A Poor Laboratory Inventory Management](https://www.pharmaadvancement.com/pharma-news/the-after-effects-of-a-poor-laboratory-inventory-management/) - Inadequate inventory control goes on to affect all the aspects of the laboratory, and hence its management needs to be done every day by the lab manpower.
- [Tomorrow Has Lots In Store With Digital Pharma Laboratories](https://www.pharmaadvancement.com/pharma-news/tomorrow-has-lots-in-store-with-digital-pharma-laboratories/) - Data is given meaning in digitalized laboratory that are also suited to detecting, interacting with one another, evaluating, and reacting on it advantageously.
- [IoT Making The Precision Lab Equipment Segment See A Surge](https://www.pharmaadvancement.com/pharma-news/iot-making-the-precision-lab-equipment-segment-see-a-surge/) - IoT boosts the functionality of precision lab equipment and operations, enhancing medical data clarity, speeding testing, and driving industrial automation.
- [Drug Delivery Innovation & Peptide-Stabilized Emulsions](https://www.pharmaadvancement.com/drug-development/drug-delivery-innovation-peptide-stabilized-emulsions/) - Short peptide consisting of four amino acids is created for drug delivery, and it can hold hydrophilic and hydrophobic compounds while stabilizing emulsions.
- [Drug Delivery Innovations Boosting Women-Health All The More](https://www.pharmaadvancement.com/drug-development/drug-delivery-innovations-boosting-women-health-all-the-more/) - From improving contraception to treating reproductive health disorders, drug delivery advances have paved path for tailored effective approach in women health.
- [Four Ways To Creating Better Flexible Lab Design Space](https://www.pharmaadvancement.com/drug-development/four-ways-to-creating-better-flexible-lab-design-space/) - Ability of labs to handle developments in technology, produce improved findings, respond to developing needs can be ensured by adhering to guiding concepts.
- [New Molecular Device Opens Door To Targeted Drug Delivery](https://www.pharmaadvancement.com/drug-development/new-molecular-device-opens-door-to-targeted-drug-delivery/) - Researchers have developed novel molecular device that uses force to control release of molecules, revolutionizing fields of material engineering and medicine.
- [Laboratory Information Management System - The 2024 Path](https://www.pharmaadvancement.com/pharma-trends/laboratory-information-management-system-the-2024-path/) - Rapid development of new technologies as well as changing demands of many sectors will drive demand for a Laboratory Information Management System in 2024.
- [Lab Bottlenecks? Digitalized Lab Management Systems Can Help](https://www.pharmaadvancement.com/pharma-news/lab-bottlenecks-digitalized-lab-management-systems-can-help/) - Digitalized Laboratory management systems can help accelerate scientific progress by streamlining processes, decreasing waste, and improving worker safety.
- [Rare Illnesses: mRNA Therapy May Swap Intracellular Proteins](https://www.pharmaadvancement.com/drug-development/rare-illnesses-mrna-therapy-may-swap-intracellular-proteins/) - As there are no treatments for propionic acidaemia, new research indicates that LNP-encapsulated mRNA therapy may offer patients with novel therapeutic choice.
- [LAI Antipsychotic - Given The Green Light Across The EU](https://www.pharmaadvancement.com/pharma-news/lai-antipsychotic-given-the-green-light-across-the-eu/) - Adults who have been diagnosed with schizophrenia are recommended to get the long-acting injectable- LAI formulation as a therapy in once every two months.
- [New Advancements - A Game-Changer In Biological Drug Delivery](https://www.pharmaadvancement.com/drug-development/new-advancements-a-game-changer-in-biological-drug-delivery/) - Distribution of biological drugs can be revolutionized by 2 interesting developments that are presently being investigated- inhalation & liquid-based delivery.
- [Innovation To Propel The Advanced Drug Delivery Sector](https://www.pharmaadvancement.com/drug-development/innovation-to-propel-the-advanced-drug-delivery-sector/) - A survey indicates that by the year 2033, the market for elevated drug delivery is expected to experience an overall compound annual growth rate- CAGR of 4.6%.
- [Europe LIMS Market Steered By Germany - Arizton Report](https://www.pharmaadvancement.com/market-moves/europe-lims-market-steered-by-germany-arizton-report/) - According to the study, the need for laboratory automation is a major element pushing the market for laboratory information management systems across Europe.
- [Consistent Growth - Global Lab Information Systems Sector](https://www.pharmaadvancement.com/market-moves/consistent-growth-global-lab-information-systems-sector/) - The global laboratory information systems market is anticipated to reach a significant value of $2,166.3 million by end of 2024, growing at a 6% annual pace.
- [Use of Automation Fuelled By Growing Pharmaceutical Output](https://www.pharmaadvancement.com/pharma-news/use-of-automation-fuelled-by-growing-pharmaceutical-output/) - Technology advancements, automation, sustainability & supply chain issues are the main factors driving the pharmaceutical machinery markets anticipated growth.
- [Drug Manufacturing Is Well-Positioned For A Potential Growth](https://www.pharmaadvancement.com/drug-development/drug-manufacturing-is-well-positioned-for-a-potential-growth/) - There is always work to be done in the pharmaceutical manufacturing industry because of the always expanding market that drives technological advancements.
- [The Manufacturing Outsourcing Trend Prompted By Biopharma](https://www.pharmaadvancement.com/drug-development/the-manufacturing-outsourcing-trend-prompted-by-biopharma/) - According to a report, contract manufacturers are helping to improve the efficiency of pharmaceutical drug development by handling manufacturing operations.
- [New Era In Drug Packaging: Redefining Safety, Sustainability](https://www.pharmaadvancement.com/packaging-logistic/new-era-in-drug-packaging-redefining-safety-sustainability/) - The way that drug packaging has evolved with time is clearest indication of the sectors commitment to efficacy, sustainability, and breakthrough technology.
- [Building A Long-Lasting Future For The Biopharma Sector](https://www.pharmaadvancement.com/pharma-news/building-a-long-lasting-future-for-the-biopharma-sector/) - As part of their effort to decarbonize operations, biopharma companies are working closely together to incorporate sustainable practices into their operations.
- [44% Predict Biotech Funding Recovery In 2024, Says Survey](https://www.pharmaadvancement.com/drug-development/44-predict-biotech-funding-recovery-in-2024-says-survey/) - Macroeconomic factors that made investors prioritize their current portfolios resulted in a decline in the private biotech venture financing in 2022 & 2023.
- [Continuous Bioprocessing Impacts Modern Biopharma Production](https://www.pharmaadvancement.com/drug-development/continuous-bioprocessing-impacts-modern-biopharma-production/) - With its potential to completely transform pharma production processes around the world, continuous bioprocessing market is leading the way in innovation.
- [Analytics & Mass Spec Enable Biotherapeutic Drug Development](https://www.pharmaadvancement.com/drug-development/analytics-mass-spec-enable-biotherapeutic-drug-development/) - Laboratories can go on to identify ultra-low-level changes and crucial site quality attributes using mass spectrometry and biopharma analytical technologies.
- [Biopharma Commits Offering Equitable Access In Pandemics](https://www.pharmaadvancement.com/drug-development/biopharma-commits-offering-equitable-access-in-pandemics/) - The pandemic agreement with biopharma offers a unique opportunity to develop a comprehensive framework for more fair preparedness and response to pandemics.
- [The Clinical Trial Participation Added More Seamlessness](https://www.pharmaadvancement.com/pharma-news/the-clinical-trial-participation-added-more-seamlessness/) - ProofPilot clients will prevent duplicate trial participants from enrolling in many studies simultaneously thanks to Verified Clinical studies integration.
- [Amid Registry Patent Listing Action, Drug Clashes Continue](https://www.pharmaadvancement.com/drug-development/amid-registry-patent-listing-action-drug-clashes-continue/) - FTC has asked that FDA delist drugs from the register in order to increase patient access to drugs & guarantee that product will always be of highest quality.
- [Tech Shift In Patient Retention Empowers Clinical Trials](https://www.pharmaadvancement.com/ipr-data-management/tech-shift-in-patient-retention-empowers-clinical-trials/) - In clinical trials, participant retention is essential to success of the study as it provides validity to trial outcomes and robustness to the data acquired.
- [NHS Gives Its Nod To New Endometrial Cancer Immunotherapy](https://www.pharmaadvancement.com/pharma-news/nhs-gives-its-nod-to-new-endometrial-cancer-immunotherapy/) - A groundbreaking immunotherapy which can potentially offer major additional time to women suffering from advanced endometrial cancer has been okayed by the NHS.
- [Lab Productivity To Be Enhanced By Digital Tools From Tecan](https://www.pharmaadvancement.com/pharma-news/lab-productivity-to-be-enhanced-by-digital-tools-from-tecan/) - LabNavigator and Next-Gen Introspect, the two digital products by Tecan have been unveiled so as to ensure a steadfast improvement in laboratory operations.
- [5 Reasons Laboratories Need Remote Temperature Monitoring](https://www.pharmaadvancement.com/facilities-operation/5-reasons-laboratories-need-remote-temperature-monitoring/) - So as to make sure that a lab functions safely, securely, and also effectively, wireless sensor technology is indeed the way forward considering modern trends.
- [Cell Therapy Production Automation Set To Be On The Horizon](https://www.pharmaadvancement.com/manufacturing/cell-therapy-production-automation-set-to-be-on-the-horizon/) - So as to further completely automate the cell therapy production process, Thermo Fischer Scientific as well as Multiply Labs have entered into an agreement.
- [Lab Automation Market Experiences Unprecedented 8.1% Growth](https://www.pharmaadvancement.com/pharma-news/lab-automation-market-experiences-unprecedented-8-1-growth/) - With a valuation of US$5.6bn in 2022, scientific research lab automation market is predicted to see rapid expansion, rising by over 8.1% between 2023 and 2030.
- [Innovation In A Laboratory Setting - Eyeing Advancements](https://www.pharmaadvancement.com/facilities-operation/innovation-in-a-laboratory-setting-eyeing-advancements/) - Be it the laboratory setting or right instruments that are a part of it, all elements surrounding them pave way for a healthcare future that looks encouraging.
- [Biden Proposes Strengthening The Medicare Drugs Price Power](https://www.pharmaadvancement.com/pharma-news/biden-proposes-strengthening-the-medicare-drugs-price-power/) - Medicare currently only has an access to 20 medication prices within IRA and the White House wants to give it the power to negotiate 50 drug prices annually.
- [The Role of Warehouse Management In Pharmaceutical Sector](https://www.pharmaadvancement.com/facilities-operation/the-role-of-warehouse-management-in-pharmaceutical-sector/) - In the complex world of pharmaceutical logistics, safe, secure, intact and within time-frame delivery holds the key and warehousing is a phenomenal part of it.
- [CPHI Japan 2024: Rising Tides manufacturing in Japan](https://www.pharmaadvancement.com/pharma-news/cphi-japan-2024-rising-tides-manufacturing-in-japan/) - CPHI Japan 2024 (17-19 April) will see a 20+% year-on-year rise, with a record attendance of an expected 20,000 attendees as the country undergoes a post pandemic boom in pharma – with biologics and tides manufacturing expected to grow quickly.
- [FDA Finally Gives Nod To DxFLEX Clinical Flow Cytometer](https://www.pharmaadvancement.com/manufacturing/fda-finally-gives-nod-to-dxflex-clinical-flow-cytometer/) - Global leader in lab automation & innovation, Beckman Coulter Life Sciences has got clearance from FDA to distribute DxFLEX Clinical Flow Cytometer across US.
- [Exploring Unlimited Packaging Opportunities at swop 2024: Bringing together the Emerging Forces of the Industry and Driving the New Development of Packaging](https://www.pharmaadvancement.com/press-statements/exploring-unlimited-packaging-opportunities-at-swop-2024-bringing-together-the-emerging-forces-of-the-industry-and-driving-the-new-development-of-packaging/) - With the expansion of the global consumer market and the development of technological updates, the packaging industry has become a major driver of economic growth.
- [UK Research On Crohns Disease Treatment For Better Outcomes](https://www.pharmaadvancement.com/pharma-news/uk-research-on-crohns-disease-treatment-for-better-outcomes/) - Research suggests top-down treatment with an immunomodulator elevates outcomes in patients as compared to accelerated step-up therapy concerning Crohns disease.
- [CROs Get To Gain From Automating The Traditional Processes](https://www.pharmaadvancement.com/drug-development/cros-get-to-gain-from-automating-the-traditional-processes/) - As big pharma continue to outsource their tasks to CROs, the latter needs to have an access to pharmacovigilance automation that helps them with huge benefits.
- [Advancing Medical Nutrition: Hologram Sciences Announces collaboration with Mayo Clinic to Develop Precision Nutrition Platform](https://www.pharmaadvancement.com/health-nutrition/advancing-medical-nutrition-hologram-sciences-announces-collaboration-with-mayo-clinic-to-develop-precision-nutrition-platform/) - Advancing Medical Nutrition: Hologram Sciences Announces collaboration with Mayo Clinic to Develop Precision Nutrition Platform
- [Biology-Driven AI Makes Its Presence Felt In Drug Discovery](https://www.pharmaadvancement.com/drug-development/biology-driven-ai-makes-its-presence-felt-in-drug-discovery/) - Biology-driven AI and its effect on drug development can be gauged by the fact that the process has become more enhanced, rapid as well as easy on pockets.
- [Clinical Trials Automation: Step Towards Sustainable Pharma](https://www.pharmaadvancement.com/pharma-news/clinical-trials-automation-step-towards-sustainable-pharma/) - The pursuit to stay ahead of the curve in a scenario marked by increased environmental consciousness, exploring automation in clinical trials is a big leap.
- [Potential of Self-Driving Labs - New Proposed Guidelines](https://www.pharmaadvancement.com/pharma-news/potential-of-self-driving-labs-new-proposed-guidelines/) - Researchers are most likely going to accurately evaluate the capabilities and performance of self-driving labs according to the newly recommended criteria.
- [Lab Automation Market - What Is In The Store Now & Future?](https://www.pharmaadvancement.com/pharma-news/lab-automation-market-what-is-in-the-store-now-future/) - With intent to minimise or replace manual equipment, produce high quality data and with CAGR of 7.67% till 2031, global lab automation market looks promising.
- [North America Leads The Laboratory Robotics Market Share](https://www.pharmaadvancement.com/pharma-news/north-america-leads-the-laboratory-robotics-market-share/) - Labs are adopting robotic technologies for critical process applications because of the necessity to protect manual workers and strict laboratory regulations.
- [Digital Labs Role In Making End-To-End Pharma Supply Better](https://www.pharmaadvancement.com/pharma-news/digital-labs-role-in-making-end-to-end-pharma-supply-better/) - In lab transformation and creating roadmap, crucial ecosystem developments must be considered to adapt to and assure success with digital laboratory design.
- [Laboratory Information Management: A Must Have In Pharma](https://www.pharmaadvancement.com/pharma-news/laboratory-information-management-a-must-have-in-pharma/) - As data integrity and strict regulatory benchmarks happen to hold the key in pharma, Laboratory Information Management Systems are more pivotal than ever.
- [Biology-Driven AI Pushing Drug Discovery To Bigger Levels](https://www.pharmaadvancement.com/drug-development/biology-driven-ai-pushing-drug-discovery-to-bigger-levels/) - A new era of drug development which is all set to make it better, faster, and affordable by way of biology-driven artificial intelligence is on the cards.
- [Analytical Laboratory Instruments Eying Record High By 2028](https://www.pharmaadvancement.com/facilities-operation/analytical-laboratory-instruments-eying-record-high-by-2028/) - As per the latest BCC Research study, the Analytical Laboratory Instruments Manufacturing globally is all set to surge to $82.5bn by 2028 with a CAGR of 6.3%.
- [Lab Automation & Digital Shift To Enhance SDG 2030 Agenda](https://www.pharmaadvancement.com/pharma-news/lab-automation-digital-shift-to-enhance-sdg-2030-agenda/) - By way of automation as well as integration, the SDG 2030 agenda by the UN for the healthcare and diagnostic sectors looks forward to innovate lab procedures.
- [Lab Connectivity - Way Forward To Data-Driven Discoveries](https://www.pharmaadvancement.com/drug-development/lab-connectivity-way-forward-to-data-driven-discoveries/) - The idea of an integrated lab, which eliminates manual work and connects work processes across all equipment for better data quality, has taken the forefront.
- [Big Pharma Plan Spending 7% Revenue On Next-Gen Labs By 2025](https://www.pharmaadvancement.com/pharma-news/big-pharma-plan-spending-7-revenue-on-next-gen-labs-by-2025/) - Big Pharma looks to invest in next-gen labs to boost processes, build necessary capabilities for lab transformation, expedite digitalization, and leverage AI.
- [Data Intelligence Is The Key To Turning Lab Outcomes Better](https://www.pharmaadvancement.com/pharma-news/data-intelligence-is-the-key-to-turning-lab-outcomes-better/) - Lab data happens to be a fertile ground for AI which can in turn result in giving out smarter data thereby assisting to offer better outcomes than present.
- [Digital Innovation In Therapeutics For Faster Market Access](https://www.pharmaadvancement.com/pharma-news/digital-innovation-in-therapeutics-for-faster-market-access/) - As AI-designed drugs begin to enter into large scale clinical trials, digital tools are indeed reshaping as well as reinventing the future drug discoveries.
- [Guidance On CAR-T Cell Product Development Issued By FDA](https://www.pharmaadvancement.com/pharma-news/guidance-on-car-t-cell-product-development-issued-by-fda/) - The final guidance by the FDA gives specific suggestions for how to plan clinical studies, do pharmacology, toxicology as well as CMC for CAR-T cell products.
- [EMA Given Aid To Support African Medicines Agency Setup](https://www.pharmaadvancement.com/pharma-news/ema-given-aid-to-support-african-medicines-agency-setup/) - European Medicines Agency has been given a grant of €10mn by the European Commission to establish African Medicines Agency with more member likely to join.
- [Possible Autoimmune Breakthrough With BCMA CAR T Therapy](https://www.pharmaadvancement.com/pharma-news/possible-autoimmune-breakthrough-with-bcma-car-t-therapy/) - Initial BCMA CAR T-cell treatment use for immune-mediated necrotising myopathy led autoantibodies to be continuously depleted for a period of over 18 months.
- [NHSs BRCA Gene Testing Programme To Ascertain Cancer Risk](https://www.pharmaadvancement.com/pharma-news/nhss-brca-gene-testing-programme-to-ascertain-cancer-risk/) - The NHS across England has gone on to launch a groundbreaking BRCA gene testing programme that will benefit a number of persons born into the Jewish ancestry.
- [Prescribe Fluoroquinolone Antibiotics As Last Resort - MHRA](https://www.pharmaadvancement.com/pharma-news/prescribe-fluoroquinolone-antibiotics-as-last-resort-mhra/) - As per the new MHRA drug safety update, only when other antibiotics are of no use should the fluoroquinolone antibiotics be prescribed as the last resort.
- [Breast Cancer Ranked Highest On Most Studied Diseases List](https://www.pharmaadvancement.com/drug-development/breast-cancer-ranked-highest-on-most-studied-diseases-list/) - Phesi Global Analysis report states that most studied diseases in 2023 had three kinds of cancers in it with breast cancer on top of all diseases put together.
- [Medicines For Europe Calls Simpler SPC Manufacturing Waiver](https://www.pharmaadvancement.com/manufacturing/medicines-for-europe-calls-simpler-spc-manufacturing-waiver/) - To make sure of a timely generic as well as biosimilars market entry across the EU, the SPC manufacturing waiver has to be seamless, says Medicines for Europe.
- [Bormioli Pharma introduces at Pharmapack Europe 2024 a brand-new consultancy approach showcasing its wide, sustainable and innovative packaging offer](https://www.pharmaadvancement.com/packaging-logistic/bormioli-pharma-introduces-at-pharmapack-europe-2024-a-brand-new-consultancy-approach-showcasing-its-wide-sustainable-and-innovative-packaging-offer/) - Bormioli Pharma introduces at Pharmapack Europe 2024 a brand-new consultancy approach showcasing its wide, sustainable and innovative packaging offer
- [E&L Testing Market Growth To Be Driven By Single-Use Systems](https://www.pharmaadvancement.com/drug-development/el-testing-market-growth-to-be-driven-by-single-use-systems/) - Extractable & leachable testing services market between 2023 to 2030 is likely to be impacted by rising biopharma demand as well as cross contamination focus.
- [Largest Reorganization In History of FDA On Table In 2024](https://www.pharmaadvancement.com/pharma-news/largest-reorganization-in-history-of-fda-on-table-in-2024/) - The proposed reorganization of the FDA may as well have food safety on the cards, however the stakeholders across the sectors are going to feel its effects.
- [CAR-NK Cell Therapy Trial Long-Term Findings Get Revealed](https://www.pharmaadvancement.com/pharma-news/car-nk-cell-therapy-trial-long-term-findings-get-revealed/) - One-year inferences from trial related to cancer therapy has reported key findings for selection of allogeneic cord blood donors in CAR NK cell manufacturing.
- [Cancer Care Whole Genome Sequencing: Compelling Proof Found](https://www.pharmaadvancement.com/drug-development/cancer-care-whole-genome-sequencing-compelling-proof-found/) - As per new research published in Nature Medicine, whole genome sequencing- WGS with the help of routine clinical data goes on to deliver precision cancer care.
- [2024 Has A Lot Many Questions In Store For Pharma Companies](https://www.pharmaadvancement.com/pharma-news/2024-has-a-lot-many-questions-in-store-for-pharma-companies/) - Be it obesity, cancer, the IRA, Alzheimers drugs or even the ones that are complex, there are umpteen questions in store for pharmaceutical companies in 2024.
- [UK Study Supports Whole Genome Sequencing In Cancer Care](https://www.pharmaadvancement.com/drug-development/uk-study-supports-whole-genome-sequencing-in-cancer-care/) - Combining the whole genome sequencing and the real-world clinical data can go on to deliver personalised cancer therapy to patients, says a landmark UK study.
- [AI Can Indeed Revolutionize The Pharma Compound Synthesis](https://www.pharmaadvancement.com/pharma-news/ai-can-indeed-revolutionize-the-pharma-compound-synthesis/) - An Artificial Intelligence platform developed in the UK can ensure to refine as well as accelerate the way the pharmaceutical drugs are designed and made.
- [Leading Pharmaceutical Packaging Trends Anticipated For 2024](https://www.pharmaadvancement.com/pharma-news/leading-pharmaceutical-packaging-trends-anticipated-for-2024/) - In a developing pharma landscape, packaging has increasingly become a major force to reckon with so that the end-users are well acquainted with the product.
- [The Digital Transition Pharma Landscape Is Going Through](https://www.pharmaadvancement.com/pharma-news/the-digital-transition-pharma-landscape-is-going-through/) - Pharmaceutical world looks very different from what it used to be 10 years back, thanks to digital push it has received making it more refined and accessible.
- [NourishedRx joins ProHealth Connect network, expanding food and nutrition access for 17 million individuals](https://www.pharmaadvancement.com/health-nutrition/nourishedrx-joins-prohealth-connect-network-expanding-food-and-nutrition-access-for-17-million-individuals/) - A partnership between digital health and nutrition company NourishedRx and healthcare fintech platform ProHealth Connect will provide additional personalized choices, including home-delivered food and nutritional support services
- [Danone enters adult medical nutrition category in China](https://www.pharmaadvancement.com/pharma-news/danone-enters-adult-medical-nutrition-category-in-china/) - Danone has announced the launch of Fortimel, its first medical nutrition product in the adult foods for special medical purposes category in China
- [Nestle unveils science-backed innovation for early-life nutrition](https://www.pharmaadvancement.com/health-nutrition/nestle-unveils-science-backed-innovation-for-early-life-nutrition/) - Nestle unveils science-backed innovation for early-life nutrition
- [Rheonix Inc Publishes Cyclospora cayetanensis Data in Collaboration With FDA Center for Food Safety and Applied Nutrition](https://www.pharmaadvancement.com/health-nutrition/rheonix-inc-publishes-cyclospora-cayetanensis-data-in-collaboration-with-fda-center-for-food-safety-and-applied-nutrition/) - Rheonix Inc Publishes Cyclospora cayetanensis Data in Collaboration With FDA Center for Food Safety and Applied Nutrition
- [Komodo Health Collaborates With Robert Wood Johnson Foundation To Advance New Research on Diet and Health](https://www.pharmaadvancement.com/health-nutrition/komodo-health-collaborates-with-robert-wood-johnson-foundation-to-advance-new-research-on-diet-and-health/) - Komodo Health Collaborates With Robert Wood Johnson Foundation To Advance New Research on Diet and Health
- [Danone partners with digital oncology company Resilience for better nutritional care for patients with cancer](https://www.pharmaadvancement.com/health-nutrition/danone-partners-with-digital-oncology-company-resilience-for-better-nutritional-care-for-patients-with-cancer/) - Danone partners with digital oncology company Resilience for better nutritional care for patients with cancer
- [Synergising SaaS & Cloud Comm With AI For Better Pharma](https://www.pharmaadvancement.com/pharma-news/synergising-saas-cloud-comm-with-ai-for-better-pharma/) - Under the pharma scenario, the SaaS & cloud communication in sync with AI are truly going to shape-up and also advance the scenario of real-time data sharing.
- [Role of GenAI In Speeding Up Pharmaceuticals To Market](https://www.pharmaadvancement.com/pharma-news/role-of-genai-in-speeding-up-pharmaceuticals-to-market/) - GenAI has ability to ensure that all aspects of drug development are duly considered while also giving thrust to bringing the pharmaceuticals to the market.
- [The State of GenAI In The Pharmaceutical Industry Today](https://www.pharmaadvancement.com/pharma-news/the-state-of-genai-in-the-pharmaceutical-industry-today/) - GenAI within the pharmaceutical landscape goes on to change the dynamic by speeding-up the automation capacity and elevating the level of innovation potential.
- [Generic Drugs Safety Test Requests Pushed Back By The FDA](https://www.pharmaadvancement.com/drug-development/generic-drugs-safety-test-requests-pushed-back-by-the-fda/) - The paperwork reviews and plant visits are an occasional aspects of FDA functioning but drug safety according to them happens to be manufacturers ownership.
- [The Biopharma Spectrum May See Regulation Shifts In 2024](https://www.pharmaadvancement.com/drug-development/the-biopharma-spectrum-may-see-regulation-shifts-in-2024/) - 2024 may see some biopharma companies making an approach re-look in R&D, cutting down on projects and also resource allocation as part of regulations changes.
- [US, UK Look To Make Regulatory Changes In Life Sciences In 2024](https://www.pharmaadvancement.com/pharma-news/us-uk-look-to-make-regulatory-changes-in-life-sciences-in-2024/) - 2024 is all set to see UK reworking on Voluntary Scheme for Branded Medicines and US looking to regulate products that make use of Artificial Intelligence.
- [7 Potential Drivers of The Life Sciences Landscape In 2024](https://www.pharmaadvancement.com/pharma-news/7-potential-drivers-of-the-life-sciences-landscape-in-2024/) - The progress within the life sciences sector in 2024 can be attributed to the advancements taking place with these 7 indicators suggestive of great potential.
- [Synthetic Antibiotics Way To Go For Critical Chronic Issues](https://www.pharmaadvancement.com/drug-development/synthetic-antibiotics-way-to-go-for-critical-chronic-issues/) - Certain superbugs such as MRSA can now be treated by way of a new synthetic antibiotic thanks to its development by The University of Liverpool researchers.
- [The Rising Challenges In The Path of Global Pharma In 2024](https://www.pharmaadvancement.com/pharma-news/the-rising-challenges-in-the-path-of-global-pharma-in-2024/) - Market expectations, economic pressures as well as regulations across the world are all going to add to the challenges of the pharmaceutical sector in 2024.
- [Federal, State Drug Pricing Plans In US Brewing Deep Issues](https://www.pharmaadvancement.com/drug-development/federal-state-drug-pricing-plans-in-us-brewing-deep-issues/) - The pharmaceutical sector in the US will continue to face the heat due to policy and regulations floated because of the federal and state drug pricing steps.
- [Biopharma Sector Witnesses M&A Revival Come Back On Track](https://www.pharmaadvancement.com/pharma-news/biopharma-sector-witnesses-ma-revival-come-back-on-track/) - Pipeline diversity, patent expiration and also availability of cash on big pharma balance sheets have led to biopharmaceutical sector eyeing the M&A revival.
- [Pharma In 2024: The Support & Challenge On Financial Aspect](https://www.pharmaadvancement.com/pharma-news/pharma-in-2024-the-support-challenge-on-financial-aspect/) - The pharmaceutical sector in 2024 is all set to see major support in the form of patent expiration and challenge comprising of drug pricing and inflation.
- [Drugmakers Look To Raise US Prices On 500 Drugs In Jan 2024](https://www.pharmaadvancement.com/pharma-news/drugmakers-look-to-raise-us-prices-on-500-drugs-in-jan-2024/) - There have been supply chain issues due to middle east conflict, one of the many reasons drugmakers will be raising prices of 500 drugs in US this January 2024.
- [Drug Development Benchmarks Driven By Quality By Design](https://www.pharmaadvancement.com/drug-development/drug-development-benchmarks-driven-by-quality-by-design/) - To adhere to the quality by design- QbD in order to set highest standards in drug development, pharma companies must attend to the regulatory expectations.
- [Global Pharma To Feel The Heat More Due To Stiff Environment](https://www.pharmaadvancement.com/pharma-news/global-pharma-to-feel-the-heat-more-due-to-stiff-environment/) - As per the Forbes and Numerof & Associates 2024 Global Pharma Outlook, the worldwide pharma sector is all set to intensify further due to stiff pressures.
- [Factors Influencing Current APAC Biopharma & Healthcare](https://www.pharmaadvancement.com/pharma-news/factors-influencing-current-apac-biopharma-healthcare/) - Singapore is leading the way in being the preferred partner across the world because of its prominence of being the centre in entrepreneurship & innovation.
- [Innovation-First Mindset: Key To Drive Advanced Therapies](https://www.pharmaadvancement.com/pharma-news/innovation-first-mindset-key-to-drive-advanced-therapies/) - Adoption of advanced therapies and working collaboratively can help in maximising the patient access which is a part of driving an innovation-first mindset.
- [2024 May See Pharma, Life Sciences Have Sound M&A Activity](https://www.pharmaadvancement.com/pharma-news/2024-may-see-pharma-life-sciences-have-sound-ma-activity/) - In 2024, M&A in the pharma and life sciences sector may witness a sound performance with the deal value almost hitting $275 billion, as anticipated by PwC.
- [Temp Resistant Pharma Packaging To Hit 945.2mn By 2030](https://www.pharmaadvancement.com/pharma-news/temp-resistant-pharma-packaging-to-hit-945-2mn-by-2030/) - The global pharmaceutical temperature control packaging market is seeing a surge due to medications that demand storage which calls for temperature control.
- [Advances making way for 2024 Cold Chain Packaging Solutions](https://www.pharmaadvancement.com/pharma-news/advances-making-way-for-2024-cold-chain-packaging-solutions/) - Temperature-controlled pharma packaging solutions especially the cold chain arena is a trend to watch out for in 2024 as consumers become growingly conscious.
- [10 Benefits of Digital Transformation In Pharma Production](https://www.pharmaadvancement.com/pharma-news/10-benefits-of-digital-transformation-in-pharma-production/) - Pharma manufacturing can gain a lot due to digitization thereby helping in production, quality control and also efficiency getting enhanced significantly.
- [Pharma Sector And Technology Trends To Watch Out For In 2024](https://www.pharmaadvancement.com/pharma-news/pharma-sector-and-technology-trends-to-watch-out-for-in-2024/) - The adoption of technology has already witnessed a growing momentum lately and in 2024 there will be a wider adoption of such tech for better outcomes.
- [AI In Pharma: Possibility European Regulators Look To Propel](https://www.pharmaadvancement.com/pharma-news/ai-in-pharma-possibility-european-regulators-look-to-propel/) - In order to maximise the advantages of AI across Pharma spectrum, EMA along with HMAs have come up with a strategy that is collaborative and also coordinated.
- [Global Advanced Empty Capsules To See A Growth of 7.4% CAGR](https://www.pharmaadvancement.com/drug-development/global-advanced-empty-capsules-to-see-a-growth-of-7-4-cagr/) - Due to growing prevalence of chronic illnesses & population that is aging, global advanced empty capsule segment is expected to grow at CAGR of 7.4% till 2033.
- [First Ever List of Critical Medicines Published By Europe](https://www.pharmaadvancement.com/drug-development/first-ever-list-of-critical-medicines-published-by-europe/) - The active substances that happen to be on the list go on to cater to a range of therapeutic possibilities which include treatment for diseases that are rare.
- [American Scientist Federation Discusses AI Biosecurity Risks](https://www.pharmaadvancement.com/pharma-news/american-scientist-federation-discusses-ai-biosecurity-risks/) - The Federation of American Scientists says that recommendations will help in making the policy development concerning biosecurity screening of synthetic DNA.
- [The White House Looks For Rebates Over Drug Price Fixing](https://www.pharmaadvancement.com/drug-development/the-white-house-looks-for-rebates-over-drug-price-fixing/) - The US Pharma manufacturers will have to pay inflation rebates back to the Centers for Medicare and Medicaid Services due to the price fixing on certain drugs.
- [Biden Administration Seeks Patents To Cut Medicine Costs](https://www.pharmaadvancement.com/pharma-news/biden-administration-seeks-patents-to-cut-medicine-costs/) - In order to lower the prices of drugs, the White House is supporting the policy which would enable the US government to sidestep the patent protection law.
- [New Pharma Legislation - Ambitious And Forward-Looking](https://www.pharmaadvancement.com/pharma-news/new-pharma-legislation-ambitious-and-forward-looking/) - The new regulations are at present under the review of European Parliament and Council of the European Union and shall heighten flexibility in pharma sector.
- [Korean & British Advanced Biotech To Cement Tech Partnership](https://www.pharmaadvancement.com/pharma-news/korean-british-advanced-biotech-to-cement-tech-partnership/) - To strengthen advanced biotech majorly in synthetic biology, brain research and drug development based on AI, South Korea & UK have signed many MoUs recently.
- [Pharma Spectrum - Using Connected Drug Delivery Devices](https://www.pharmaadvancement.com/drug-development/pharma-spectrum-using-connected-drug-delivery-devices/) - Pharma companies must surely look into the decision making as well as product development stages to make the most out of the connected drug delivery devices.
- [NPRA In Malaysia Has Broadened Reference Approval Guidelines](https://www.pharmaadvancement.com/drug-development/npra-in-malaysia-has-broadened-reference-approval-guidelines/) - The NPRA in Malaysia has revised its guideline pertaining to medicine approvals and gone on to identify USFDA and EMA as agencies which can be referenced.
- [Pharmaceutical Packaging - Finding Its Way Beyond Borders](https://www.pharmaadvancement.com/pharma-news/pharmaceutical-packaging-finding-its-way-beyond-borders/) - With a CAGR of 9.7% until end of this decade, growth in global pharma packaging market is fuelled by aging population and further use in developing nations.
- [Vetter's European Clinical Site Receives Permanent Manufacturer's Authorization](https://www.pharmaadvancement.com/packaging-logistic/vetters-european-clinical-site-receives-permanent-manufacturers-authorization/) - Vetter's European Clinical Site Receives Permanent Manufacturer's Authorization
- [New Pharma Legislation May Affect Europe R&D Significantly](https://www.pharmaadvancement.com/drug-development/new-pharma-legislation-may-affect-europe-rd-significantly/) - If the proposal comes into effect share of R&D investment of Europe will see a decrease from 32% to 21% by 2040 which will be a loss of €2 billion in funding.
- [Vetter In Rankweil Gets Permanent Manufacturer Authorization](https://www.pharmaadvancement.com/pharma-news/vetter-in-rankweil-gets-permanent-manufacturer-authorization/) - Austrian Agency for Health & Food Safety has inspected Vetter site at Rankweil, Austria and has made it earn the coveted permanent manufacturing authorization.
- [Global Healthcare Access Improved By Indian Pharma Cos.](https://www.pharmaadvancement.com/drug-development/global-healthcare-access-improved-by-indian-pharma-cos/) - Global healthcare access has elevated as India has stressed on giving assistance to research apart from addressing issues on local production, distribution.
- [Rapid Cutback of Intracranial Pressure By Injectable Peptide](https://www.pharmaadvancement.com/drug-development/rapid-cutback-of-intracranial-pressure-by-injectable-peptide/) - A phase II study reveals that patients suffering from idiopathic intracranial hypertension can be treated successfully with the help of injectable peptide.
- [Fujitsu and Aichi Cancer Center Develop AI System to Offer Patients Personalized Cancer Treatment](https://www.pharmaadvancement.com/drug-development/fujitsu-and-aichi-cancer-center-develop-ai-system-to-offer-patients-personalized-cancer-treatment/) - Aichi Cancer Center (1) and Fujitsu Limited announced the development of an AI solution able to select effective medical treatment from a wide range of drugs based on patients' individual cancer types and various genomic variants.
- [Faster Clinical Trial Nods Planned By The UK To Curb Issues](https://www.pharmaadvancement.com/pharma-news/faster-clinical-trial-nods-planned-by-the-uk-to-curb-issues/) - The UK intends to have its status of the most preferred location when it comes to clinical trials back and is doing all it can to ensure faster approvals.
- [FDA Advisors Help Drug Amylyx For ALS, Altering Prior Stance](https://www.pharmaadvancement.com/drug-development/fda-approvals/fda-advisors-help-drug-amylyx-for-als-altering-prior-stance/) - According to the results of the trial, patients who took the Amylyx drug lived slightly longer and declined more gradually than those who received a placebo.
- [Alzheimers Medicine Change Helped Biden Win Medicare Costs](https://www.pharmaadvancement.com/drug-development/fda-approvals/alzheimers-medicine-change-helped-biden-win-medicare-costs/) - According to Biden, the lower rates are a result of his and other Democratic lawmakers efforts to slash the healthcare costs for seniors, a critical vote bloc.
- [Addressing Cholestatic Liver Disease Upon Cognitive Decline](https://www.pharmaadvancement.com/drug-development/research-development/addressing-cholestatic-liver-disease-upon-cognitive-decline/) - There is presently no treatment for neurological symptoms that cholestatic liver disease patients may experience, including weariness and cognitive decline.
- [Pharma Alliance Worth $5 Billion In Bispecific Antibodies](https://www.pharmaadvancement.com/facilities-operation/pharma-alliance-worth-5-billion-in-bispecific-antibodies/) - Ivonescimab, a PD-1-based bispecific antibody, will be given access to Summit Therapeutics via an out-licensing deal that is part of a partnership worth $5bn.
- [Pharma Drugs Gain From Tardigrade Proteins, Says Research](https://www.pharmaadvancement.com/drug-development/pharma-drugs-gain-from-tardigrade-proteins-says-research/) - Pharma meds temperature can very well be taken care off as tardigrade proteins can help Factor VIII with stability which is vital to a drugs effectiveness
- [Pharma Packaging Market In Europe To Hit $35bn Come 2028](https://www.pharmaadvancement.com/pharma-news/pharma-packaging-market-in-europe-to-hit-35bn-come-2028/) - The European pharmaceutical packaging as well as labelling market is all set to reach $35bn by 2028 considering that it consistently expands at a CAGR of 4.78%.
- [Biden Designates 31 Tech Hubs, With 10 For Pharma, Biotech](https://www.pharmaadvancement.com/pharma-news/biden-designates-31-tech-hubs-with-10-for-pharma-biotech/) - Each listed hub will be eligible to apply for a grant between $50mn to $75mn so as to drive innovation within all the designated exclusive focus category.
- [Unlocking The Possibilities of Point-of-Care Manufacturing](https://www.pharmaadvancement.com/pharma-news/unlocking-the-possibilities-of-point-of-care-manufacturing/) - Industry leaders and regulators are having a closer look at advantages associated with decentralised manufacturing that are closer to point of care locations.
- [Machine Conditioning Monitoring - Making Inroads In Pharma](https://www.pharmaadvancement.com/pharma-news/machine-conditioning-monitoring-making-inroads-in-pharma/) - Machine conditioning monitoring can help going a long way in establishing a benchmark in terms of better asset management within the pharmaceutical sector.
- [Predictive Maintenance - AI Aspect In Pharma Manufacturing](https://www.pharmaadvancement.com/pharma-news/predictive-maintenance-ai-aspect-in-pharma-manufacturing/) - Predictive maintenance which holds the key in pharma manufacturing can offer more benefits than one by making sure to enhance productivity and reduce downtime.
- [US Patent Law Suit For Actemra Solved Between Roche & Biogen](https://www.pharmaadvancement.com/pharma-news/us-patent-law-suit-for-actemra-solved-between-roche-biogen/) - A patent lawsuit filed by the Swiss Pharma giant Roche against Biogen, the US Biotech firm for formers rheumatoid arthritis drug, Actemra has been settled.
- [Innovation Can Grow When Big Pharma & Big Tech Collaborate](https://www.pharmaadvancement.com/facilities-operation/innovation-can-grow-when-big-pharma-big-tech-collaborate/) - Although tech firms focus on revenues from technology license and pharma firms depend on blockbuster drugs, their ties can help in better industry innovation.
- [CDMO-Biotech Ties Help Cut Business Risk In Drug Development](https://www.pharmaadvancement.com/drug-development/research-development/cdmo-biotech-ties-help-cut-business-risk-in-drug-development/) - Biotech companies face severe risk in the clinical stage of the research but by collaborating with the CDMOs they can de-risk the drug development journey.
- [Improving Approach of UK Through Future Clinical Trials Bill](https://www.pharmaadvancement.com/pharma-news/improving-approach-of-uk-through-future-clinical-trials-bill/) - Quicker regulatory nods due to transparent trial registrations are some of the many advantages of the Future Clinical Trials Bill that the UK can expect.
- [IP Waivers, Pathogen Sharing Benefits In Draft Pandemic Deal](https://www.pharmaadvancement.com/ipr-data-management/ip-waivers-pathogen-sharing-benefits-in-draft-pandemic-deal/) - Provision for time-bound intellectual property rights waivers and benefits for nations sharing hazardous pathogens info included in draft pandemic accord.
- [Industry 5.0 Has Plenty To Offer To Pharma Manufacturing](https://www.pharmaadvancement.com/pharma-news/industry-5-0-has-plenty-to-offer-to-pharma-manufacturing/) - Industry 5.0 is all about placing a higher stress on employee empowerment by making use of new technologies to offer satisfaction going beyond jobs & growth.
- [Prominent Pharma Antitrust Lawsuits Over The Last Decade](https://www.pharmaadvancement.com/pharma-news/prominent-pharma-antitrust-lawsuits-over-the-last-decade/) - A slump in innovation and price rise will result if in case the antitrust laws are not put in place to prevent unlawful activities by pharmaceutical giants.
- [Xtandi Clones By Sun Pharma - Astellas-Pfizer Settle Case](https://www.pharmaadvancement.com/pharma-news/xtandi-clones-by-sun-pharma-astellas-pfizer-settle-case/) - Astellas, Pfizer as well as University of California filed a lawsuit against Sun stating that its proposed generic versions of Xtandi violated the patent law.
- [EUGC Sets Last Pin On Pharma Reverse Payment Patent Deals](https://www.pharmaadvancement.com/pharma-news/eugc-sets-last-pin-on-pharma-reverse-payment-patent-deals/) - Certain judgements have been made by the European Union General Court where the pharma patent settlements have been reversed and the firms have been fined.
- [Vetter looks ahead to further expansions to meet supply chain demand](https://www.pharmaadvancement.com/packaging-logistic/vetter-looks-ahead-to-further-expansions-to-meet-supply-chain-demand/) - Vetter looks ahead to further expansions to meet supply chain demand
- [Veramed expands its global footprint by acquiring Clinical Trial Data Services](https://www.pharmaadvancement.com/drug-development/clinical-trials/veramed-expands-its-global-footprint-by-acquiring-clinical-trial-data-services/) - Veramed expands its global footprint by acquiring Data Management, Biostatistics and Medical Writing services company Clinical Trial Data Services (CTDS)
- [Drug Delivery Via Drones - Get Ready For Exciting Times Ahead](https://www.pharmaadvancement.com/pharma-news/drug-delivery-via-drones-get-ready-for-exciting-times-ahead/) - Although the delivery of drugs through drones is still at a nascent stage, it can surely become a reality with more effective technology advances taking place.
- [APAC Pandemic Readiness - A Workforce Training Efforts Goal](https://www.pharmaadvancement.com/pharma-news/apac-pandemic-readiness-a-workforce-training-efforts-goal/) - To enhance the vaccine production capabilities in Asia-Pacific, South Korea is collaborating with ADB by way of joint training and be ready for next pandemic.
- [New MHRA Regulation Revamps Lowest-Risk UK Clinical Trials](https://www.pharmaadvancement.com/pharma-news/new-mhra-regulation-revamps-lowest-risk-uk-clinical-trials/) - MHRA regulation overhaul has meant that new scheme will help clinical trial authorisations have a streamlined approach in case of late-stage clinical trials.
- [Alternative Tools For Facility Assessments Provided By FDA](https://www.pharmaadvancement.com/pharma-news/alternative-tools-for-facility-assessments-provided-by-fda/) - The US Food and Drug Administration will go on to evaluate alternative tools for facility evaluation in an application as required on a case-to-case basis.
- [EU Pharma Reforms Need Revisions - Swedish Stakeholders](https://www.pharmaadvancement.com/pharma-news/eu-pharma-reforms-need-revisions-swedish-stakeholders/) - The Swedish Association has raised concerns that are related to pricing as well as equal access to medicines and treatments throughout EU member countries.
- [Why Pharmaceutical Packaging Needs a complete overhaul?](https://www.pharmaadvancement.com/pharma-news/why-pharmaceutical-packaging-needs-a-complete-overhaul/) - Be it artificial intelligence or blockchain technology, innovations to keep pharmaceutical packaging upbeat and upgraded have begun to take the centre stage.
- [Pharmaceutical Cold Chain - Moving Towards Better Outcomes](https://www.pharmaadvancement.com/pharma-news/pharmaceutical-cold-chain-moving-towards-better-outcomes/) - Post COVID-19, the pharmaceutical cold chain players have made consistent strides towards making themselves more adept to the requirements of modern medicines.
- [Drugmakers Sign Up For First US Medicare Price Discussions](https://www.pharmaadvancement.com/pharma-news/drugmakers-sign-up-for-first-us-medicare-price-discussions/) - Amidst suing U.S. Department of Health and Human Services, which controls the medicare, drugmakers have gone on to call the price setting as unconstitutional.
- [CDMO Strategies Are Key To Success In The Biopharma Sector](https://www.pharmaadvancement.com/drug-development/cdmo-strategies-are-key-to-success-in-the-biopharma-sector/) - Customer-centricity alongside cohesive teams matters when choosing a CDMO in biopharma; success through teamwork as well as expertise is definitely achievable.
- [AAV Gene Therapy CDMOs Shaping The Future With A $2.57B Goal](https://www.pharmaadvancement.com/manufacturing/aav-gene-therapy-cdmos-shaping-the-future-with-a-2-57b-goal/) - AAV-focused cell & gene therapy CDMO market is set for growth; challenges in scalability, competition, tie-ups, and more accelerates AAV therapy availability.
- [Rising Demand For CDMOs Amid COVID-19 Reshaping API Market](https://www.pharmaadvancement.com/drug-development/rising-demand-for-cdmos-amid-covid-19-reshaping-api-market/) - The COVID-19 pandemic drove demand for CDMO services and reshaped the API market; the Asia-Pacific region emerged, with India and China as the main players.
- [The Impact of DSCSA EDDS Guidance On Pharmaceutical Industry](https://www.pharmaadvancement.com/pharma-news/the-impact-of-dscsa-edds-guidance-on-pharmaceutical-industry/) - The DSCSA EDDS guidance by the FDA underscores ongoing progress in pharmaceutical traceability & compliance, emphasizing data exchange and operational aspects.
- [Drug Supply Chain Security Act Enforcement Delayed To 2024](https://www.pharmaadvancement.com/pharma-news/drug-supply-chain-security-act-enforcement-delayed-to-2024/) - The implementation of the Drug Supply Chain Security Act is postponed to Nov 2024, allowing pharmacies time for compliance with electronic tracing requirements.
- [Enhancing Medication Security Through Pharma Traceability](https://www.pharmaadvancement.com/pharma-news/the-future-of-pharma-traceability-in-healthcare-packaging/) - Pharma traceability through healthcare packaging, utilizing serialization, RFID, barcoding, and blockchain, enhances medication safety and compliance in pharma.
- [Antibiotic Waste Management In Pharmaceutical Manufacturing](https://www.pharmaadvancement.com/drug-development/antibiotic-waste-management-in-pharmaceutical-manufacturing/) - Antibiotic manufacturers must adopt responsible practices, including waste management, to mitigate AMR risk amid evolving regulations and market expectations.
- [Deciphering The Impact of EU HTA On Emerging Biopharma](https://www.pharmaadvancement.com/pharma-news/deciphering-the-impact-of-eu-hta-on-emerging-biopharma/) - Emerging biopharmaceutical companies have to navigate increased evidence demands as well as uncertainties in the upcoming EU HTA for accelerated market access.
- [More Than 600 Medicines At Risk If European PFAS Restriction](https://www.pharmaadvancement.com/pharma-news/more-than-600-medicines-at-risk-if-european-pfas-restriction/) - If the PFAS restriction takes place, there will be a dearth of more than 600 critical medicines throughout Europe with their manufacturing coming to a halt.
- [Overall Access To Pharma Info Made Easy With Digital & Paper](https://www.pharmaadvancement.com/pharma-news/overall-access-to-pharma-info-made-easy-with-digital-paper/) - To facilitate those with zero digital prowess, it is pivotal that digital and paper information gets available along with the medications to make process easy.
- [Crucial Role of FAP Partners In Pharmaceutical Supply Chains](https://www.pharmaadvancement.com/pharma-news/crucial-role-of-fap-partners-in-pharmaceutical-supply-chains/) - FAP partners play a significant role in the pharma supply chain, ensuring liability management, and network optimization, propelled by data-driven approaches.
- [Freight Audit & Payment Services Advance Pharma Supply Chain](https://www.pharmaadvancement.com/pharma-news/freight-audit-payment-services-advance-pharma-supply-chain/) - Digital transformation as well as collaboration with suppliers are unparalleled strategies to advance supply chain visibility in the biopharmaceutical sector.
- [Importance Of Supply Chain Traceability In The Pharma Sector](https://www.pharmaadvancement.com/pharma-news/importance-of-supply-chain-traceability-in-the-pharma-sector/) - Pharmaceutical companies must adapt to Industry 4.0 for digital traceability, and compliance, alongside combating counterfeits amid rising ESG expectations.
- [6 Vital Compulsions For Cell And Gene Therapy Supply Chain](https://www.pharmaadvancement.com/pharma-news/6-vital-compulsions-for-cell-and-gene-therapy-supply-chain/) - Navigating the gene and cell therapy supply chain demands precision, real-time monitoring, and advanced logistics to ensure timely, quality treatment delivery.
- [Globalizing Pharma Cold Chains With Specialized Partners](https://www.pharmaadvancement.com/pharma-news/globalizing-pharma-cold-chains-with-specialized-partners/) - Pharmaceutical cold chain transport is significantly complex; specialized partners help ensure compliance, and reduce risks as well as promote sustainability.
- [Cell And Gene Therapy Market To Reach $82.24 Billion By 2032](https://www.pharmaadvancement.com/drug-development/cell-and-gene-therapy-market-to-reach-82-24-billion-by-2032/) - The global cell and gene therapy market is growing fast, with a projected value of $82.24B by 2032, driven by a robust therapy pipeline and strategic tie-ups.
- [7% CAGR Propels The Aseptic Fill Finish Services Market](https://www.pharmaadvancement.com/drug-development/7-cagr-propels-the-aseptic-fill-finish-services-market/) - The aseptic fill finish operations in the pharma industry are on the rise, with outsourcing to service providers, a 7% CAGR, and Europe leading the market.
- [Pharmaceutical Industry Thriving Amidst Economic Challenges](https://www.pharmaadvancement.com/drug-development/pharmaceutical-industry-thriving-amidst-economic-challenges/) - The pharmaceutical industry is leveraging past lessons to thrive amidst economic challenges, ensuring innovations reach those in need swiftly and efficiently.
- [The Impact of Automation On Prefilled Syringe Production](https://www.pharmaadvancement.com/pharma-news/the-impact-of-automation-on-prefilled-syringe-production/) - Advances in automation technology have boosted the popularity of prefilled syringes in pharma, enhancing safety and precision while meeting diverse demands.
- [DoKaSch Temperature Solutions expands its business in India](https://www.pharmaadvancement.com/packaging-logistic/dokasch-temperature-solutions-expands-its-business-in-india/) - The Indian pharmaceutical industry worldwide ranks third in pharmaceutical production by volume, according to the Indian government. In order to position itself even better in this region
- [Streamlining Development To Production In Pharma With CDMOs](https://www.pharmaadvancement.com/drug-development/streamlining-development-to-production-in-pharma-with-cdmos/) - The shift of pharma towards innovative drugs and the demand for active ingredients require capable CDMO partners for cost-effective development and production.
- [11.95% CAGR Forecast For Prefilled Syringes Through 2030](https://www.pharmaadvancement.com/pharma-news/11-95-cagr-forecast-for-prefilled-syringes-through-2030/) - The global prefilled syringes market is set to grow at a CAGR of 11.95% within 2030, driven by user-friendly drug delivery and COVID-19 vaccine distribution.
- [Reviving UK-EU Research Collaboration With Horizon Europe](https://www.pharmaadvancement.com/drug-development/reviving-uk-eu-research-collaboration-with-horizon-europe/) - The return of the UK to Horizon Europe ensures access to a £95.5B program, promoting collaboration in life sciences and ensuring fair funding for researchers.
- [Rentschler Biopharma UK Site Approved For AAV Production](https://www.pharmaadvancement.com/pharma-news/rentschler-biopharma-uk-site-approved-for-aav-production/) - The UK ATMP facility of Rentschler Biopharma achieves cGMP compliance by MHRA, enabling AAV vector production for gene therapy, marking a significant milestone.
- [The New Head Office Tax System For The Cross-Border SMEs](https://www.pharmaadvancement.com/pharma-news/the-new-head-office-tax-system-for-the-cross-border-smes/) - Introducing the Head Office Tax System will allow cross-border SMEs to interact directly with the Head Office Tax Administration, reducing compliance costs.
- [Over 50% Of FDA-Approved Drugs To Incorporate AI By 2030](https://www.pharmaadvancement.com/pharma-news/over-50-of-fda-approved-drugs-to-incorporate-ai-by-2030/) - The Director for Pharma at Informa Markets notes that AI reshapes the pharmaceutical industry by improving manufacturing process efficiency and clinical trials.
- [Enhancing Gene Therapy Manufacturing, The PAT Project Vision](https://www.pharmaadvancement.com/pharma-news/enhancing-gene-therapy-manufacturing-the-pat-project-vision/) - The PAT project promises faster viral vector development through multi-parameter optimization, leading to higher output, process robustness, and better control.
- [Drug Portfolio Restrictions Imposed By The FTC On Amgen](https://www.pharmaadvancement.com/pharma-news/drug-portfolio-restrictions-imposed-by-the-ftc-on-amgen/) - Amgen must seek the approval of the FTC before acquiring products or therapeutic equivalents related to TED or CRG, as stipulated in the proposed consent order.
- [Developing Pharma Skills With Life Sci For Growth Initiative](https://www.pharmaadvancement.com/drug-development/developing-pharma-skills-with-life-sci-for-growth-initiative/) - The Minister of State for Science and Innovation stresses the importance of a world-class workforce in the life sciences sector to remain competitive globally.
- [Chinese Drug Packaging Reshaped By Plastics, Composites](https://www.pharmaadvancement.com/pharma-news/chinese-drug-packaging-reshaped-by-plastics-composites/) - To attain cost efficiency as well as safeguard drugs, the pharma packaging sector in China has transitioned to plastics thereby elevating opportunity levels.
- [Pharma Sector Fuels Demand For Asia Pacific Glass Packaging](https://www.pharmaadvancement.com/pharma-news/pharma-sector-fuels-demand-for-asia-pacific-glass-packaging/) - Emerging economies, including BRICS and MIST nations, are driving the expansion of the pharmaceutical glass packaging market, with a 5.29% growth rate in 2023.
- [2.8 Billion Dollars Projection By 2031 For CGT Manufacturing](https://www.pharmaadvancement.com/manufacturing/2-8-billion-dollars-projection-by-2031-for-cgt-manufacturing/) - The global market for quality control in cell and gene therapy manufacturing is predicted to reach an impressive $2.8 billion by 2031 with a 24.6% CAGR.
- [Innovative Cold Chain Logistics For Pharmaceutical Products](https://www.pharmaadvancement.com/pharma-news/innovative-cold-chain-logistics-for-pharmaceutical-products/) - Pharma cold chains tackle last-mile temperature challenges, adapting to personalized therapies, embracing passive solutions, and prioritizing sustainability.
- [Temperature Management For Pharmaceutical Logistics Success](https://www.pharmaadvancement.com/facilities-operation/temperature-management-for-pharmaceutical-logistics-success/) - The pharmaceutical supply chain can enhance resilience by adopting temperature-controlled solutions, real-time data monitoring, as well as predictive insights.
- [Temperature Controlled Pharma Packaging - Onwards & Upwards](https://www.pharmaadvancement.com/pharma-news/temperature-controlled-pharma-packaging-onwards-upwards/) - Temperature controlled pharma protective packaging is on its way to prominent growth with COVID-19 playing a significant role in its consistent acceptance.
- [Evolving Trends In Pharma Temperature-Controlled Packaging](https://www.pharmaadvancement.com/pharma-news/evolving-trends-in-pharma-temperature-controlled-packaging/) - The growing pharma temperature-controlled packaging market meets drug integrity demand, driven by COVID-19 vaccine distribution and diverse sector reliance.
- [Pharma Giants Spearhead Eco-Friendly Healthcare Transition](https://www.pharmaadvancement.com/facilities-operation/pharma-giants-spearhead-eco-friendly-healthcare-transition/) - Pharma giants tie up with WHO via the Sustainable Markets Initiative, setting stricter emission goals for suppliers to drive net-zero transition in healthcare.
- [Overcoming Emission Challenges For Pharma Sustainability](https://www.pharmaadvancement.com/facilities-operation/overcoming-emission-challenges-for-pharma-sustainability/) - Pharma industry seeks sustainability amid challenges; high emissions, complex supply chains, and regulatory gaps call for greener practices and accountability.
- [New Trends Revolutionizing Pharma Development And Packaging](https://www.pharmaadvancement.com/pharma-news/new-trends-revolutionizing-pharma-development-and-packaging/) - Pharma trends like sustainability, AI, and more are reshaping drug development and packaging, demanding collaboration with Contract Packaging Organizations.
- [Membrane Fouling Prevention In SP-TFF Through PAT Approach](https://www.pharmaadvancement.com/pharma-news/membrane-fouling-prevention-in-sp-tff-through-pat-approach/) - A novel PAT-based approach has been introduced that prevents membrane fouling in robust single-pass tangential flow filtration operations during bioprocessing.
- [Next-Gen Platforms To Make Pharma Supply Chains More Able](https://www.pharmaadvancement.com/facilities-operation/next-gen-platforms-to-make-pharma-supply-chains-more-able/) - A daunting but unavoidable issue is faced by pharma firms to create sustainable, transparent supply chains and they are turning to next-gen platforms for it.
- [AI-Powered Quality Management In Pharma And Medtech Sectors](https://www.pharmaadvancement.com/pharma-news/ai-powered-quality-management-in-pharma-and-medtech-sectors/) - AI-powered QMS revolutionizes the product quality teams in the life sciences industries, optimizing operations and boosting compliance for pharma and MedTech.
- [Biologics And Regulations Propel Aseptic Fill-Finish Growth](https://www.pharmaadvancement.com/manufacturing/biologics-and-regulations-propel-aseptic-fill-finish-growth/) - Increasing drug expenditure propels demand for aseptic fill-finish services due to biologics and complex drugs, which necessitate controlled manufacturing.
- [Advancing Biopharmaceuticals With Novel Drug Modalities](https://www.pharmaadvancement.com/manufacturing/advancing-biopharmaceuticals-with-novel-drug-modalities/) - The adoption of novel drug modalities by the biopharmaceutical industry poses challenges in manufacturing and regulations, requiring streamlined CMO solutions.
- [Optimizing CDMO Competitiveness Through Pricing Innovation](https://www.pharmaadvancement.com/drug-development/optimizing-cdmo-competitiveness-through-pricing-innovation/) - Pharma CDMOs face competitiveness risks due to inadequate pricing strategies; adopting value-based pricing and standardized costs is essential for success.
- [Rising Analytics Use Shapes Pharmaceutical CDMO Industry](https://www.pharmaadvancement.com/manufacturing/rising-analytics-use-shapes-pharmaceutical-cdmo-industry/) - Fueled by increased analytics use, biologics demand, and global vaccine production, the Pharmaceutical CDMO market is set for a 7.29 percent CAGR till 2028.
- [Cancer Research Boosts Small Molecule CDMO Market Expansion](https://www.pharmaadvancement.com/pharma-news/cancer-research-boosts-small-molecule-cdmo-market-expansion/) - The Small Molecule Innovator CDMO Market, driven by cancer research and outsourcing, is set to reach $76.5B by 2031, led by North America and APAC regions.
- [Reshaping Parenteral Drug Production Amid COVID Disruption](https://www.pharmaadvancement.com/pharma-news/reshaping-parenteral-drug-production-amid-covid-disruption/) - COVID-19 disrupts parenteral drug production, transforming market trends, with rising demand for MAbs and the influence of mRNA technology and outsourcing.
- [PPWR Proposal To Shake Up Pharmaceutical Packaging Industry](https://www.pharmaadvancement.com/pharma-news/ppwr-proposal-to-shake-up-pharmaceutical-packaging-industry/) - To be in sync with circular economy principles and recycling objectives, Packaging and Packaging Waste Regulation proposal looks to have sustainable packaging.
- [FDA And DEA Join Forces To Increase Stimulant Production](https://www.pharmaadvancement.com/pharma-news/fda-and-dea-join-forces-to-increase-stimulant-production/) - FDA & DEA collaborate, urging the manufacturers to boost prescription stimulant production to alleviate Adderall shortage and to prevent future scarcities.
- [Swift Biomanufacturing: Automated PAT Systems Efficiency](https://www.pharmaadvancement.com/pharma-news/swift-biomanufacturing-automated-pat-systems-efficiency/) - Cutting-edge automated PAT systems - SI & A2P2 - enable rapid testing and release of biopharmaceutical products, revolutionising biomanufacturing efficiency.
- [Rapid Growth Predicted In The Small Molecule API Market](https://www.pharmaadvancement.com/drug-development/rapid-growth-predicted-in-the-small-molecule-api-market/) - The small molecule API market is predicted to reach $284.7 billion by 2032 with a CAGR of 5.9% as emerging markets and niche sectors offer growth opportunities.
- [AI And Intelligent Automation In The Pharmaceutical Industry](https://www.pharmaadvancement.com/drug-development/ai-and-intelligent-automation-in-the-pharmaceutical-industry/) - Intelligent automation has started to get recognised as being of an immense value for pharma supply chain and has in a way overtaken artificial intelligence.
- [Draft Reflection Paper On AI In Medicines Published By EMA](https://www.pharmaadvancement.com/pharma-news/draft-reflection-paper-on-ai-in-medicines-published-by-ema/) - The paper goes on to highlight the role and capability of artificial intelligence and valid approach drug developers should take with it to make it effective.
- [Employee - Driven Digital Transformation In Life Science](https://www.pharmaadvancement.com/pharma-news/employee-driven-digital-transformation-in-life-science/) - Amidst complex challenges, digitalization drives success in the evolving life science industry through employee involvement along with a consistent strategy.
- [Empowering Pharma 4.0 Data Management with PAT Software](https://www.pharmaadvancement.com/pharma-news/empowering-pharma-4-0-data-management-with-pat-software/) - Optimal Industrial Automation emphasizes the importance of PAT software for Pharma 4.0 data management with advanced techniques in biopharmaceutical facilities.
- [Critical Elements of Pharmaceutical Cold Chain Logistics](https://www.pharmaadvancement.com/facilities-operation/critical-elements-of-pharmaceutical-cold-chain-logistics/) - Monitoring of pharma cold chain which leads to critical data roll out that in-turn helps to maintain efficacy of drugs is crucial element of the supply chain.
- [Startups Impact Pharma Supply Chain, Improving Patient Care](https://www.pharmaadvancement.com/facilities-operation/startups-impact-pharma-supply-chain-improving-patient-care/) - Pharma supply chain faces critical challenges, but startups are bringing unique solutions to enhance efficiency and transparency, benefiting patients globally.
- [Assessing The Impact of Localization On Pharma Supply Chains](https://www.pharmaadvancement.com/facilities-operation/assessing-the-impact-of-localization-on-pharma-supply-chains/) - Pharmaceutical supply chains move towards regional hubs for resilience, while carefully evaluating the impact of localization on agility and other metrics.
- [Combating Antibiotic Resistance With AI & Machine Learning](https://www.pharmaadvancement.com/pharma-news/combating-antibiotic-resistance-with-ai-machine-learning/) - Machine learning could revolutionize the landscape of drug discovery, including antibiotic research, offering hope for effective solutions against resistance.
- [Active Ingredient Identification Made Faster Via UHPT Method](https://www.pharmaadvancement.com/drug-development/active-ingredient-identification-made-faster-via-uhpt-method/) - UHPT method in NMR enables precise analysis of complex structures, accelerating the identification of active ingredients and also benefiting drug development.
- [Breakthrough Cell & Gene Therapies To Transform Healthcare](https://www.pharmaadvancement.com/drug-development/research-development/breakthrough-cell-gene-therapies-to-transform-healthcare/) - Cell and gene therapies have transformative potential to reprogram the immune system and address diseases that are tough to treat with traditional medicine.
- [Making The Right CDMO Choice For Novel Antibody Creation](https://www.pharmaadvancement.com/pharma-news/making-the-right-cdmo-choice-for-novel-antibody-creation/) - For the biopharmaceutical companies that are looking to come up with innovative antibody development projects, a right CDMO choice is a prominent decision.
- [Technology And Policy To Drive Biopharma And Medtech Growth](https://www.pharmaadvancement.com/middle-east-and-south-asia/technology-and-policy-to-drive-biopharma-and-medtech-growth/) - New insights recommend technology and government policy solutions to tackle challenges and foster economic growth in the biopharmaceutical and Medtech sectors.
- [AI Unveils Novel Treatment Pathways In Biomedical Research](https://www.pharmaadvancement.com/drug-development/ai-unveils-novel-treatment-pathways-in-biomedical-research/) - The convergence of AI and biotechnology brings immense opportunities for faster drug discovery, accurate diagnoses, gene editing, and personalized medicine.
- [Japan, Norway Partner To Strengthen Global Pandemic Response](https://www.pharmaadvancement.com/pharma-news/japan-norway-partner-to-strengthen-global-pandemic-response/) - In order to accelerate the global preparedness and also response to any future pandemics, Japan and Norway shall share expertise, knowledge and experience.
- [Biomedical Research Sector In Australia All Set To Expand](https://www.pharmaadvancement.com/pharma-news/biomedical-research-sector-in-australia-all-set-to-expand/) - Monash University, Australia has bought the prominent Parkville Property which will enable in advancement of biomedical research capabilities of the country.
- [China Continues To Attract Multinational Pharma Investment](https://www.pharmaadvancement.com/facilities-operation/china-continues-to-attract-multinational-pharma-investment/) - Despite political tensions, multinational pharma companies still want to invest in China, as evident from the recent developments in the Chinese pharma sector.
- [CRO Market Outlook: Growth Potential & Regulatory Obstacles](https://www.pharmaadvancement.com/pharma-news/cro-market-outlook-growth-potential-regulatory-obstacles/) - By 2033, the global CRO market is anticipated to reach $139.56 billion, although non-uniform regulations across governments may pose challenges to its growth.
- [Biotech M&A Is Set For Rebound With Billion-Dollar Deals](https://www.pharmaadvancement.com/facilities-operation/biotech-ma-is-set-for-rebound-with-billion-dollar-deals/) - Biotech M&A faced a decline in 2022, but the billion-dollar acquisitions of major pharmaceutical companies signal a potential rebound and hope for the future.
- [Centogene, Lifera Join Forces To Improve Multiomic Testing](https://www.pharmaadvancement.com/drug-development/centogene-lifera-join-forces-to-improve-multiomic-testing/) - Lifera partners with Centogene to establish a Joint Venture aimed at expanding access to multiomic testing for rare diseases in Saudi Arabia and the GCC region.
- [US - China Trade In Pharmaceuticals Soars In Recent Years](https://www.pharmaadvancement.com/middle-east-and-south-asia/us-china-trade-in-pharmaceuticals-soars-in-recent-years/) - US-China trade dynamics have shifted, with pharma products emerging as winners, comprising nearly 3% of the trading relationship driven by advanced medicines.
- [ACHEMA 2024: Shaping the future of the process industries](https://www.pharmaadvancement.com/pharma-news/achema-2024-shaping-the-future-of-the-process-industries/) - From 10 to 14 June 2024, ACHEMA will once again be the place to go for the entire range of technologies and services for the process industries.
- [New Guidelines: Medicare To Directly Negotiate Drug Prices](https://www.pharmaadvancement.com/facilities-operation/new-guidelines-medicare-to-directly-negotiate-drug-prices/) - The Biden administration guidelines allow Medicare to negotiate drug prices with manufacturers, offering transparency and public involvement opportunities.
- [Swiss Pharma Sector In EU Negotiations- Stakes Are Sky High](https://www.pharmaadvancement.com/facilities-operation/swiss-pharma-sector-in-eu-negotiations-stakes-are-sky-high/) - The Swiss government has made an announcement that they are looking out to balance their relations with the European Union by way of working on a new strategy.
- [EU Pharma Legislation Reform Aims For Affordable Medicines](https://www.pharmaadvancement.com/pharma-news/eu-pharma-legislation-reform-aims-for-affordable-medicines/) - Pharma legislation reform of the EU aims to ensure affordable and available medicines in the UK, while also expediting equal access to new drugs across borders.
- [Environmental Consciousness Rising In Global Healthcare](https://www.pharmaadvancement.com/facilities-operation/environmental-consciousness-rising-in-global-healthcare/) - The global healthcare sector, including the pharma industry, is prioritizing ESG initiatives to meet consumer demands for environmentally responsible practices.
- [Assessing Q1 2023: Indian Pharma Industry Growing Rapidly](https://www.pharmaadvancement.com/pharma-news/assessing-q1-2023-indian-pharma-industry-growing-rapidly/) - As revenues decline in the USA and Europe, pharma companies are turning their attention to the booming market of India, driven by its strong industry growth.
- [2028 May See European Pharma Firms Cross US Giants In Sales](https://www.pharmaadvancement.com/drug-development/2028-may-see-european-pharma-firms-cross-us-giants-in-sales/) - As per the GlobalData analysis, the rapid biologic sales is anticipated to be the driving force behind European companies going ahead of US firms by 2028.
- [Buyouts Dwindle As Pharma Sector Faces Pricing Concerns](https://www.pharmaadvancement.com/pharma-news/buyouts-dwindle-as-pharma-sector-faces-pricing-concerns/) - Pharma industry battles pricing concerns under the Inflation Reduction Act, and FTC scrutiny on merger deals, jeopardizing buyouts to counter the patent cliff.
- [Unconstitutional Price-Setting Provisions: PhRMA Asserts](https://www.pharmaadvancement.com/pharma-news/unconstitutional-price-setting-provisions-phrma-asserts/) - NICA, GCCA, and PhRMA assert that the price-setting provisions in the IRA are unconstitutional and seek relief in the form of proper implementation processes.
- [Pharma May Lose Out To Competition Due To EU Health Package](https://www.pharmaadvancement.com/drug-development/pharma-may-lose-out-to-competition-due-to-eu-health-package/) - As per new measures, EU is looking to reverse the dip in regional manufacturing, improve drug access, avoid drug shortage, put an end to parallel medicines.
- [Pharma Trade Group Sues Biden Admin Over Medicare Drug Costs](https://www.pharmaadvancement.com/pharma-news/pharma-trade-group-sues-biden-admin-over-medicare-drug-costs/) - Largest lobbying group in the US pharma sector has sued Biden administration on the new powers of Medicare to cut drug prices for senior citizens under IRA.
- [Adapting Digital Transformation In The Life Sciences Sector](https://www.pharmaadvancement.com/ipr-data-management/adapting-digital-transformation-in-the-life-sciences-sector/) - Life sciences organizations adopt digital transformation strategies to overcome limitations, prioritize data-driven operations, and thrive in a shifting market.
- [Cell & Gene Therapy CDMO Market - Steady Growth On The Cards](https://www.pharmaadvancement.com/drug-development/cell-gene-therapy-cdmo-market-steady-growth-on-the-cards/) - The cell and gene therapy CDMO services market has seen a growth of significant nature due to the rise in the number of chronic diseases throughout the world.
- [Cell And Gene Therapy CDMO Services Set For Rapid Growth](https://www.pharmaadvancement.com/drug-development/cell-and-gene-therapy-cdmo-services-set-for-rapid-growth/) - The cell and gene therapy CDMO services market worldwide, valued at USD 5,193.7 million in 2022, is projected to expand at a CAGR of 17.5% during 2023-2029.
- [Growth Forecast For Asia Pacific Pharmaceutical CDMO Market](https://www.pharmaadvancement.com/drug-development/growth-forecast-for-asia-pacific-pharmaceutical-cdmo-market/) - The Asia Pacific Pharmaceutical CDMO market is set to grow and reach US$140.03B by 2031 with a CAGR of 9.9% due to rising demand, R&D focus, and outsourcing.
- [Small Molecule Innovator CDMO Market Set For Heavy Growth](https://www.pharmaadvancement.com/drug-development/small-molecule-innovator-cdmo-market-set-for-heavy-growth/) - The small molecule innovator CDMO market is expected to reach $89.43 billion in 2033, driven by rising demand for small-molecule drugs and increased R&D costs.
- [Pharma Sterility Testing Market Set For Remarkable Growth](https://www.pharmaadvancement.com/pharma-news/pharma-sterility-testing-market-set-for-remarkable-growth/) - Propelled by quality, increased government investments, and new drug introductions, the pharma sterility testing market is to expand to $1.0223 billion by 2032.
- [CU Medicine Reveals That Neutrophils Can Combat Lung Cancer](https://www.pharmaadvancement.com/drug-development/cu-medicine-reveals-that-neutrophils-can-combat-lung-cancer/) - CU Medicine uncovers the role of neutrophils in lung cancer, showcasing the potential of gene-edited neutrophils as a viable treatment option in animal models.
- [$85bn M&A Splurge Helps In Big Pharma Dealmaking Recovery](https://www.pharmaadvancement.com/facilities-operation/85bn-ma-splurge-helps-in-big-pharma-dealmaking-recovery/) - Although there has been an increase in the drugmakers appetite when it comes to takeovers, action by the FTC in cases of certain deals raises megadeal risk.
- [Inexperience Makes CDMOs Struggle With Cell And Gene Therapy](https://www.pharmaadvancement.com/drug-development/inexperience-makes-cdmos-struggle-with-cell-and-gene-therapy/) - CDMOs face difficulty in scaling cell and gene therapy manufacturing for Phase III trials due to a lack of experience, overshadowing physical capacity concerns.
- [FDA Releases Draft Guidance On Digital Health Technologies](https://www.pharmaadvancement.com/pharma-news/fda-releases-draft-guidance-on-digital-health-technologies/) - FDA releases draft guidance on good clinical practices to enhance clinical trial design and implementation, maintaining data accuracy and participant safety.
- [Researchers Utilize AI To Combat Drug-Resistant Bacterium](https://www.pharmaadvancement.com/pharma-news/researchers-utilize-ai-to-combat-drug-resistant-bacterium/) - Scientists use artificial intelligence to discover abaucin, an antibiotic against drug-resistant Acinetobacter baumannii, revolutionizing screening methods.
- [Targeting Tumor-Positive Lymph Nodes Boosts Cancer Treatment](https://www.pharmaadvancement.com/pharma-news/targeting-tumor-positive-lymph-nodes-boosts-cancer-treatment/) - Scientists from Tohoku University advance cancer treatment by targeting tumor-positive lymph nodes with immune checkpoint inhibitors, minimizing side effects.
- [AMR Certification For Responsible Antibiotic Manufacturing](https://www.pharmaadvancement.com/manufacturing/amr-certification-for-responsible-antibiotic-manufacturing/) - BSI introduces AMR certification for responsible antibiotic manufacturing, and environmental protection, with independent waste stream control verification.
- [Ovarian Cancer Type Gets An Effective Targeted Drug Combo](https://www.pharmaadvancement.com/drug-development/ovarian-cancer-type-gets-an-effective-targeted-drug-combo/) - Patients having advanced low-grade serous ovarian cancer can benefit by a focused drug combination which can be twice as effective, a Phase II study says.
- [New Singapore Therapy For Antibiotic Resistant Lung Issues](https://www.pharmaadvancement.com/pharma-news/new-singapore-therapy-for-antibiotic-resistant-lung-issues/) - Singapore study says that by combining rifaximin and clarithromycin, treatment of non-tuberculosis mycobacterium- chronic lung related infections is possible.
- [Diosynvax - A Needle-Free Revolution In COVID-19 Vaccination](https://www.pharmaadvancement.com/drug-development/diosynvax-a-needle-free-revolution-in-covid-19-vaccination/) - DIOSynVax Covid-19 vaccine administered through air-jet technology provides long-lasting protection against SARS-CoV-2 by overcoming spike protein variations.
- [Genome Analysis Offers New Hope For Severe Skin Condition](https://www.pharmaadvancement.com/drug-development/genome-analysis-offers-new-hope-for-severe-skin-condition/) - Genomic variants in the STAT4 gene lead to an overactive protein that worsens skin inflammation and impairs wound healing in disabling pansclerotic morphea.
- [Vorasidenib - A Potential Game-Changer In Glioma Treatment](https://www.pharmaadvancement.com/pharma-news/vorasidenib-a-potential-game-changer-in-glioma-treatment/) - Vorasidenib, a targeted therapy drug, extends treatment duration and more than doubles progression-free survival in patients with glioma, a deadly brain cancer.
- [Advancing RNA Therapeutics With UK Drug Delivery Centre](https://www.pharmaadvancement.com/facilities-operation/advancing-rna-therapeutics-with-uk-drug-delivery-centre/) - Top UK institutions tie up with CPI to set up a �10M-funded Intracellular Drug Delivery Centre, focused on developing innovative LNPs for RNA-based medicines.
- [DoKaSch Temperature Solutions appoints Sales & Business Development Manager for China](https://www.pharmaadvancement.com/pharma-news/dokasch-temperature-solutions-appoints-sales-business-development-manager-for-china/) - DoKaSch Temperature Solutions appoints Sales & Business Development Manager for China
- [Adapting To The Changing Virus By Enhancing Vaccine Immunity](https://www.pharmaadvancement.com/pharma-news/adapting-to-the-changing-virus-by-enhancing-vaccine-immunity/) - Updating vaccine composition based on emerging evidence on SARS-CoV-2 variants is crucial to enhance immunity against new strains and prevent severe disease.
- [Emerging Trends Reshaping The Pharmaceutical Supply Chain](https://www.pharmaadvancement.com/pharma-news/emerging-trends-reshaping-the-pharmaceutical-supply-chain/) - Pharmaceutical supply chain undergoes significant challenges due to pandemics, conflicts, and escalating costs, compelling the industry to embrace new trends.
- [UK Boosts Life Sciences Sector With £650 Million Funding](https://www.pharmaadvancement.com/pharma-news/uk-boosts-life-sciences-sector-with-650-million-funding/) - The UK Chancellor allocates £650M for a life sciences growth package, comprising 10 policies, to drive scientific and technological advancements in the UK.
- [WHO And Korea Sign MoU For Biomanufacturing Training Hub](https://www.pharmaadvancement.com/facilities-operation/who-and-korea-sign-mou-for-biomanufacturing-training-hub/) - WHO and the Republic of Korea will establish a global biomanufacturing training hub, expanding local vaccine production and essential health products in LMICs.
- [Chinese Market Regulator Fines Two Monopolistic Pharma Firms](https://www.pharmaadvancement.com/pharma-news/chinese-market-regulator-fines-two-monopolistic-pharma-firms/) - China imposes a 136 million yuan fine on Grand Pharmaceutical and a 4.13 million yuan fine on Wuhan Healcare Pharmaceuticals for their monopolistic behaviour.
- [Enhancing Patient Care In The UK Through Recognition Routes](https://www.pharmaadvancement.com/pharma-news/enhancing-patient-care-in-the-uk-through-recognition-routes/) - The MHRA will establish international regulatory recognition routes for medicines, enabling faster access to cutting-edge treatments for patients in the UK.
- [Battling Global Medicine Shortages With EMA Recommendations](https://www.pharmaadvancement.com/drug-development/battling-global-medicine-shortages-with-ema-recommendations/) - EMA recommendations aim to address medicine shortages and ensure the availability of authorized medicines through prompt notification and detailed information.
- [Machine Learning - A Game-Changer In The Pharma Industry](https://www.pharmaadvancement.com/pharma-news/machine-learning-a-game-changer-in-the-pharma-industry/) - Machine learning in the pharma industry is set to rise to $26.2B, with a CAGR of 37.9 per cent until 2031, streamlining drug discovery through data analysis.
- [Impact of AI On The Pharmaceutical Industry Sparks Debates](https://www.pharmaadvancement.com/pharma-news/impact-of-ai-on-the-pharmaceutical-industry-sparks-debates/) - Scientists in the pharma sector are divided on the potential of AI, while researchers have long relied on computer assistance to create life-saving treatments.
- [Advancing Pharma Logistics - Smart Contracts And Blockchain](https://www.pharmaadvancement.com/pharma-news/advancing-pharma-logistics-smart-contracts-and-blockchain/) - Despite its potential to combat a $200B counterfeit market, the integration of blockchain technology in the pharmaceutical supply chain remains incomplete.
- [Switzerland Emerges As The Headquarters For European Biotech](https://www.pharmaadvancement.com/facilities-operation/switzerland-emerges-as-the-headquarters-for-european-biotech/) - Switzerland emerges as the preferred base for 20 per cent of European biotech companies, with biotech becoming the second most significant industry after ICT.
- [Genomics Market Growth In India To Accelerate Affordability](https://www.pharmaadvancement.com/pharma-news/genomics-market-growth-in-india-to-accelerate-affordability/) - Indian genomics market is expected to grow by 18% in the next 5 years, driven by decreasing test costs, enhanced affordability, and cost-effective genomic kits.
- [EMA Reviews Hydroxyprogesterone Caproate For Safety Concerns](https://www.pharmaadvancement.com/pharma-news/ema-reviews-hydroxyprogesterone-caproate-for-safety-concerns/) - EMA reviews hydroxyprogesterone Caproate for safety, and potential cancer risks during pregnancy while addressing their efficacy in preventing premature birth.
- [WHO Utilizes Pathogen Genomics For Global Disease Protection](https://www.pharmaadvancement.com/pharma-news/who-utilizes-pathogen-genomics-for-global-disease-protection/) - WHO establishes the IPSN to enhance global defence against infectious diseases using pathogen genomics, enabling data-driven public health decision-making.
- [EMA Recommendations To Address Medicine Shortages In Europe](https://www.pharmaadvancement.com/pharma-news/ema-recommendations-to-address-medicine-shortages-in-europe/) - EMA publishes ten recommendations to tackle medicine shortages in Europe, aiming to ensure a consistent supply and mitigate the negative impact on patients.
- [Concerns Rise Over Shortage of Medical Products In The USA](https://www.pharmaadvancement.com/drug-development/concerns-rise-over-shortage-of-medical-products-in-the-usa/) - Critical shortages of lead poisoning reversal drugs, sterile fluids, antibiotics, and other medications in the US expose the disrupted supply chain challenges.
- [Impact of Global Events On The Biopharmaceutical Industry](https://www.pharmaadvancement.com/pharma-news/impact-of-global-events-on-the-biopharmaceutical-industry/) - Amidst lower valuations benefitting acquirers and a slowdown in IPOs and venture funding, the biopharmaceutical industry must focus on clinical achievements.
- [Transparency In Global Pharma Supply Chains To Tackle Fraud](https://www.pharmaadvancement.com/facilities-operation/transparency-in-global-pharma-supply-chains-to-tackle-fraud/) - Global pharmaceutical supply chains face the threat of fraud, theft, and counterfeit goods, highlighting the need for end-to-end visibility and transparency.
- [Pharmaceutical Setups To Adopt Supply Chain Digitalization](https://www.pharmaadvancement.com/packaging-logistic/pharmaceutical-setups-to-adopt-supply-chain-digitalization/) - Global pharmaceutical companies face scrutiny for issues including inconsistent drug availability, necessitating digitalization and supply chain traceability.
- [Temperature Control In Pharmaceutical Cold Chain - Key Areas](https://www.pharmaadvancement.com/facilities-operation/temperature-control-in-pharmaceutical-cold-chain-key-areas/) - To meet regulations, storage areas require continuous temperature monitoring throughout the pharmaceutical cold chain, including mapping and sensor calibration.
- [Pharma Adopts Digitalization For Improved Drug Manufacturing](https://www.pharmaadvancement.com/manufacturing/pharma-adopts-digitalization-for-improved-drug-manufacturing/) - Automation, digitalization, and data analytics reshape drug manufacturing, propelling the market growth for global pharmaceutical quality management systems.
- [Role of Blockchain In Pharmaceutical Supply Chain Efficiency](https://www.pharmaadvancement.com/pharma-news/role-of-blockchain-in-pharmaceutical-supply-chain-efficiency/) - Quality issues and contamination in COVID-19 vaccine production due to fragmented communication and its consequences caused global supply chain disruptions.
- [Last-Mile Delivery For Pharmaceutical Cold Chain Complicacy](https://www.pharmaadvancement.com/facilities-operation/last-mile-delivery-for-pharmaceutical-cold-chain-complicacy/) - From lab to patient, the intricate journey of pharmaceutical products hinges on last-mile delivery with temperature-controlled solutions for product integrity.
- [Sandoz, Evotec Launch AI-Driven Biosimilar Manufacturing](https://www.pharmaadvancement.com/manufacturing/sandoz-evotec-launch-ai-driven-biosimilar-manufacturing/) - Sandoz and Evotec Biologics partner to use AI in biosimilar manufacturing. This collaboration aims to lower costs, enhance quality, and scale up production.
- [Key Areas For AI/ML Drug Development - FDA Discussion Paper](https://www.pharmaadvancement.com/pharma-news/key-areas-for-ai-ml-drug-development-fda-discussion-paper/) - The FDA releases a discussion paper on AI and ML in drug development to engage stakeholders, initiate discussions, and gather feedback for future guidance.
- [Mettler-Toledo Launches X2 Series of X-ray Solutions to Bring Enhanced Product Safety to a Wider Audience](https://www.pharmaadvancement.com/drug-development/mettler-toledo-launches-x2-series-of-x-ray-solutions-to-bring-enhanced-product-safety-to-a-wider-audience/) - Mettler-Toledo Launches X2 Series of X-ray Solutions to Bring Enhanced Product Safety to a Wider Audience
- [Rising Pharmaceuticals Demand Drives Tablet Coatings Market](https://www.pharmaadvancement.com/drug-development/rising-pharmaceuticals-demand-drives-tablet-coatings-market/) - The global tablet coatings market is to reach $4.1 billion by 2031, driven by growing demand for pharmaceuticals, technological advancements and other factors.
- [European Medicines Agency Ends COVID-19 Prioritization Plan](https://www.pharmaadvancement.com/pharma-news/european-medicines-agency-ends-covid-19-prioritization-plan/) - The EMA and European regulators have ended COVID-19 business continuity measures, moving towards normal regulatory processes as pandemic conditions change.
- [Connected Drug Delivery Devices To Revolutionize Healthcare](https://www.pharmaadvancement.com/pharma-news/connected-drug-delivery-devices-to-revolutionize-healthcare/) - The connected drug delivery device market is expected to grow significantly and reach $25.6 billion by 2030, driven by IoT adoption and consumer device trends.
- [Particle Size Distribution Real-Time Monitoring With PEACE](https://www.pharmaadvancement.com/drug-development/particle-size-distribution-real-time-monitoring-with-peace/) - A new machine learning algorithm, PEACE, can monitor particle size distributions of pharmaceutical powders through laser speckle, aiding in process control.
- [ABPI and NHS Are in Talks for New Medicines Scheme in the UK](https://www.pharmaadvancement.com/pharma-news/abpi-and-nhs-are-in-talks-for-new-medicines-scheme-in-the-uk/) - The new voluntary scheme laid down by UK for Branded Medicines Pricing and Access aims to promote the development of cost-effective and innovative medicines.
- [Mettler-Toledo Showcases a Suite of Affordable Smart Inspection Technologies at Interpack to Boost Pharma Productivity](https://www.pharmaadvancement.com/drug-development/mettler-toledo-showcases-a-suite-of-affordable-smart-inspection-technologies-at-interpack-to-boost-pharma-productivity/) - Mettler-Toledo Showcases a Suite of Affordable Smart Inspection Technologies at Interpack to Boost Pharma Productivity
- [FDA approves the manufacture of new microbiome-based therapeutic VOWSTTM at Recipharm site](https://www.pharmaadvancement.com/drug-development/fda-approves-the-manufacture-of-new-microbiome-based-therapeutic-vowsttm-at-recipharm-site/) - FDA approves the manufacture of new microbiome-based therapeutic VOWSTTM at Recipharm site
- [New Approach To Gene Editing For Improved Cancer Treatment](https://www.pharmaadvancement.com/pharma-news/new-approach-to-gene-editing-for-improved-cancer-treatment/) - New gene-editing approach using virus-derived peptides promises improved cell therapies for cancer and other diseases with higher efficiency and lower toxicity.
- [Report Predicts OSD Contract Manufacturing Market Growth](https://www.pharmaadvancement.com/pharma-news/report-predicts-osd-contract-manufacturing-market-growth/) - OSD contract manufacturing market is to grow significantly because of the demand for specialized manufacturers to create complex oral solid drug formulations.
- [Driving Factors Behind Digital Bioprocessing Market Growth](https://www.pharmaadvancement.com/drug-development/driving-factors-behind-digital-bioprocessing-market-growth/) - The market for digital biomanufacturing is expected to grow significantly in 2023-35, with digital bioprocessing improving drug quality and process robustness.
- [Harnessing Blockchain Technology For Better Pharma Functions](https://www.pharmaadvancement.com/pharma-news/harnessing-blockchain-technology-for-better-pharma-functions/) - The pharmaceutical industry leverages blockchain technology for optimizing the supply chain processes, improving operational efficiency, and boosting profits.
- [FDA Draft Guidance Supports Decentralized Clinical Trials](https://www.pharmaadvancement.com/pharma-news/fda-draft-guidance-supports-decentralized-clinical-trials/) - The FDA has issued draft guidance supporting decentralized clinical trials, in order to enhance patient participation and streamline the overall trial process.
- [Pharma Industry Groups Criticise Proposed EU Drug Regulation](https://www.pharmaadvancement.com/drug-development/pharma-industry-groups-criticise-proposed-eu-drug-regulation/) - The EU proposing revisions to its drug regulations, with changes to the authorisation process, pricing, and more, has sparked concerns from the pharma industry.
- [EU States Seek Reduced Reliance On Chinese Pharma Imports](https://www.pharmaadvancement.com/manufacturing/eu-states-seek-reduced-reliance-on-chinese-pharma-imports/) - EU states aim to reduce dependency on Chinese pharma imports, so propose a Critical Medicines Act, a critical medicine list and measures to support each other.
- [Phase I Trial of The South Korean DuoChol Vaccine In Sweden](https://www.pharmaadvancement.com/drug-development/phase-i-trial-of-the-south-korean-duochol-vaccine-in-sweden/) - A Phase I clinical trial of DuoChol, a new low-cost, oral cholera vaccine in capsule form, developed by South Korea-based IVI is set to be conducted in Sweden.
- [EU Drug Manufacturing Law Changes Disappoint Manufacturers](https://www.pharmaadvancement.com/pharma-news/eu-drug-manufacturing-law-changes-disappoint-manufacturers/) - The proposed drug manufacturing law overhaul by the EU aims to increase access and affordability to medicine but manufacturers threaten to leave the region.
- [AMR Is The Main Focus of New Research Consortium In World](https://www.pharmaadvancement.com/pharma-news/amr-is-the-main-focus-of-new-research-consortium-in-world/) - A global consortium, CAMO-Net, is established to combat antimicrobial resistance and optimize antimicrobial use, with teams from five universities across globe.

## Pages

- [Home](https://www.pharmaadvancement.com/) - Pharma Advancement is your source for global pharmaceutical and biopharma news, FDA approvals, clinical trial updates, drug development insights and analysis.
- [List your Events and Conferences](https://www.pharmaadvancement.com/event-listing-form/) - List your pharmaceutical industry events, trade shows, conferences or biotech summit on Pharma Advancement to gain global exposure, attract attendees worldwide.
- [About Us](https://www.pharmaadvancement.com/about-us/) - Pharma Advancement is the premier platform for global pharmaceutical news and biopharma updates covering innovations, articles, insights, events and happenings.
- [Submit Your Content](https://www.pharmaadvancement.com/submit-your-content/) - Share your pharmaceutical expertise on Pharma Advancement. Submit articles on drug development, clinical trials, biotech and regulatory insights globally.
- [Newsletter Subscription](https://www.pharmaadvancement.com/newsletter-subscription/) - Subscribe to Pharma Advancement newsletter for curated pharmaceutical news, FDA approval alerts, clinical trial updates and drug development insights monthly.
- [Privacy Policy](https://www.pharmaadvancement.com/privacy-policy/) - Learn how Pharma Advancement collects and protects your data. Our privacy policy outlines your data rights, information usage, and security practices online.
- [Cookie Policy](https://www.pharmaadvancement.com/cookie-policy/) - Read how Pharma Advancement uses cookies to enhance your browsing, personalize content, and analyze site traffic. Manage your cookie preferences at any time.
- [Newsletters Archive](https://www.pharmaadvancement.com/newsletter-archive/) - Browse the Pharma Advancement newsletter archive for past issues covering pharmaceutical news, FDA approvals, clinical trials, drug development and biotech.
- [Mediapack](https://www.pharmaadvancement.com/mediapack/) - Download the Pharma Advancement media pack for advertising rates, audience demographics and reach data for the global pharmaceutical and biopharma sectors.
- [Advertise with us](https://www.pharmaadvancement.com/advertise-with-us/) - Advertise on Pharma Advancement to connect with global pharma executives and decision-makers via targeted banner ads and sponsored content campaigns.
- [Events & Conferences](https://www.pharmaadvancement.com/events-conferences/) - Discover global pharmaceutical and biopharma events, biotech conferences and trade shows on Pharma Advancement. Stay updated on upcoming pharma summits.
- [Contact Us](https://www.pharmaadvancement.com/contact-us/) - Reach Pharma Advancement for advertising, content partnerships and media inquiries targeting global pharmaceutical executives and healthcare decision-makers.

## Event

- [interpack China 2026](https://www.pharmaadvancement.com/events/interpack-china-2026/) - Attend interpack China 2026 from Nov 16–18 in Shanghai, a leading packaging expo covering machinery, materials, automation and sustainable innovations.
- [Reuters Events: Pharma Commercial Data & Tech 2026](https://www.pharmaadvancement.com/events/reuters-events-pharma-commercial-data-tech-2026/) - Join Pharma Commercial Data & Tech 2026, bringing together leaders across commercial, data, digital and artificial intelligence on November 4–5 in London.
- [16th American Drug Delivery & Formulation Summit](https://www.pharmaadvancement.com/events/16th-american-drug-delivery-formulation-summit/) - Join the 16th American Drug Delivery & Formulation Summit 2026, exploring pharmaceuticals, biologics, device development and innovation in Boston on Sept 28–29
- [Reuters Events: Pharma Clinical Innovation USA 2026](https://www.pharmaadvancement.com/events/reuters-events-pharma-clinical-innovation-usa-2026/) - Join Pharma Clinical Innovation USA 2026, bringing clinical leaders together to advance smarter, faster, scalable trials and patient outcomes on October 5 - 6
- [Reuters Events: Pharma Customer Engagement USA 2026](https://www.pharmaadvancement.com/events/reuters-events-pharma-customer-engagement-usa-2026/) - Attend Pharma Customer Engagement USA 2026, advancing customer engagement, AI, personalization, data and commercial excellence on Oct 27–28 in Philadelphia
- [PharmaXcelerate – Building Resilient Pharma / Biotech Facilities & Quality Systems](https://www.pharmaadvancement.com/events/pharmaxcelerate-building-resilient-pharma-biotech-facilities-quality-systems/) - Join PharmaXcelerate 2026 in Dubai to explore resilient pharma and biotech facilities, quality systems, digital transformation and manufacturing excellence.
- [Women’s HealthX](https://www.pharmaadvancement.com/events/womens-healthx/) - Join Women's HealthX in Boston to explore healthcare exhibitions, expert conferences and global networking opportunities for industry leaders on 3-4 Dec 2026.
- [ACHEMA Middle East 2026](https://www.pharmaadvancement.com/events/achema-middle-east/) - ACHEMA Middle East - a premier pharma and industrial innovation summit linking global tech with Middle East markets to be held in Riyadh, 26–28 Oct 2026

## Company

- [Mark Allen Group](https://www.pharmaadvancement.com/companies/event-organisers/mark-allen-group/) - Founded in 1985 by former journalist, Mark Allen, the group has grown to be a global business operating across several sectors. Today, we\'re recognised for our outstanding multi-platform digital and print media, powerful insights, innovative exhibitions and events, prestigious awards and informative conferences. Content is key to everything we do. That\'s why our organisation prides
- [Reuters News & Media Ltd](https://www.pharmaadvancement.com/companies/event-organisers/reuters-news-media-ltd/) - REUTERS NEWS & MEDIA LIMITED is located in LONDON, United Kingdom and is part of the Other Information Services Industry. REUTERS NEWS & MEDIA LIMITED has 770 employees at this location and generates $232.55 million in sales (USD). (Employees figure is estimated). There are 110 companies in the REUTERS NEWS & MEDIA LIMITED corporate family.

## Categories

- [Uncategorised](https://www.pharmaadvancement.com/uncategorised/)
- [Drug Development](https://www.pharmaadvancement.com/drug-development/) - Follow drug development news on Pharma Advancement, covering research breakthroughs, clinical trials, regulatory submissions, FDA approvals and pipeline updates
- [FDA Approvals](https://www.pharmaadvancement.com/drug-development/fda-approvals/) - Stay informed on FDA drug approvals on Pharma Advancement, featuring breakthrough therapy designations, new molecular entities and biologic approvals globally.
- [Clinical Trials](https://www.pharmaadvancement.com/drug-development/clinical-trials/) - Follow the latest clinical trials news on Pharma Advancement, covering Phase 1, 2 and 3 studies, drug development breakthroughs and key global trial results.
- [IPR Data Management](https://www.pharmaadvancement.com/ipr-data-management/) - Stay informed on intellectual property rights and data management in pharma on Pharma Advancement, covering patent news, compliance and data governance trends.
- [Manufacturing](https://www.pharmaadvancement.com/manufacturing/) - Get pharmaceutical manufacturing news on Pharma Advancement, covering GMP compliance, biotech production, automation, process optimization and innovations.
- [Whitepapers](https://www.pharmaadvancement.com/pharma-whitepapers/) - This section of Pharma Advancement includes pharma...
- [Trends](https://www.pharmaadvancement.com/pharma-trends/) - Latest pharma and biopharma trends on Pharma Advancement, covering AI in drug development, market shifts, regulatory changes, innovations, events and updates.
- [Projects](https://www.pharmaadvancement.com/pharma-projects/) - Track pharma and biopharma industry project updates on Pharma Advancement, covering facility expansions, investments, infrastructure, news and other updates.
- [Insights](https://www.pharmaadvancement.com/market-moves/) - Explore pharma market insights and business trends on Pharma Advancement, covering strategic developments, mergers, pipeline shifts and drug opportunities.
- [Press Statements](https://www.pharmaadvancement.com/press-statements/) - Pharma Advancement press statements include latest...
- [News](https://www.pharmaadvancement.com/pharma-news/) - Get the latest pharmaceutical and biopharma news on Pharma Advancement, covering global FDA approvals, clinical trial results, drug development updates.
- [Americas](https://www.pharmaadvancement.com/americas/) - Get pharmaceutical and biopharma news from the Americas on Pharma Advancement, covering FDA approvals, drug launches, clinical trials and industry developments.
- [Featured](https://www.pharmaadvancement.com/featured/) - Pharmaceutical and Biopharma featured articles and news on Pharma Advancement highlighting top drug approvals, clinical breakthroughs, industry insights and more.
- [Featured Events](https://www.pharmaadvancement.com/featured-events/) - Top-featured pharmaceutical and biopharma events on Pharma Advancement, including global conferences, biotech summits and key healthcare networking events.
- [Asia](https://www.pharmaadvancement.com/asia/) - Follow pharma and biopharma news from Asia on Pharma Advancement, covering drug approvals, clinical trials, regulatory updates and manufacturing innovations.
- [Europe](https://www.pharmaadvancement.com/europe/) - Updates on Pharma and Biopharma news from Europe on Pharma Advancement, covering EMA approvals, clinical research, drug launches, pharma regulatory and more.
- [Africa](https://www.pharmaadvancement.com/africa/) - Pharma and BioPharma news from Africa on Pharma Advancement, covering drug access, regulatory developments, clinical research and biopharma growth trends.
- [Middle East and South Asia](https://www.pharmaadvancement.com/middle-east-and-south-asia/) - Get pharma and biopharma news from the Middle East and South Asia on Pharma Advancement, covering drug approvals, regulatory updates and healthcare developments
- [Articles](https://www.pharmaadvancement.com/articles/) - Browse in-depth pharma articles on Pharma Advancement, featuring expert analysis, drug development insights, clinical research updates and biopharma commentary.
- [Nutraceutical](https://www.pharmaadvancement.com/nutraceutical/) - Explore nutraceutical and supplement news on Pharma Advancement, covering functional foods, health innovations, nutrition research and regulatory developments.
- [Interviews](https://www.pharmaadvancement.com/interviews/) - Read in-depth pharma interviews on Pharma Advancement featuring perspectives from biopharma leaders, regulatory experts, clinical researchers and drug innovators.